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Synthesis of Cortistatin Alkaloids and a Versatile Synthesis of Isoquinolines 
  
Abstract 
The cortistatins are a recently identified class of marine natural products that were 
found to exhibit potent and selective inhibition of human umbilical vein endothelial cells 
(HUVECs), making them promising leads for the development of anti-angiogenic drugs. 
In our synthesis, we envisioned that natural cortistatins and unnatural analogs could be 
prepared by late-stage introduction of isoquinolines to 17-keto precursors, and that these 
differentially substituted precursors could all be derived from a common key intermediate 
112.   
We developed a robust synthetic route to prepare gram quantities of key 
intermediate 112 starting from readily available benzylzinc reagent 116 and enol triflate 
117. Key intermediate 112 was next converted to cortistatin precursors 108, 109, 110, 
and 111 in three to eight steps, representing each of the four natural cortistatin ABC-ring 
substitution patterns. Subsequently, a generally applicable method was developed to 
introduce the isoquinoline moiety. After complexation to N,N,N',N'-
tetramethylethylenediamine (TMEDA), 7-lithio-isoquinoline added to 17-keto precursors 
to provide the corresponding 1,2-addition products; the resulting tertiary alcohols 
underwent radical deoxygenation via their trifluoroacetates to afford the desired (17S)-
products. This organolithium-addition-deoxygenation sequence provided cortistatins A (1, 
on a 20-mg scale), J (9), K (10), and L (11) in good overall yields. We also synthesized 
 iv 
 
cortistatin primary amines (176 and 186) and used them to prepare several cortistatin 
based affinity reagents. By employing these reagents in pull-down experiments, we 
identified a 55-kD membrane kinase as a putative protein target of cortistatins. 
We wanted to prepare cortistatin analogs with isoquinoline modifications due to 
the importance of this ring for the biological activity of cortistatins. This led us to 
develop a novel and versatile synthesis of substituted isoquinolines. In our method, 
lithiated o-tolualdehyde tert-butylimines were condensed with different nitriles to 
generate eneamido anion intermediates, which were trapped in situ with various 
electrophiles at the C4-position, affording a wide range of substituted isoquinolines. 
Further diversification was achieved by modification of the work-up conditions and by 
subsequent transformations.  
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Chapter 1 
Introduction to the Cortistatin Family of Natural Products 
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Isolation and Biological Activities of the Cortistatins 
 
The cortistatins are a family of eleven steroidal alkaloids isolated from the marine 
sponge Corticium simplex by the Kobayashi group in 2006 and 2007 (Figure 1.1).1 
Structurally, there are four types of substitution patterns in the ABC-ring part among all 
the cortistatins, as in cortistatin A (1), B (2), C (3), and D (4); cortistatin E (5), G (7), H 
(8), and K (10); cortistatin F (6), and J (9); and cortistatin L (11).  They all share the same 
9(10→19)-abeo-androstane core structure2 with an unusual C5,C8 oxa-bridge and a C3 
dimethylamino group, but are different in the degree and position of oxygenation and 
unsaturation along the northern edge of ABC-ring. In the D-ring part, most cortistatins 
have a unique isoquinoline substituent attached at C17 position, while cortistatin E (5), F 
(6), G (7), and H (8) have an N,3-dimethylpiperidine or 3-methylpyridine ring in their 
C17 side chains. 
More significantly, several of cortistatins exhibit strong inhibition against the 
proliferation of human umbilical vein endothelial cells (HUVECs), but are much less 
potent against a panel of other cancerous and normal human cell lines (Table 1.1).1,3 The 
HUVECs are isolated from normal human umbilical vein, and are a standard model to 
study angiogenesis.4  Angiogenesis is the growth of new capillary blood vessels from pre- 
                                                 
1 (a) Aoki, S.; Watanabe, Y.; Sanagawa, M.; Setiawan, A.; Kotoku, N.; Kobayashi, M. J. Am. Chem. Soc. 
2006, 128, 3148−3149. (b) Watanabe, Y.; Aoki, S.; Tanabe, D.; Setiawan, A.; Kobayashi, M. Tetrahedron 
2007, 63, 4074−4079. (c) Aoki, S.; Watanabe, Y.; Tanabe, D.; Setiawan, A.; Arai, M.; Kobayashi, M. 
Tetrahedron Lett. 2007, 48, 4485−4488. 
2 In the 9(10→19)-abeo-androstane structure,  the C19 angular methyl group of a typical steroid framework 
(androstane) is incorporated into the B-ring to form a seven-membered ring. 
3 The authors showed that cortistan A also inhibites the migration and tubular formation of HUVECs: Aoki, 
S.; Watanabe, Y.; Tanabe, D.; Arai, M.; Suna, H.; Miyamoto, K.; Tsujibo, H.; Tsujikawa, K.; Yamamoto, 
H.; Kobayashi, M. Bioorg. Med. Chem. 2007, 15, 6758−6762. 
4 Rhim, J. S.; Tsai, W.; Chen, Z.; Chen, Z.; Van Waes, C.; Burger, A. M.; Lautenberger, J. A. 
Carcinogenesis 1998, 19, 673−681. 
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Figure 1.1 The Cortistatin Family of Natural Products. 
 
 
Table 1.1 Growth Inhibitions of Cortistatins against HUVECs and other Cell Lines. 
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existing ones.  Physiological angiogenesis could occur during reproduction, development, 
or wound healing, and is strictly controlled by a host of angiogenic factors; while 
pathological angiogenesis can be unregulated and persistent, 5 and is responsible for a 
wide range of diseases, including many types of cancers, autoimmune disease, age-
related macular degeneration, and atherosclerosis.6  
In 1971, Judah Folkman, a young surgeon at that time, first hypothesized that 
angiogenesis is necessary for the growth and metathesis of tumor cells,7  and identified 
the first angiogenesis promoting factor named tumor angiogenesis factor (TAF).8 Nine 
years later, the same laboratory isolated the first angiogenesis inhibitor, interferon-α/β.9  
Following the pioneering work of the Folkman group, more than 30 additional 
angiogenic factors, and over 400 endogenous and synthetic angiogenesis inhibitors have 
been discovered over the past three decades. 10   Noteworthily, the Folkman group 
identified several steroids (e.g. medroxyprogesterone, cortisone, and dexamethasone) that 
inhibit angiogenesis in vivo in the presence of heparin or a heparin fragment with an 
unknown mechanism.11  In the mid-1990s, a couple of anti-angiogenic drugs started to 
enter clinical trials. In 2004, Bevacizumab, an antibody that neutralizes vascular 
endothelial growth factor (VEGF), was approved by the Food and Drug Administration 
(FDA) to treat colorectal cancer, which is the first drug developed solely as an 
                                                 
5 Hanahan, D.; Weinberg, R. A. Cell 2000, 100, 57−70. 
6 Folkman, J. Nat. Rev. Drug Discovery 2007, 6, 273−286. 
7 Folkman, J. N. Engl. J.  Med. 1971, 285, 1182−1186. 
8 Folkman, J.; Merler, E.; Abernathy, C.; Williams, G. J. Exp. Med. 1971, 133, 275−288.  
9 Langer, R.; Conn, H.; Vacanti, J.;  Haudenschild, C.; Folkman, J. Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 
4331–4335. 
10 Cao, Y.; Arbiser, J.; D’Amato, R. J.; D’Amato, P. A.; Ingber, D. E.; Kerbel, R.; Klagsbrun, M.; Lim, S.; 
Moses, M. A.; Zetter, B.; Dvorak, H.; Langer, R. Sci. Transl. Med. 2011, 3, 114rv3.  
11 (a) Crum, R.; Szabo, S.; Folkman, J.; Science 1985, 230, 1375–1378; (b) Gross, J.; Azizkhan, R. G.; 
Biswas, C.; Bruns, R. R.; Hsieh, D. S.; Folkman, J. Proc. Natl. Acad. Sci. U.S.A. 1981, 78, 1176–1180. 
 5 
 
angiogenesis inhibitor.12 ,13 A number of small molecule entities, including Sorafenib 
(Bayer and Onyx, approved in 2005), 14   Sunitinib (Pfizer, approved in 2006), 15  
Pazopanib (GlaxoSmithKline, approved in 2009), 16   and Vandetanib (AstraZeneca, 
approved in 2011), 17   have been developed as tyrosine kinase inhibitors (TKIs) of 
vascular endothelial growth factor receptors (VEGFRs) and other related receptor 
tyrosine kinases to treat different types of cancers (Figure 1.2). Anti-angiogenic drugs 
have also been approved to treat diseases other than cancer: Ranibizumab, a fragment of 
Bevacizumab, 18  and Pegaptanib, an anti-VEGF aptamer,19 were both approved for the 
treatment of age-related macular degeneration (AMD). In addition, several drugs that 
were previously approved for unrelated purposes, like Thalidomide,20  Bortezomib,21 and 
                                                 
12 Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, 
A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar,  F.  N. Engl. J. Med. 
2004, 350, 2335–2342. 
13 Bevacizumab has since also been approved for the treatment of certain lung cancers, renal cancers, and 
glioblastoma multiforme of the brain; but its approval for the treatment of breast cancer was revoked in 
2011; its major side effects include high blood pressure and bleeding. 
14 Wilhelm, S. M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; 
Vincent,P.; McHugh, M.; Cao,Y.; Shujath,J.; Gawlak,S.; Eveleigh, D.; Rowley,B.; Liu, L.; Adnane,L.; 
Lynch, M.; Auclair, D.; Taylor, I.; Gedrich,R.; Voznesensky, A.; Riedl, B.; Post, L. E.; Bollag, G.; Trail, P. 
A. Cancer. Res. 2004, 64, 7099–7109. 
15 Roskoski, R. Jr.  Biochem. Biophys. Res. Commun. 2007, 356, 323–328. 
16 Sleijfer, S.; Ray-Coquard, I.; Papai. Z.; Le Cesne, A.; Scurr, M.; Schöffski, P.; Collin, F.; Pandite, L.; 
Marreaud, S.; De Brauwer, A.; van Glabbeke, M.; Verweij, J.; Blay, J. Y. J. Clin. Oncol. 2009, 27, 3126–
3132. 
17 Herbst, R. S.; Heymach, J. V.; O’Reilly, M. S.; Onn, A.; Ryan, A. J.  Expert Opin. Investig. Drugs 2007, 
16, 239–249. 
18 Ranieri, G.; Patruno, R.; Ruggieri, E.; Montemurro, S.; Valerio, P.; Ribatti, D. Curr. Med. Chem. 2006, 
13, 1845−1857. 
19 Ng, E. W. M.; Shima, D. T.; Calias, R.; Cunningham, E. T. Jr.; Guyer D. R.; Adamis, A. P. Nat. Rev. 
Drug Discovery 2006, 5, 123−132. 
20 Thalidomide was used to treat morning sickness in the late 1950s but was later withdrawn as it caused 
severe birth defects; in 2006, thalidomide was approved by the FDA to treat multiple myeloma in 
combination with dexamethasone: Weber, D.; Rankin, K.; Gavino, M.; Delasalle, K.; Alexanian, R. J. Clin. 
Oncol. 2003, 21, 16–19. 
21 Bortezomib was initially approved as a protease inhibitor but later identified to have potent 
antiangiogenic activity: Yasui, H.; Hideshima, T.; Richardson, P. G.; Anderson, K. C. Curr. Pharm. 
Biotechnol. 2006, 7, 381–393. 
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Celecoxib,22  were found to also have potent anti-angiogenic effects. To date, no fewer 
than 14 anti-angiogenic-related drugs have been approved in the United States, along 
with more than 30 anti-angiogenic drug candidates in clinical trials.23 
 
Figure 1.2 Selected FDA Approved Small Molecule Entities with Anti-angiogenic Effect. 
 
 
The potent and selective inhibition of cortistatins against HUVECs made them 
promising lead compounds for anti-angiogenic therapeutics; yet the molecular 
mechanism of cortistatins of inhibiting angiogenesis remains unclear to date. Kobayashi 
and co-workers observed an unidentified 110 kDa protein whose phosphorylation was 
inhibited by the treatment of cortistatin A.3   In collaboration with Amgen, the 
Nicolaou−Chen group used an activity-based kinase profiling assay and screened 359 
                                                 
22 Celecoxib was developed as a cyclooxygenase-2 enzyme (COX-2) inhibitor and also identified to possess 
anti-angiogenic properties: Greene, A. K.; Alwayn, I. P.; Nose, V. Ann. Surg. 2005, 242, 140–146. 
23 Li, W. W.; Li, V. W.; Hutnik, M.; Chiou, A. S. J. Oncology 2012, Article ID 879623, 1−23. 
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kinases in vitro.24  The top four putative targets identified in the study were ROCK I, 
ROCK II, CDK8, and CDK 11, with CDK8 and CDK11 having binding constants (Kd 
values of 10 nM and 17 nM respectively) in the same range of the IC50 of cortstatin A in 
HUVECs.  They further conducted homology modeling and suggested that cortistatin A 
might bind to the kinase hinge region through its isoquinoline substituent, with its polar 
A-ring exposing to solvent. 
The hypothesis that the isoquinoline ring is essential for the cortistatin activity, 
while the ABC-ring part could tolerate certain degrees of modifications is consistent with 
the preliminary structure-activity relationship (SAR) data obtained from natural 
cortistatins as well as several synthetic cortistatin analogs (Figure 1.3). The  Kobayashi 
group found that with different oxidation states at C16 and C17, cortistatin B (2), C (3), 
and D (4) exhibited different degrees of reduced activities in comparison with cortistatin 
A (1); and cortistatin E (5), G (7), and H (8), which share the same ABC-ring substitution 
pattern as cortistatin K (10) but do not possess the C17 isoquinoline substituent, lost most 
of their activities; in contrast, cortistatin A (1), J (9), K (10), and L (11), which contain 
the same D-ring pattern but are different in the ABC ring functionality, had similar low 
nano-molar activities against HUVECs.1,3 The Baran group reported that Δ16-cortistatin A 
(12) is almost as active as cortistatin A (1), while C17-epi-cortistatin A (13), with an 
inverse stereochemistry at C17 isoquinoline moiety, is 500-fold less active.25  In addition, 
a late-stage synthetic intermediate 14 reported by the Nicolaou−Chen group, which lacks 
the C3 dimethylamino group and A-ring hydroxyl groups but has the C17 isoquinoline 
                                                 
24 Cee, V. J.; Chen, D. Y. K.; Lee, M. R.; Nicolaou, K. C. Angew. Chem., Int. Ed. 2009, 48, 8952−8957. 
25 Shi, J.; Shigehisa, H.; Guerrero, C. A.; Shenvi, R. A.; Li, C. C.; Baran, P. S. Angew. Chem., Int. Ed. 
2009, 48, 4328−4331. 
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substituent installed, retained the potency of cortistatins;26 an estrone-derived cortistatin 
analog 15 synthesized by the Corey group, 27  and a simplified cortistatin analog 16 
prepared in the Kobayashi group, 28  both lacking the oxabicyclo[3.2.1]octene core 
structure but keeping the isoquinoline appendage, also exhibited good  GI50 values 
against HUVECs.  
 
Figure 1.3 GI50 Values against HUVECs of Selected Natural Cortistatins and Synthetic 
Cortistatin Analogs. 
 
                                                 
26 Nicolaou, K. C.; Peng, X. S.; Sun, Y. P.; Polet, D.; Zou, B.; Lim, C. S.; Chen, D. Y. K. J. Am. Chem. 
Soc. 2009, 131, 10587−10597. 
27 Czakó, B.; Kürti, L.; Mammoto, A.; Ingber, D. E.; Corey, E. J. J. Am. Chem. Soc. 2009, 131, 9014−9019. 
28 Kobayashi, M.; Kotoku, N. patent no.: WO/2012/036287. 
 9 
 
Synthetic Approaches towards the Cortistatins 
 
The remarkable biological profile, the unique molecular architecture, and the 
scarce of cortistatins (as the isolation chemists were also pursuing a total synthesis of 
cortistatins, see below) have attracted enormous efforts towards the synthesis of this class 
of natural products during the past few years. To date, five research groups (including our 
own laboratory) have accomplished the synthesis of cortistatin A, and four have finished 
synthesizing cortistatin J. In addition, at least two formal syntheses of cortistatins have 
been reported, along with numerous synthetic studies towards the cortistatin pentacyclic 
core structure.29,30 
In early 2008, the Baran group form Scripps reported the first synthesis of 
cortistatin A starting from prednisone (17) (Scheme 1.1).31,32   This inexpensive steroid 
was first converted to amide 18 in a six-step sequence. Subsequent Mukaiyama hydration 
was followed by a couple protection group manipulations to afford orthoamide 19. The 
C19 angular methyl group was then selectively bis-brominated by an in situ generated 
acetoxy hypobromite (AcOBr) from bromine and bisacetoxyiodobenzene, and the C2 free 
alcohol was protected, providing β-keto dibromide 20. Treating this bromide with 1,8-
                                                 
29 For two reviews, see: (a) Nising, C. F.; Brase, S.  Angew. Chem., Int. Ed. 2008, 47, 9389−9391; (b) Chen, 
D. Y.-K.; Tseng, C.-C.; Org. Biomol. Chem. 2010, 8, 2900−2911. 
30 Due to the limitation of this thesis, only several representative synthetic strategies towards cortistatins 
were selected and presented here, for additional references, see (a) Kurti, L.; Czako, B.; Corey, E. J. Org. 
Lett. 2008, 10, 5247−5250.  (b) Kotoku, N.; Sumii, Y.; Hayashi, T.; Kobayashi, M. Tetrahedron Lett. 2008, 
49, 7078−7081. (c) Sato, Y.; Kamiyama, H.; Usui, T.; Saito, T.; Osada, H.; Kuwahara, S.; Kiyota, H. 
Biosci. Biotechnol. Biochem. 2008, 72, 2992−2997.  (d) Craft, D. T.; Gung, B. W. Tetrahedron Lett. 2008, 
49, 5931−5934 (e) Dai, M. J.; Wang, Z.; Danishefsky, S. J. Tetrahedron Lett. 2008, 49, 6613−6616;   (f) 
Dai, M. J.; Danishefsky, S. J. Heterocycles 2009, 77, 157−161. (g) Gung, B. W.; Craft, D. T. Tetrahedron 
Lett. 2009, 50, 2685−2687; see also  reference 25, reference 27 and reference 28. 
31 Shenvi, R. A.; Guerrero, C. A.; Shi, J.; Li, C.-C.; Baran, P. S. J. Am. Chem. Soc. 2008, 130, 7241−7243. 
32 For a later report in which the route was further optimized and scaled up, see: Shi, J.; Manolikakes, G.; 
Yeh, C.-H.; Guerrero, C. A.; Shenvi, R. A.; Shigehisa, H.; Baran, P. S. J. Am. Chem. Soc. 2011, 133, 
8014−8027. 
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diazabicycloundec-7-ene (DBU) gave a cyclopropane intermediate, which was opened by 
exposure to samarium diiodide; the resulting samarium enolate intermediate was trapped 
with 2,4,4,6-tetrabromo-2,5-cyclohexadienone (TBCHD) to furnish bromide 21. Allylic 
bromide elimination followed by alane reduction and then deprotection afforded 
intermediate 22, setting the stage ready for the C5,C8 oxa-bridge closure. Bismuth(III) 
chloride was found to be an optimal Lewis acid which also effected deketalization after 
heating with water to afford cortistatinone 23.32 This ketone was converted to a vinyl 
iodide by Barton’s method via a hydrazone and then cross-coupled with 7- 
 
 
Scheme 1.1 Baran’s Synthesis of Cortistatin A. 
 
 
Reagents and conditions: (a) BH3•THF; NaIO4, acetone−H2O, 0→23 °C; (b) ethylene glycol, p-
TsOH•H2O, PhCH3, 110 °C, 92% (2 steps); (c) t-BuO2H, DBU, THF, 23 °C, 72 h, 82%; (d) NH4OAc, 
Na(BH3)CN, CH3OH, THF, 23 °C; then HCO2Et, Et3N, 54 °C, 73%; (e) TBAA, Co(acac)2, PhH, 90 °C, 
48%; (f) Co(acac)2, PhSiH3, O2, THF, HC(OCH3)3, 23 °C; then TsOH•H2O, 23 ºC; then K2CO3, CH3OH, 
65%; (g) PhI(OAc)2, Br2, CH2Cl2, −30 °C; then TMSCl, imidazole, 0 °C, 57%; (h) DBU, LiCl, THF, 23 °C, 
85%; (i) SmI2, DMPU−THF (1:9), 23 °C; then TBCHD, 23 °C; (j) LiBr, Li2CO3, DMF, 80 °C, 65% (2 
steps); (k) AlH3, THF, 23 °C; then K2CO3, CH3OH, 23 °C, 85%; (l) BiCl3, CH3CN, 40°C; then water , 40°C, 
73%; (m) N2H4, Et3N, EtOH, 50 °C; (n) I2, Et3N, THF; (o) 7-(trimethylstannyl)isoquinoline, Pd(PPh3)4, 
CuCl, LiCl, DMSO, 23 °C, 53% (3 steps); (p) Raney Ni, i-PrOH, H2O, 50 °C, 25% (50% brsm). 
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-(trimethylstannyl)isoquinoline. Finally, the trisubstituted olefin in Δ16-cortistatin A (12) 
was reduced with Raney Nickel to complete the semi-synthesis of cortistatin A (1). 
A couple months later, the Nicolaou−Chen group in Singapore completed the 
second synthesis of cortistatin A;33   and in 2009, the same group reported the first 
synthesis of cortistatin J (Scheme 1.2).26  Commencing from a known α-methylene 
ketone 24 prepared in five steps from Hajos-Parrish ketone, dihydroxylation, diol 
protection, and triflation gave intermediate 25, which was elaborated to aldehyde 26 in 
another five steps. Subsequent acetylene formation and Sonogashira coupling provided 
alkyne 27, the thioketal in which was cleaved and the triple bond hydrogenated, affording 
aldehyde 28. An impressive oxa-Michael–Aldol–dehydration cascade reaction was 
subsequently accomplished by heating a solution of 28 with potassium carbonate in 
dioxane at 125°C to provide cortistatin core structure 29. The C1 ketone was then 
temporally ketalized and the C17 tert-butyldimethylsilyl ether group was removed and 
oxidized to give ketone 30.  The isoquinoline substituent was incorporated at this stage 
by converting the C17 ketone to a vinyl triflate and Suzuki−Miyaura coupling with 7-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinoline. Selective hydrogenation of the 
C16,C17 tri-substituted olefin was achieved after deprotection of the C-1 ketal. The 
resulting ketone 14 underwent Saegusa desaturation and nucleophilic epoxidation to 
afford keto epoxide 31, which was reduced under Luche conditions to give a 1:1 mixture 
of diastereomers 32 and 33. 32 was treated with dimethylamine in the presence of 
titanium tetraisopropoxide to effect nucleophilic epoxide opening to afford cortistatin A 
(1); while 33 was converted to cortistatin J (9) in three steps: the epoxide was opened 
                                                 
33 Nicolaou, K. C.; Sun, Y. P.; Peng, X. S.; Polet, D.; Chen, D. Y. K. Angew. Chem., Int. Ed. 2008, 47, 
7310−7313. 
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with dimethylamine in the presence of titanium tetraisopropoxide, the resulting cis-diol 
product was converted to a thiocarbonate and then eliminated with Corey−Winter’s 
conditions. 
 
Scheme 1.2 Nicolaou−Chen’s Synthesis of Cortistatin A and Cortistatin J. 
 
Reagents and conditions: (a) OsO4, NMO, acetone−H2O, 73%; (b) (CH3)2C(OCH3)2, p-TsOH, acetone, 
87%; (c) NaHMDS, PhNTf2, THF, 0 °C; (d) Pd(PPh3)4, Et3N, CO, DMF–CH3OH, 70 °C, 72% (2 steps); (e) 
DIBAL-H, PhCH3, −78 °C, 79%; (f) DMP, NaHCO3, CH2Cl2, 23 °C, 86%; (g) HS(CH2)3SH, BF3•OEt2, 
CH2Cl2, −78°C, 70%; (h) SO3•Py, Et3N, CH2Cl2−DMSO, 72%; (i) p-TsN3, dimethyl-2-oxopropyl-
phosphonate, K2CO3, CH3CN, CH3OH−THF−CH3CN, 45% (2 cycles); (j) Pd(PPh3)4, CuI, Et3N, 3-
oxocyclohex-1-enyl trifluoromethanesulfonate, DMF, 85%; (k) IBX, DMSO, 0→23 °C, 81%; (l) 
Pd/BaSO4, H2, CH3OH−THF (1:1), 64%; (m) K2CO3, dioxane, 125 °C, 52%; (n) TMSO(CH2)2OTMS, 
TMSOTf, CH2Cl2, −60→ −10 °C; (o) TBAF, THF, 56% (2 steps); (p) SO3•Py, Et3N, CH2Cl2−DMSO, 80%; 
(q) KHMDS, THF, −78 °C, then PhNTf2; (r) 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinoline, 
Pd(PPh3)4, K2CO3, THF, 80 °C, 50% (2 steps); (s) p-TsOH, acetone−H2O, 88%; t) Pd/C, H2, CH3OH, 23 
°C, 50%; (u) TMSOTf , Et3N, THF, −78→0 °C; (v) IBX•MPO, DMSO, 23 ºC, 6 h, 46% (2 steps); (w) t-
BuO2H, DBU, CH2Cl2, 0→23 °C, 70%; (x) NaBH4, CeCl3, CH3OH, 0 °C, 80% (1:1 mixture of 
diastereomers 32 and 33); (y) (CH3)2NH, Ti(O-i-Pr)4, THF, 80 °C, 45%; (z) (CH3)2NH, Ti(O-i-Pr)4, THF, 
80 °C, 60%; (a’)  thiocarbonyl diimidazole, PhCH3, 110 °C, 81%; (b’) P(OEt)3, 160 °C, 40%. 
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Scheme 1.3 Shair’s Synthesis of Cortistatin A. 
 
Reagents and conditions: (a) NaH, DMSO, 2-(2-bromoethyl)-2-methyl-1,3-dioxolane, 23 °C, 63%; (b) 
TBSOTf, 2,6-lutidine, CH2Cl2, 0 °C; (c) H2, Pd/C, EtOAc, 23 °C; (d) m-CPBA, NaHCO3, PhCH3, −10 °C; 
then HF, THF−PhCH3, 0 °C, 66% (4 steps); (e) MEMCl, i-PrNEt2, 1,2-dichloroethane, 80 °C, 88%; (f) 
PPTS, acetone−water, 60 °C; (g) NaOCH3, CH3OH, 70 °C, 49% (2 steps); (h) SOCl2, pyridine, CH2Cl2, 
−10 °C; (i) NaHMDS, −78 °C, PhNTf2, 0 °C; (j) CH3(O-i-Pr)2SiCH2MgCl (37), Pd(PPh3)4, THF, 62% (3 
steps); (k) CHBr3, KO-t-Bu, hexane, 0 °C; (l) TASF, DMF, 80 °C, 66% (2 steps); (m) TESOCH2CH=CH-
B(pin), Pd(PPh3)4, K2CO3, THF−H2O, 80 °C, 84%; (n) K2OsO4•2H2O, (DHQD)2PHAL, K3Fe(CN)6, 
K2CO3, CH3SO2NH2, t-BuOH−H2O, 0 °C; (o) Ac2O, Et3N, DMAP, CH2Cl2, 51% (2 steps); (p) HF•Py, 
THF; DMP, CH2Cl2; (q) (CH3)2NH, ZnBr2, CH3CN, 50 °C, 65% (3 steps); (r) TBAF, THF, 70 °C, 70%; (s) 
TPAP, NMO, CH2Cl2, 100%; (t) K2CO3, CH3OH, 82%; (u) N2H4•H2O, Et3N, EtOH, 80 °C; Et3N, I2, THF; 
(v) Pd(PPh3)4, 7-(trimethylstannyl)isoquinoline, LiCl, CuCl, DMSO, 60 °C, 61% (3 steps); (w) 2,4,6-
triisopropylbenzenesulfonylhydrazide, Et3N, THF, 60 °C, 20%. 
 
In the fall of 2008, the Shair group at Harvard reported the third synthesis of 
cortistatin A (Scheme 1.3).34  In the Shair synthesis, known enone 34 was alkylated with 
2-(2-bromoethyl)-2-methyl-1,3-dioxolane and  then  converted  to  an extended silyl  enol  
ether; subsequent hydrogenation and Rubottom oxidation afforded tertiary alcohol 35.  
This alcohol was converted to ketone 36 in four steps (including methoxyethoxymethyl 
ether protection, deketalization, aldol reaction and dehydration), which was further 
transformed to an extended enol triflate and then cross-coupled with a Grignard reagent 
                                                 
34 Lee, H. M.; Nieto-Oberhuber, C.; Shair, M. D. J. Am. Chem. Soc. 2008, 130, 16864−16866. 
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37 to give allylsilane 38. Cyclopropane formation with dibromocarbene followed by its 
opening trigged by tris(dimethylamino)sulfonium difluorotrimethylsilicate (TASF) 
furnished vinyl bromide 39.  Another palladium catalyzed cross-coupling, then selective 
Sharpless dihydroxylation and a couple functional group manipulations afforded 
aldehyde 40. In the subsequent key step, a remarkable tandem aza-Prins-transannular 
etherification cascade was realized by heating aldehyde 40 with dimethylamine in the 
presence of zinc bromide, to provide compound 41 with a full cortistatin A ABC-ring 
skeleton. The C-17 tert-butyldimethylsilyl ether group was then cleaved and the 
secondary alcohol was oxidized; after deacetylation, the same cortistatinone 23 reported 
by the Baran group was obtained.31  The isoquinoline appendage was then introduced by 
a similar Stille coupling between the 23-derived vinyl iodide and 7-(trimethylstannyl)-
isoquinoline to provide Δ16-cortistatin A (12). Finally, diimide reduction of 12 afforded 
the natural product cortistatin A (1). 
In 2011, the Hirama group from Tohoku University finished the total synthesis of 
cortistatin A and cortistatin J (Scheme 1.4).35,36  Starting from enone 34, alkylation, 
nickel boride reduction and Saegusa reaction provided intermediate 42, which was 
converted to aldehyde 43 in four straightforward steps. In the subsequent key step, 
Knoevenagel condensation of 43 with cyclo-hexane-1,3-dione was followed by a tandem 
6π-electrocyclization to afford intermediate 44. C6 tert-butyldimethylsilyl ether was then 
selectively removed and the primary alcohol product was converted to iodide 45. A 
radical cyclization initiated with triethylborane and oxygen closed the C6,C7 carbon 
                                                 
35 Yamashita, S.; Iso, K.; Kitajima, K.; Himuro, M.; Hirama, M. J. Org. Chem. 2011, 76, 2408−2425. 
36 For two earlier synthetic studies reported by the Hirama group, see: (a) Yamashita, S.; Iso, K.; Hirama, 
M. Org. Lett. 2008, 10, 3413−3415; (b) Yamashita, S.; Kitajima, K.; Iso, K.; Hirama, M. Tetrahedron Lett. 
2009, 50, 3277−3279. 
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bridge, affording the Nicolaou−Chen intermediate 29.33 29 was then transformed to 
ketone 30, and the isoquinoline ring was introduced to C17 ketone of 30 by the addition 
of an organocerium reagent derived from 1-chloro-7-iodoisoquinoline (46). The addition 
product 47 underwent radical deoxygenation via its 17-O-thiocarbamate to give 
intermediate 48 with C1'-chloride dehalogenated in the same operation. Deketalization 
 
Scheme 1.4 Hirama’s Synthesis of Cortistatin A and Cortistatin J. 
 
Reagents and conditions: (a) NaH, TBSOCH2CH2I, DMSO−THF, 23 °C, 53%; (b) NiCl2•6H2O, NaBH4, 
CH3OH, −70 °C, 60%; (c) TMSCl, HN(TMS)2, NaI, CH3CN, 23 °C; (d) Pd(OAc)2, CH3CN, 23 °C, 90% (2 
steps); (e) Tf2O, LDA, THF, −100→−90 °C, 95%; (f) Pd(PPh3)4, CO, Et3N, CH3OH−DMF, 55 °C, 90%; 
(g) DIBAL-H, PhCH3, −78 °C; (h) DMP, NaHCO3, CH2Cl2, 23 °C, 85% (2 steps); (i) cyclohexane-1,3-
dione, piperdine, EtOAc, 23 °C, 87%, 5:1 dr; (j) HF•Py, THF, 23 °C; (k) I2, PPh3, imidazole, THF, 23 °C, 
87% (2 steps); (l) Et3B, (TMS)3SiH, THF, −78 °C, 78%. (m) TMSO(CH2)2OTMS, TMSOTf, CH2Cl2, 
−60→ −20 °C; (n) TBAF, THF, 0 ºC; (o) DMP, NaHCO3, CH2Cl2, 23 ºC, 73% (3 steps); (p) n-BuLi, CeCl3, 
isoquinoline 46, THF, −78 ºC, 99%; (q) KH, PhNCS, THF, 23 ºC; (r) AIBN, Bu3SnH, PhCH3, 90 ºC, 74% 
(2 steps);  (s) TsOH•H2O, acetone−H2O, 71%. (t) LDA, Ph(Cl)S=Nt-Bu, THF, −78 ºC, 80%; (u) t-BuO2H, 
DBU, CH2Cl2, 0→23 °C, 75%; (v) NaBH4, CeCl3, CH3OH, 0 °C, 51%; (w) (CH3)2NH, Yb(OTf)3, THF, 80 
°C, 48%; (x) (CH3)2NH, THF, 23 °C; (y) LiAlH4, ether, 0 °C, 60% (two steps); (z) MsCl, Et3N, THF, 0 °C; 
DBU, 23 °C, 42%. 
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and Mukaiyama unsaturation provided enone 49, which was converted to cortistatin A (1) 
in three steps analog to the Nicolaou−Chen synthesis;33 and converted to cortistatin J (9) 
also in three steps including dimethylamine conjugate addition, LAH reduction, and 
finally mesylation and elimination of the resulting C1 allylic alcohol. 
In the summer of 2011, the Funk group from Pennsylvania State University 
reported a racemic synthesis of cortistatin J starting from furan 50 (Scheme 1.5).37 This 
furan was first metallated and added conjugatively to enone 51; the resulting enolate 
intermediate was trapped with trimethylsilyl trifluoromethanesulfonate (TMSOTf) and 
 
Scheme 1.5 Funk’s Synthesis of (±)-Cortistatin J. 
 
 
Reagents and conditions: (a) n-BuLi; AlMe3; TMSOTf, 51; (b) CH3Li; ICH2CO2CH3, 75% (two steps); (c) 
NaHMDS, PhNTf2; (d) DIBAL-H, 82% (two steps); (e) PPh3, I2; (f) 54+55; AcOH, H2O, 75%; (g) 
NaHMDS, TESCl, 94%; (h) PhCH3, 100 °C, quant.; (i) 50 mol% TfOH, CH2Cl2, −78 °C; pyridine, CH3OH, 
79%; (j) Pd(PPh3)4, 7-(trimethylstannyl)isoquinoline, LiCl, CuCl, 70%; (k) KO2N=NCO2K, AcOH, 97%; (l) 
DMSO, (COCl)2, Et3N, 81%; (m) NaH; PhNTf2, 83%; (n) Bu3SnH, Pd(PPh3)4, 70% (o) LiHMDS, HMPA, 
PhNTf2, 81%;  (p) 6N HCl, 81%; (q) (Z)-TMS-CH=CH-BF3K, Cs2CO3, Pd(PPh3)4, 84%; (r) Py·SO3, 
DMSO, Et3N, 75%; (s) (CH3)2NH·HCl, CH3CN, 60 °C, 90%. 
                                                 
37 Nilson, M. G.; Funk, R. L.  J. Am. Chem. Soc. 2011, 133, 12451−12453. 
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the silyl enol ether product was subsequently converted to primary iodide 53 in a four-
step sequence (including alkylation, triflation, DIBAL-H reduction, and iodination). An 
azaenolate 54 was then alkylated with this iodide, and the resulting alkylation product 
underwent triethylsilyation formation and thermal retro-cycloadditon to afford 
intermediate 55. A key [4+3] cycloaddition to construct the cortistatin core 
oxabicyclo[3.2.1]octene structure was triggered by treating a solution of 55 in 
dichloromethane with trflic acid (0.5 equiv) at −78°C, affording intermediate 56 in good 
yield. The isoquinoline moiety was then introduced by Stille cross-coupling with 7-
(trimethylstannyl)isoquinoline, and a global diimide reduction afforded tetrahydrofuran 
57.  Swern oxidation, triflation, and palladium catalyzed triflate reduction with 
ammonium formate provided enone 58. This enone underwent another triflation, then 
Suzuki−Miyaura coupling, and a couple functional group manipulations to provide 
aldehyde 59 with a (Z)-vinyl silane installed. Finally, a solution of aldehyde 59 in 
acetonitrile was treated with excess dimethylamine hydrochloride at 60°C to effect a 
stereoselective A-ring closure, affording (±)-cortistatin J (9) as a single diastereomer. 
The Sarpong group at Berkeley completed a formal synthesis of racemic 
cortistatins in 2010 (Scheme 1.6).38   Starting from aldol condensation between indanone 
60 and aldehyde 61, reduction and subsequent elimination afforded indene 62. This 
indene underwent a platinum dichloride catalyzed enyne cycloisomerization, a 
methodology previously developed in the Sarpong group, affording diene 63.  The C6,C7 
disubstituted double bond in 63 was then selectively reduced under diimide reduction 
conditions to give 64; the remaining tetra-substituted olefin was epoxidized with sodium 
                                                 
38 (a) Simmons, E. M.; Hardin-Narayan, A. R.; Guo, X.; Sarpong, R. Tetrahedron, 2010, 66, 4696−4700 
(b)Simmons, E. M.; Hardin, A. R.; Guo, X.; Sarpong, R. Angew. Chem., Int. Ed. 2008, 47, 6650−6653. 
 18 
 
bicarbonate neutralized 3-chloroperoxybenzoic acid (mCPBA), and the epoxide product 
was eliminatively opened with n-butyllithium at the benzylic position to afford allylic 
alcohol 65 (obtained after a couple protection group manipulations). This phenol 65 was 
subsequently oxidatively cyclized by exposure to bisacetoxyiodobenzene, a hypervalent 
iodine reagent, to provide cortistatin core structure 66. Selective epoxidation of C9,C19 
trisubstituted olefin was followed by acidic opening of the epoxide product and then 
elimination of the resulting C9 allylic alcohol, affording diene 67. The C2 enone was then 
reduced under Luche conditions and temporarily protected; a palladium catalyzed, 
ammonium formate promoted reduction and rearrangement provided intermediate 68. 
Finally, hydrogenation and isomerization afforded Nicolaou−Chen’s intermediate 29.33 
 
Scheme 1.6 Sarpong’s Formal Synthesis of (±)-Cortistatins. 
 
 
Reagents and conditions: (a) KOH, EtOH−CH2Cl2, 76%; (b) K-Selectride, THF, −78→23 °C; (c) NaBH4, 
CH3OH−CH2Cl2, 0 °C; (d) KHSO4, PhCH3, 50 °C, 67% (3 steps); (e) PtCl2, PhH, 50 °C, 82%; (f) 
TsNHNH2, Et3N, 1,2-DCE, 65 °C, (2 cycles); (g) Na/naphthalene, DME, 23 °C, 77% (2 steps); (h) TESCl, 
imidazole, DMF, 23 °C; (i) m-CPBA, NaHCO3, CH2Cl2, 0 °C, 53% (2 steps); (j) n-BuLi, THF, 0 °C; (k) 
PhI(OAc)2, CH2Cl2−i-PrOH−TFE, −78 °C, 57% (2 steps). (l) m-CPBA, NaHCO3, CH2Cl2, 0°C; (m) CSA, 
CH2Cl2-CH3OH, 0 °C; (n) TFAA, DMAP, DCE-Et3N, 23→60°C , 58% (three steps); (o) NaBH4, CeCl3, 
CH3OH, 0 °C ; (p) (BocO)2O, DMAP, DCE, 40 °C, 69% (two steps); (q) Pd(dppf)Cl2, NH4CO2H, 
23→60°C;(r) H2 (100 psi), Rh(PPh3)3Cl, PhH; (s) 1% aq HCl, THF, 0→23°C, 77% (three steps). 
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The Yang-Li group from Peking University also reported a formal synthesis of 
cortistatins in early 2011 (Scheme 1.7).39 Enone 34 was first alkylated with iodide 69 to 
provide intermediate 70, which was subsequently transformed to alkyne 71 in five steps. 
An intramolecular furan Diels−Alder reaction was catalyzed by ethylaluminium 
dichloride to forge the 7-membered B ring, providing phenol product 72. The C14,C15 
double bond was then selectively hydrogenated, and a tertiary hydroxyl group was 
introduced at C5 with modest diastereoselectivity by bisacetoxyiodobenzene promoted 
oxidative dearomatization of A-ring phenol in the presence of water, affording dienone 
intermediate 73. Finally, sodium acetate triggered oxa-Michael addition, selective 
reduction of C19 ketone, and subsequent mesylation and elimination of the C19 allylic 
alcohol product furnished Myers’ intermediate 74.40 
 
Scheme 1.7 Yang-Li’s Formal Synthesis of Cortistatins. 
 
 
Reagents and conditions: (a) NaH, 69, DMSO, 46%; (b) collidine, Tf2O; (c) Pd(OAc)2, PPh3, CO, CH3OH, 
76% (two steps); (d) DIBAL-H, −78 °C, 90%; (e) MnO2, CH2Cl2, 94%; (f) TMSC≡CH, n-BuLi, THF, 
−78°C, 95%; (g) MnO2, CH2Cl2, 91%; (h) EtAlCl2, CH2Cl2, −78→0 °C, 51%; (i) Pd/BaSO4, H2 (1 atm), 
60%; (j) BAIB, CH3CN-H2O, 60%,  73:5-epi-73 = 1:1.5; (k) NaOAc·3H2O, EtOH, 50°C, 70%; (l) LiBHEt3, 
THF, −78 °C; (m) MsCl, Et3N, DMAP, CH2Cl2; (n) LiBr, Li2CO3, DMF, 100°C, 28% (three steps). 
                                                 
39 (a) Fang, L.; Chen, Y.; Huang, J.; Liu, L.; Quan, J.; Li, C.-C.; Yang, Z. J. Org. Chem. 2011, 76, 
2479−2487; (b) Liu, L. Z.; Gao, Y. X.; Che, C.; Wu, N.; Wang, D. Z.; Li, C. C.; Yang, Z. Chem. Commun. 
2009, 662−664. 
40 Flyer, A. N.; Si, C.; Myers, A. G. Nature Chemistry 2010, 2, 886–892. 
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Scheme 1.8 Danishefsky’s Approach to Cortistatins via a Sniekus Reaction Cascade. 
 
 
Reagents and conditions: (a) t-BuLi, 76, Et2O, −78 °C, then 130 °C, 50%, 80 : C8-epi-80 = 1 : 10; (b) 
192→198 °C, 80 : C8-epi-80 = 2.3 : 1; (c) I2, CH3OH, 54%; (d) TsCl, Py, DMAP, CH2Cl2, 0→23 °C, 95%; 
(e) TBAF, THF, 70 °C, 94%. 
 
The Danishefsky group developed two different strategies to construct the 
cortistatin core structure30e,f and the approach via a Sniekus reaction initiated cascade is 
presented here (Scheme 1.8).41  Lithiated aryl bromide 75 added to aldehyde 76 at −78 °C 
to form intermediate 77; the crude reaction mixture was then heated to 130 °C to trigger a 
Sniekus rearrangement; the C19 carbamate of the resulting intermediate 78 was believed 
to eliminate at this temperature and the resulting o-quinonemethide 79 underwent a 
tandem 6π-electrocyclization to afford 2H-pyran 80. The C8-epi isomer which dominated 
in the product mixture, was mostly epimerized to the desired isomer by heating at 
192−198 °C. Selective desilyation and tosylation at C6 provided compound 81, which 
was alkylatively dearomatized by the treatment with tetra-n-butylammonium fluoride in 
                                                 
41 (a) Wang, Z.; Dai, M. J.; Park, P. K.; Danishefsky, S. J. Tetrahedron 2011, 67, 10249−10260; (b) Dai, M. 
J.; Danishefsky, S. J. Tetrahedron Lett. 2008, 49, 6610−6612. 
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refluxing tetrahydrofuran, affording cortistatin core structure 82. This enone was then 
elaborated to 83 in a couple of steps, which possessed a fully functionalized cortistatin A 
ABC-ring system. 
The Magnus group developed an efficient approach to (±)-cortistatin BCD rings 
commencing from Lewis acid promoted addition of 2-methylfuran to enone 51 (Scheme 
1.9).42  The addition product was then converted to aldehyde 84 in a couple of steps. 
Cyclopropenyllithium 85 added to this aldehyde at −50 °C; upon warming the reaction 
mixture to 23 °C, a cyclopropene-furan [2+4] cycloaddition proceeded to afford 
compound 86 as a 1:1 mixture of diastereomers at C10. Hydrogenation of C6,C7 olefin 
with Adam’s catalyst followed by cyclopropylcarbinyl rearrangement triggered by 
triflation of the C10 hydroxyl group provided compound 87 in good yield with a 
cortistatin BCD-ring skeleton.  
 
Scheme 1.9 Magnus’s Approach to (±)-Cortistatin BCD Rings via Cyclopropene-Furan 
[2+4] Cycloaddition followed by Cyclopropylcarbinyl Rearrangement.  
 
Reagents and conditions: (a) 85, −50→23 °C, 85%, 1:1 dr at C-10; (b) H2, PtO2·H2O, THF-EtOH, AcOH 
(cat.), 98%; (c) Tf2O, DTBMP, CH2Cl2,  0→23 °C, 70%. 
 
The Sorensen synthesis started from a [3+2] dipolar cycloaddition of nitrone 88 
and α-methylene ketone 24, and the addition product was transformed to oxime 89 in a 
                                                 
42 Magnus, P.; Littich, R. Org. Lett. 2009, 11, 3938−3941. 
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couple of steps (Scheme 1.10).43  Upon treatment of a solution 89 in trifluoroethanol with 
bisacetoxyiodobenzene at 23 °C, the phenol underwent oxidative dearomatization to form 
the C5,C8 oxa-bridge and the oxime was also oxidized to give nitrile oxide  90; when this 
crude reaction mixture was further  heated to 50 °C, an intramolecular [3+2] dipolar 
cycloaddition proceeded,  yielding compound 91 with the cortistatin pentacyclic core 
structure. 
 
Scheme 1.10 Sorensen’s Approach to Cortistatin Core Structure via Hypervalent Iodine-
Induced Double Annulation. 
 
Reagents and conditions: (a) PhI(OAc)2, CF3CH2OH, 23 °C; then 50 °C, 80%. 
 
The Stoltz group approached the pentacyclic cortistatin core structure using a 
cascade enyne-ene metathesis strategy (Scheme 1.11).44  Lithiated iodide 92 was added to 
ketone 93, affording a tertiary alcohol 94 after desilyation. The C5,C8 oxa-bridge was 
constructed by a magnesium bromide catalyzed SN2' reaction, providing tetrahydrofuran 
95 and 96 as a 1:1 mixture of diastereomers at the C5 position. When this mixture was 
subjected to Grubbs second-generation catalyst, the desired diastereomer 95 underwent 
the expected enyne-ene metathesis to yield the 14-epi-cortistatin core structure 97, while 
the undesired diastereomer 96 stopped at the diene stage to afford compound 98. 
                                                 
43 Frie, J. L.; Jeffrey, C. S.; Sorensen, E. J. Org. Lett. 2009, 11, 5394−5397.  
44 Baumgartner, C.; Ma, S.; Liu, Q.; Stoltz, B. Org. Biomol. Chem. 2010, 8, 2915−2917. 
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Scheme 1.11 Stoltz’s Approach to 14-epi-Cortistatin Core via Enyne-ene Metathesis. 
 
Reagents and conditions: (a) t-BuLi, 93, Et2O-THF, −78 °C; (b) TBAF, THF, 25 °C, 77% (two steps), 94: 
8-epi-94 = 2.2 : 1; (c) DDQ, CH2Cl2-H2O, 25 °C, 75%; (d) Ac2O, pyridine, CH2Cl2, 25 °C, 94%; (e) 
MgBr2·Et2O, 2,6-DTBP, PhH-CH3CN, 80°C, 79%, 95 : 96 = 1 : 1; (f) Grubbs-II, CH2Cl2, 25 °C, 37% of 97 
and 44% of  98. 
 
 
The Zhai group constructed a racemic cortistatin core structure also starting from 
furan (Scheme 1.12).45 The core oxabicyclo[3.2.1]octene structure was constructed by an 
intermolecular [4+3] cycloaddition of 2,5-disubstituted furan 99 with 1,1,3-
trichloroacetone and then zinc-copper mediated dehalogenation to give ketone 100. 
Following bis-dihydroxylation of the two terminal olefins, hydrogenation of the 
remaining C6,C7 double bond, and bis-vicinal diol cleavages afforded ketodialdehyde 
101. This aldehyde then underwent a double, intramolecular aldol reaction upon treating 
with potassium carbonate to furnish the cortistatin core structure 102. 
 
Scheme 1.12 Zhai’s Approach to (±)-Cortistatin Core via Double Aldol Reaction. 
 
 
Reagents and conditions: (a) Cl2CHCOCH2Cl, Et3N, (CF3)2CHOH; (b) Zn-Cu, NH4Cl, CH3OH, 46%;  (c) 
OsO4, NMO, acetone, H2O; (d) H2, Pd/C, EtOH; (e) NaIO4, acetone, H2O, 68% (three steps); (f) K2CO3, 
CH3OH, 23 °C, 82%. 
                                                 
45 Yu, F.; Li, G.; Gao, P.; Gong, H.; Liu, Y.; Wu, Y.; Cheng. B.; Zhai, H. Org. Lett. 2010, 12, 5135−5137.  
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The Kobayashi group (the isolation chemists) also developed several different 
strategies to construct the cortistatin core structure28,30b and their intramolecular Heck 
approach is described here (Scheme 1.13).46  In this approach, the Hajos−Parrish ketone 
derived enone 103 was alkylated with primary iodide 104, and in a couple steps 
transformed to triflate 105. Intramolecular 7-endo Heck reaction was catalyzed by 
tris(dibenzylidene-acetone)dipalladium(0) and the ligand 1,3-bis(diphenylphosphino)-
propane (dppp) in the presence of cesium acetate and tetra-n-butylammoniumacetate to 
afford intermediate 106. After C5 desilyation, C10 deacetylation and oxidation, the oxa-
bridge was then constructed by acid catalyzed, intramolecular oxa-Michael addition of 
the C5 tertiary alcohol to enone at C8 position. Finally, diene 107 was obtained after 
sodium borohydride reduction of C10 ketone and then Burgess elimination of the 
resulting secondary alcohol. 
 
Scheme 1.13 Kobayashi’s Approach to Cortistatin Core via Intramolecular Heck Reaction. 
 
 
Reagents and conditions: (a) Pd2(dba)3, dppp, CsOAc, n-Bu4NOAc, DMF, 70 °C, 56%; (b) TBAF, THF, 
0 °C, 88%; (c) DIBAL, CH2Cl2, −78 °C, 94%; (c) DMP, NaHCO3, CH2Cl2, 0 °C, 81%; (e) CSA, THF, 0 °C, 
60%; (f) NaBH4, CH3OH, 0 °C, 83%; (g) Burgess’ reagent, toluene, 85 °C, 62%. 
 
                                                 
46 Kotoku, N.; Sumii, Y.; Kobayashi, M.  Org. Lett. 2011, 13, 3514−3517. 
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A Divergent Synthetic Strategy towards the Cortistatins 
 
In our synthetic planning, we wished to develop a general approach that would 
allow us to access not only different members of cortistatin natural products, but also a 
diverse array of cortistatin analogs and biological probes. We envisioned that this goal 
could be achieved by efficient preparation of a suitable key intermediate which could be 
easily diversified to different cortistatin precursors,47 and then installing the isoquinoline 
moiety at the final stage in order to maximize the possibility of diversification on this 
important ring substituent (see SAR data for details). 
With these principles in mind, we believed that the isoquinoline substituent could 
be introduced to different C17-keto cortistatin precursors 108, 109, 110, and 111 under 
suitable conditions to afford the final products (Figure 1.4). In order to access these 
different cortistatin precursors, we identified azido alcohol 112 as an appropriate 
candidate for the key intermediate: it possesses the pentacyclic core structure of 
cortistatins; the azido group at C3 provides a versatile handle for the introduction of the 
dimethylamino group in the natural cortistatins, as well as other nitrogen-containing 
functional groups in analog preparation; in addition, the C2 allylic alcohol and northern 
diene moiety should be readily transformed to obtain diverse cortistatin ABC-ring 
substitution patterns; to meet the requirements as a key intermediate, what we need would 
be to develop a robust and scalable route to prepare this azido alcohol. 
                                                 
47The Myers group has used similar principles in the preparation of a number of natural products and their 
analogs, including tetracycline,a,b,c avrainvillamide,d,e and trioxacarcins,f see: (a) Charest, M.; Lerner, C. D.; 
Brubaker, J. D.; Siegel, D. R.; Myers, A. G. Science, 2005, 308, 395–398. (b) Sun, C.; Wang, Q.; Brubaker, 
J. D.; Wright, P. M.; Lerner, C. D.; Noson, K.; Charest, M.; Siegel, D. R.; Wang, Y. M.; Myers, A. G. J. 
Am. Chem. Soc. 2008, 130, 17913–17927;(c) Wright, P. M.; Myers, A. G. Tetrahedron 2011, 67, 9853–
9869; (d) Herzon, S. B.; Myers, A. G. J. Am. Chem. Soc. 2005, 127, 5342–5344. (e) Wulff, J. E.; Siegrist, 
R.; Myers, A. G. J. Am. Chem. Soc. 2007, 129, 14444–14451; (f) Svenda, J.; Hill, N.; Myers, A. G. Proc. 
Natl. Acad. Sci. USA 2011, 108, 6709–6714. 
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Figure 1.4 Syntheses of Cortistatins by Late Stage Introduction of Isoquinoline Moiety to 
17-Keto Cortistatin Precursors Derived from a Common Key Intermediate 112. 
 
 
Retrosynthetically, this azido alcohol 112 could be derived from a 
cyclohexadienone 74 by selectively functionalizing the A-ring enone moiety (Figure 1.5). 
This cortistatin core structure 74 could be further simplified to phenol 113 by installing 
the C5,C8 oxa-bridge via oxidative dearomatization, a strategy independently conceived 
and previously demonstrated by Sarpong and coworkers, as well as others.30f,38,42  Phenol 
113 could be prepared from diene 114, and the seven-membered B-ring in 114 could be 
constructed from triene 115 by ring-closing metathesis. Triene 115 could be in turn 
assembled from a benzylzinc reagent 116 and an enol triflate 117 via Negishi cross-
coupling. Benzylzinc reagent 116 could be obtained from a known phenyl iodide 118,48 
                                                 
48 Moss, R. A.; Alwis, K. W.; Shin, J. S. J. Am. Chem. Soc. 1984, 106, 2651–2655.  
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while the enol triflate 117 could be synthesized from a known α-methylene ketone 24 
derived from Hajos-Parrish ketone. 49,50  
 
Figure 1.5 Retrosynthetic Analysis of Key Intermediate 112.  
 
 
In this thesis, Chapter 2 presents an efficient synthesis of key intermediate 112 
and diversification of this azido alcohol to different cortistatin precursors 108, 109, 110, 
and 111, representing each of the four ABC-ring substitution patterns in natural 
cortistatins; Chapter 3 details the conversion of these cortistatin 17-keto precursors to 
different cortistatin natural products as well as unnatural cortistatin analogs using a 
generally applicable isoquinoline-addition-radical-deoxygenation sequence; and Chapter 
4 describes a versatile methodology to synthesize a diverse array of substituted 
isoquinolines, allowing the preparation of cortistatin analogs with isoquinoline 
modifications.   
                                                 
49 (a) Isaacs, R. C. A.; Digrandi, M. J.; Danishefsky, S. J. J. Org. Chem. 1993, 58, 3938−3941; (b) Micheli, 
R. A.; Hojos, Z. G.; Cohen, N.; Parrish, D. R.; Portland, L. A.; Sciamanna, W.; Scott, M. A.; Wehrli, P. A. 
J. Org. Chem. 1975, 40, 675−681. 
50 This α-methylene ketone  24 was also used by the  Nicolaou group and the Sorensen group independently 
in the synthesis of cortistatins: see: Ref 33 and Ref 43. 
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Chapter 2 
Synthesis of Cortistatin Precursors from a Common Key Intermediate 
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Introduction 
 
As outlined in Chapter 1, this chapter presents an efficient synthesis of the azido 
alcohol 112 as the key intermediate on gram quantities starting from A-ring precursor 
118 and CD-ring precursor 24 (Figure 2.1). This key intermediate was subsequently 
converted to different cortistatin 17-keto precursors 108, 109, 110, and 111, representing 
all four natural cortistatin ABC-ring substitution patterns.  
 
 
Figure 2.1 Converting Key Intermediate 112 to Different Cortistatin Precursors. 
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Synthesis of the Key Intermediate Azido Alcohol  
 
Graduate student Dr. Alec Flyer developed an efficient synthesis of the cortistatin 
core structure 74 (Scheme 2.1).1  I was able to further optimize and scale up this route to 
produce this cyclohexadienone on gram quantities. Benzyl bromide 119 was prepared in 
amounts up to 47 g by a straightforward five-step sequence [including methylation, 
phenol protection, Negishi cross-coupling, diisobutylaluminium hydride (DIBAL-H) 
reduction, and bromination] from a known phenyl iodide 118,2 and then transformed to 
the o-vinyl benzylzinc reagent 116 by magnesium insertion and transmetallation with 
zinc chloride.  Meanwhile, a known α-methylene ketone 24 3 , 4   was subjected to a 
phosphorniosilylation-Wittig reaction sequence to afford the α-vinyl triethylsilyl enol 
ether 120,5  which was then converted to enol triflate coupling partner 117 on a 15-g 
scale by using Corey’s triflation conditions.6  
Coupling of the enol triflate 117 with the benzylzinc reagent 116 was achieved in 
the presence of tris(dibenzylideneacetone)dipalladium (0.045 equiv) and the ligand 2-
dicyclohexylphosphino-2′,6′-dimethoxy-biphenyl (S-Phos, 0.18 equiv) in a mixture of N-
methylpyrrolidone, tetrahydrofuran, and ether  (the latter two from the preparation of the  
                                                 
1 For another approach to the same cyclohexadienone structure, see: Flyer, A. N. (2010) A Synthetic Route 
to Cortistatin A and L. Ph.D. thesis, Harvard University. 
2 Iodide 118 was prepared in one step from commercial available 2-amino-5-hydroxylbenzoic acid as 
reported: Moss, R. A.; Alwis, K. W.; Shin, J. S. J. Am. Chem. Soc. 1984, 106, 2651–2655. 
3 (a) Isaacs, R. C. A.; Digrandi, M. J.; Danishefsky, S. J. J. Org. Chem. 1993, 58, 3938−3941; (b) Micheli, 
R. A.; Hojos, Z. G.; Cohen, N.; Parrish, D. R.; Portland, L. A.; Sciamanna, W.; Scott, M. A.; Wehrli, P. A. 
J. Org. Chem. 1975, 40, 675−681. 
4  This α-methylene ketone 24 was also used by the Nicolaou groupa,b and the Sorensen groupc 
independently in the synthesis of cortistatins: (a) Nicolaou, K. C.; Sun, Y. P.; Peng, X. S.; Polet, D.; Chen, 
D. Y. K. Angew. Chem., Int. Ed. 2008, 47, 7310−7313. (b) Nicolaou, K. C.; Peng, X. S.; Sun, Y. P.; Polet, 
D.; Zou, B.; Lim, C. S.; Chen, D. Y. K. J. Am. Chem. Soc. 2009, 131, 10587−10597. (c) Frie, J. L.; Jeffrey, 
C. S.; Sorensen, E. J. Org. Lett. 2009, 11, 5394−5397. 
5 (a) Kozikowski, A. P.; Jung, S. H. J. Org. Chem. 1986, 51, 3400−3402;  (b) Evans, D. A.; Hurst, K. M.; 
Takacs, J. M. J. Am. Chem. Soc. 1978, 100, 3467−3477. 
6 Mi, Y.; Schreiber, J. V.; Corey, E. J. J. Am. Chem. Soc. 2002, 124, 11290−11291. 
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Scheme 2.1 Synthesis of Cortistatin Core Structure 74. 
 
 
benzylzinc reagent 116) at 70 ºC to afford triene 115 in 70% yield on a 16-g scale.7 
Warming the triene product with the second-generation Grubbs catalyst (0.025 equiv) in 
dichloromethane at 45 ºC furnished the tetracyclic diene 114;8  the crude reaction mixture 
was diluted with dichloromethane, cooled in an ice-bath and treated with a solution of 
dimethyldioxirane (DMDO) in acetone, 9  which led to a stereoselective epoxidation of 
the tetrasubstituted alkene, providing a tetracyclic diene monoepoxide 121. Without 
purification, this epoxide was hydrogenated in benzene under 500 psi hydrogen in the 
                                                 
7 Walker, S. D.; Barder, T. E.; Martinelli, J. R.; Buchwald, S. L. Angew. Chem., Int. Ed. 2004, 43, 
1871−1876. 
8 Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. Org. Lett. 1999, 1, 953−956.  
9 Murray, R. W.; Singh, M. Organic Syntheses; Wiley & Sons: New York, 1997; Vol. 74, pp 91−100. The 
procedure was slightly modified and scaled up to produce DMDO solution in acetone (typically 0.06 M) on 
liter-scale. 
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presence of Wilkinson’s catalyst (0.15 equiv) to afford epoxide 122.  The latter product 
then underwent selective eliminative opening at C19 benzylic position with lithium 
diethylamide,10 furnishing the conjugated allylic alcohol 123 in 50% yield over three 
steps. Selective removal of the phenolic triisopropylsilyl protective group with tetra-n-
butylammonium fluoride (TBAF) at 0 ºC was followed by oxidative cyclization of the 
resulting phenol 113 with [bis(trifluoroacetoxy)-iodo]benzene in a mixture of 
dichloromethane and hexafluoroisopropanol, 11   providing the cyclohexadienone core 
structure 74 in 50% yield on a 2-g scale.12  By applying this optimized procedure, over 10 
g of the cyclohexadienone 74 have been prepared to date. 
With gram-quantities of cyclohexadienone 74 in hand, the next stage was to 
functionalize the A ring to prepare the key intermediate 112. It was found that the 
disubstituted C3,C4 double bond of 74 could be selectively hydrogenated under 500 psi 
hydrogen in the presence of Wilkinson’s catalyst (0.1 equiv) to provide mono-enone 124 
in 80% yield (Scheme 2.2). This enone was converted to an extended silyl enol ether 126 
by treating with triethylsilyl trifluoromethanesulfonate (1.5 equiv) in the presence of 2,6-
lutidine (2 equiv), which was brominated in the same pot with N-bromosuccinimide 
(NBS, 2 equiv) to afford keto-bromide 125 as a single diastereomer in 75% yield. The 
exclusive axial bromination selectivity was likely due to a favorable chair-like 
conformation rather than a twisted-boat-like conformation in the transition state.13 
                                                 
10 Thummel, R. P.; Rickborn, B. Base J. Org. Chem. 1972, 37, 3919−3923. 
11 The incorporation of fluorinated solvents improves yields in phenolic oxidations: Kita, Y.; Tohma, H.; 
Kikuchi, K.; Inagaki, M.; Yakura, T. J. Org. Chem. 1991, 56, 435–438. 
12 Similar oxidative cylization strategies were also used by the Sarpong group,a,b  the Danishefsky group,c 
and the Sorensen group4c independently in the synthesis of cortistatins, see Chapter 1 for details: (a) 
Simmons, E. M.; Hardin-Narayan, A. R.; Guo, X.; Sarpong, R. Tetrahedron, 2010, 66, 4696−4700 
(b)Simmons, E. M.; Hardin, A. R.; Guo, X.; Sarpong, R. Angew. Chem., Int. Ed. 2008, 47, 6650−6653.(c) 
Dai, M. J.; Danishefsky, S. J. Heterocycles 2009, 77, 157−161. 
13 Kirby, A. J. In Stereoelectronic Effects; Oxford University Press Inc., New York, 1996; pp 59–60. 
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Scheme 2.2 Synthesis of Keto Bromide 74 by Hydrogenation and Bromination. 
 
 
The knowledge learned in the two-step synthesis of keto bromide 125 informed a 
more efficient, one-pot hydrosilylation-bromination sequence (Scheme 2.3).  After 
extensive experimentation, it was found that heating cyclohexadienone 74 with 
triethylsilane (2 equiv) in the presence of Wilkinson’s catalyst (0.05 equiv) in toluene at 
50 ºC provided the same extended triethylsilyl enol ether intermediate 126;14 without 
isolation, pyridine was added as a co-solvent (14% by volume) followed by N-
bromosuccinimide (NBS, 2 equiv), affording the (3R)-keto bromide 125, again as a single 
diastereomer, in 70% yield.  In the absence of pyridine, or with lesser quantities of 
pyridine,15 the bromination reaction was much less stereoselective, which suggested that 
Wilkinson’s catalyst might not be innocent during the bromination.   
 
Scheme 2.3 Synthesis of Keto Bromide 125 by a One-pot Hydrosilylation-Bromination.  
 
                                                 
14 Kogure, T.; Ojima, I. Organometallics 1982, 1, 1390–1399. 
15 It is known that pyridine complexed to Wilkinson’s catalyst and reduced its hydrogenation ability: 
Heaton, B.T.; Iggo, J. A.; Jacob, C.; Nadarajah, J.; Fontaine, M. A.; Messere, R.; Noels. A. F. J. Chem. Soc.  
Dalton. Trans. 1994, 2875–2880. 
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The keto bromide in 125 was subsequently displaced to introduce a C3 azide as a 
nitrogen-containing handle. However, when 125 was treated with excess sodium azide 
(10 equiv) in N,N-dimethylformamide at room temperature for 12 h, an unexpected keto 
enamine product 127 was isolated as the major product (Scheme 2.4).16  Mechanistically, 
we speculated that after the initial SN2 substitution, the α-proton of the keto azide 128 
could be deprotonate by the basic azide anion to afford intermediate 129; a molecule of 
nitrogen was then released and the resulting imine 130 was isomerized to afford the more 
stable keto enamine 127.17,18 
 
Scheme 2.4 Unexpected Formation of Keto Enamine 127 from Keto Bromide 125. 
 
 
The problem was solved by using a milder organic azide, tetramethylguanidinium 
azide (TMGA, 2 equiv)19,20 which is soluble in a number of organic solvents, and the 
reaction could be conducted in a much less polar solvent system (a mixture of 2:1 
                                                 
16  When 1 equiv of sodium azide was used in the same reaction condition for 12 h, an approximately 1:1:1 
mixture of starting keto bromide 125, keto enamine 12, and desired keto azide 125 was observed. 
17 For a similar reaction mechanism, see: Salunke, D. B.; Hazra, B. G.; Gonnade, R. G.; Bhadbhadeb, M. 
M.; Pore, V. S. Tetrahedron 2005, 61, 3605–3612. 
18 In a recent report, Danishefsky and co-workers also observed a similar reaction in their cortistatin 
synthesis, see: Wang, Z.; Dai, M. J.; Park, P. K.; Danishefsky, S. J. Tetrahedron 2011, 67, 10249−10260. 
19 Papa, A. J. J. Org. Chem. 1966, 31, 1426–1427. 
20 For a review article on the use of TMGA, see: Błaszczyk, R. Synlett 2008, 299–300. 
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acetonitrile and tetrahydrofuran), which we believed to help suppressing the formation of 
the undesired keto enamine side product. In the optimal conditions, the displacement 
proceeded within 5 h at room temperature with clean inversion of C3-stereochemistry, 
providing desired (3S)-α-azido ketone 131 as a yellow solid, with less than 5% of keto 
enamine 127 observed. 
 
Scheme 2.5 Synthesis of Keto Azide 131 with Tetramethylguanidinium Azide (TMGA). 
 
 
Without purification, this azido ketone 131 was directly reduced to give the key 
intermediate azido alcohol 112 (Scheme 2.6). In order to achieve high diastereoselectivity, 
a number of different conditions were screened. Metal hydride reductions gave modest 
selectivity in favor of the desired (2S)-alcohol (entries 1–3); (S)-Corey-Bakshi-Shibata 
(CBS) catalyst (0.2 equiv) provided mostly (2R)-alcohol (entry 4), while (R)-CBS with 
borane dimethyl sulfide complex catalyst afforded almost exclusively (2S)-alcohol (>20:1 
dr, entry 5).21  This selectivity is in agreement with Corey’s model if considering the 
azide side as the large group and the diene side as the small group.21  Despite the great 
selectivity, reduction by employing borane dimethyl sulfide complex gave only modest 
yield, most likely due to competing hydroboration on the diene moiety during the 
transformation.  Thus, a more hindered borane source, catecholborane (2 equiv) was used  
                                                 
21 Corey, E. J.; Helal, C. J. Angew. Chem., Int. Ed. 1998, 37, 1986–2012. 
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Scheme 2.6 Redution of Keto Azide 131 to Key Intermediate 112. 
 
 
at a lower temperature (–40 ºC) in the presence of (R)-CBS catalyst (0.2 equiv) and an 
additive tetramethylguanidine (1 equiv), and the yield was improved to 85% over two 
steps with a slightly diminished diastereoselectivity (15:1 dr, entry 7). Addition of 
tetramethylguanidine was found to be beneficial for the reproducibility of the reaction 
(entry 6); a similar phenomena was observed by Corey and coworkers by using N,N’-
diethylaniline as an additive in their catecholborane mediated CBS reduction.22  With this 
optimized sequence (Scheme 2.7), the key intermediate 112 was prepared on 1.0-g 
batches, and over 3 g of this azido alcohol has been produced to date. 
 
Scheme 2.7 Optimized Synthesis of Key Intermediate 112 from Cyclohexadienone 74. 
 
                                                 
22 Chein, R. J.; Yeung, Y. Y.; Corey, E. J. Org. Lett. 2009, 11, 1611–1614. 
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Synthesis of Cortistatin J, Cortistatin K, and Cortistatin L Precursors  
 
With gram-quantities of the key intermediate 112 in hand, the next step was to 
convert it to different cortistatin 17-keto precursors 108, 109, 110 and 111 (Figure 2.1). 
In cortistatin J, a triene is present along the northern edge of the ABC-ring (Scheme 2.8). 
The azide was first reduced under Staudinger reaction conditions with excess 
trimethylphospine (5 equiv) in a mixture of tetrahydrofuran and 1N aqueous sodium 
hydroxide solution (4:1) to provide an amino alcohol 132;23 without isolation, this amine 
intermediate was reductively (di)aminated with a large excess of sodium formalin and 
cyanoborohydride under slightly acidic condition to afford dimethylamino alcohol 133 in 
85% yield. When this amino-alcohol product was treated with concentrated 
hydrochloride acid in chloroform at 23 ºC, a 1,6-elemination reaction took place cleanly 
and the C17 tert-butyldemethylsilyl ether was also cleaved at the same time, giving triene 
134 with a cortistatin J skeleton in good yield. Finally, the resulting C17 alcohol was 
  
Scheme 2.8 Synthesis of a Cortistatin J Precursor 109. 
 
                                                 
23 Aqueous sodium hydroxide solution was found to be necessary for the Staudinger reduction; using water 
instead led to no desired product. 
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oxidized with Dess−Martin periodinane24 to provide a 17-keto cortistatin J precursor 109 
in 90% yield (three steps from key intermediate 112 in 65% overall yield). 
Interestingly, it was found that amino acohol 132 also underwent a facile 1,6-
elemination upon mesylation in the presence of triethylamine to give triene 135 in good 
yields (Scheme 2.9), which served as a good evidence for the biosynthetic origins of 
cortistatin J.1, 25  Meanwhile, my coworker, Dr. Ge Zou found that treating the key 
intermediate 112 directly with hydrofluoric acid also led to a 1,6-elemination-desilylation 
product 136, which was used in the synthesis of a cortistatin J-based affinity probe (see 
Chapter 3 for details). 
 
Scheme 2.9 Base and Acid Induced 1,6-Elemination to Give Cortistatin J Frameworks. 
 
 
 
In the synthesis of a cortistatin K precursor 110, the C2 allylic alcohol needs to be 
removed (Scheme 2.10). Key intermediate 112 was converted to dimethylamino alcohol 
133 via the same Staudinger-reductive-(di)amination sequence as described in the 
cortistatin J series. Initial attempts to remove the hydroxyl group under radical 
                                                 
24 Dess, D. B.; Martin, J. C. J. Org. Chem. 1983, 48, 4155–4158. 
25 Flyer, A. N.; Si, C.; Myers, A. G. Nature Chemistry 2010, 2, 886–892. 
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deoxygenation,26 ionic hydrogenation,27 or nickel boride reduction conditions28 were not 
successful, thus reduction via palladium π-allyl complex was next pursued. After 
acetylation of C2 alcohol with excess acetic anhydride in the presence of scandium 
triflate (0.003 equiv),29  regioselective reductive cleavage of the allylic C-O bond of 
acetate 137 was achieved by employing tetrakis(triphenylphosphine)palladium (0.2 equiv) 
and excess lithium borohydride (2 equiv) at 23 ºC, 30   producing an unexpected 
dimethylamino-borane complex 138 as a non-polar, chromatography-stable white solid. 
Decomplexation was achieved in the same pot by using a known protocol with catalytic 
amount of Raney nickel in methanol,31 affording the free amine 139, also as a white solid, 
in excellent yield. Subsequently, silyl ether cleavage with tetra-n-butylammonium 
fluoride (TBAF) and Dess−Martin periodinane oxidation completed the route to the 
cortistatin K precursor 110 (five steps from key intermediate 112 in 54% overall yield). 
 
Scheme 2.10 Synthesis of a Cortistatin K Precursor 110. 
 
                                                 
26 For a general review of  radical deoxygenation, see: Hartwig, W. Tetrahedron 1983, 39, 2609−2645. 
27 (a) Kursanov, D. N.; Parnes, Z. N.; Loim, N. M. Synthesis 1974, 633–651;(b) Layton, M. E.; Morales, C. 
A.; Shair, M. D. J. Am. Chem. Soc. 2002, 124, 773–775. 
28 He, Y.; Pan, X.; Wang, S.; Zhao, H. Synth. Commun. 1989, 19, 3051–3054. 
29 Ishihara, K.; Kubota, M.; Kurihara, H.; Yamamoto, H.  J. Am. Chem. Soc. 1985, 117, 4413−4414. 
30 Hutchins, R. O.; Learn, K.; Fulton, R. P. Tetrahedron Lett. 1980, 21, 27–30. 
31 Couturier, M.; Tucker, J. L.; Andresen, B. M.; Dube, P.; Negri, J. T. Org. Lett. 2001, 3, 465–467. 
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In the synthesis of a cortistatin L precursor 111 (in corporation with Dr. Alec 
Flyer, Scheme 2.11), hydrofluoric acid promoted C17 desilylation of 112 was followed 
by selective protection of its less hindered C2 hydroxyl group by using a combination of 
tert-butyldimethylsilyl chloride and 1,8-diaza-bicycloundec-7-ene (DBU) in 
tetrahydrofuan32 to provide intermediate 140 in 78% yield over two steps.  The C3 azide 
group was then reduced to amine. However, standard Staudinger conditions proved to be 
slow and low-yielding, presumably due to the bulk of the adjacent tert-butyl-
dimethylsilyl ether. After much experimentation, a novel procedure was developed, in 
which azide 140 was first stirred with excess anhydrous trimethylphosphine (5 equiv) for 
20 h to allow its complete conversion to an iminophosphorane intermediate 141; then 
formalin was added to react with 141 in an aza-Wittig manner;33 and the resulting imine 
142 was reductive (di)aminated with excess sodium cyanoborohydride in the presence of 
formalin under acidic conditions, furnishing dimethylamine 143 in 90% yield. Finally, 
the C17 hydroxyl group of 143 was oxidized with Dess−Martin periodinane to afford 
cortistatin L precursor 111 (four steps from key intermediate 112 in 67% overall yield). 
 
Scheme 2.11 Synthesis of a Cortistatin L Precursor 112. 
 
                                                 
32 Moon, S. S.; Stuhmiller, L. M.; McMorris, T. C. J. Org. Chem. 1989, 54, 26–28. 
33 Treatment of the iminophosphorane 141 with water led to low yield of the desired product. 
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A Formal Synthesis of Cortistatin A and Synthesis of a Cortistatin A Precursor 
 
Dr. Alec Flyer observed that treating diene 144 (prepared in two steps from keto 
bromide 125) with dimethyldioxirane (DMDO) afforded a highly sensitive epoxide 145 
as the primary product, which upon standing in benzene solution underwent spontaneous 
1,4-eliminative opening to form dienyl alcohol 146 (Scheme 2.12).  
 
Scheme 2.12 A Formal Synthesis of a Cortistatin A. 
 
 
From 146, a three-step sequence was developed to synthesize Shair’s intermediate 
41.34  The C-3 secondary bromide in 146 was displaced with a large excess sodium azide 
(50 equiv) in a 4:1 mixture of N,N-dimethylformamide and pH=7 aqueous potassium 
phosphate buffer solution at 100 ºC, in which the pH=7 buffer was found to significantly 
reduce the amount of the bromide elimination side product; the C-2 triethylsilyl ether was 
also cleaved in the same operation, affording azido trans-diol 147 in 60% yield. 
Subsequently, a Staudinger-reductive-(di)aminaition sequence similar to the one used in 
                                                 
34 Lee, H. M.; Nieto-Oberhuber, C.; Shair, M. D. J. Am. Chem. Soc. 2008, 130, 16864−16866. 
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the cortistatins J and K series afforded dimethylamino trans-diol 148 in 80% yield, which 
was bis-acetylated with excess acetic anhydride (10 equiv) and 4-dimethylaminopyridine 
(DMAP, 2 equiv) in pyridine as a solvent to provid the Shair’s intermediate 41 in modest 
yield.  
Despite the successful preparation of acetate 41, the lengthy and low-yielding 
sequence prevented us from large-scale production of the cortistatin A precursor. 
Therefore, a more efficient route was developed (Scheme 2.13). Dr. Alec Flyer was able 
to convert key intermediate 112 to azido trans-diol 153 in six steps. The C2 hydroxyl 
group of key intermediate 112 was temporarily protected as a chloroacetate, and C17 tert-
butyldimethylsilyl ether was cleavage with hydrofluoric acid at 0 ºC to provide 
intermediate 149 in 80% yield over two steps. This C17 alcohol was oxidized with Dess-
Martin periodinane, and in the same pot, the C2 chloroacetate was removed by addition 
of methanol and potassium carbonate, to afford ketone 150 in 85% yield. Addition of N-
bromosuccinimide (1.02 equiv) to a solution of 150 in a 3:1 mixture of acetonitrile and 
methanol led to a stereoselective, trans-diaxial 1,4-bromoetherification of the conjugated 
diene to provide C1 axial, allylic bromide product 151.35  Without purification, this 
bromide was displaced with potassium superoxide in the presence of 18-crown-6,36  
affording trans-diol methyl ether 152 in 41% yield over two steps. The C9 axial methyl 
ether in 152 then underwent 1,2-elimination by exposure to a mixture of scandium triflate 
(0.03 equiv) and excess trifluoroacetic acid (9.4 equiv) in dioxane, furnishing azido 
trans-diol 153. 
                                                 
35 (a) Deagostino, A.; Tivola, P. B.; Prandi, C.; Venturello, P. Synlett 1999, 1841–1843; (b) Fraser-Reid. B; 
Radatus, B. J. Chem. Soc. Chem. Comm. 1970, 779–780.  
36 (a) San Filippo, J.; Chern, C. I. ; Valentine, J. S. J. Org. Chem. 1975, 40, 1678−1680; (b) Corey, E. J.; 
Nicolaou, K. C.; Shibasaki, M.; Machida, Y.; Shiner, C. S. Tetrahedron Lett. 1975, 37, 3183−3186. 
 43 
 
Scheme 2.13 Synthesis of a Cortistatin A Precursor 108. 
 
 
The azido diol 153 was subsequently transformed to a cortistatin A precursor 108. 
A previously described Staudinger-reductive-(di)aminaition sequence in which the azide 
153 was first reduced by exposure to excess trimethylphospine (5 equiv) in a 2:1mixture 
of tetrahydrofuran and 1N aqueous sodium hydroxide solution, then (di)aminated in the 
same pot with a large excess of sodium cyanoborohydride and formalin under slightly 
acidic environment afforded dimethylamino diol 23. The two hydroxyl groups of 23 were 
subsequently protected with chlorotriethylsilane (6 equiv) in the presence of 
triethylamine (12 equiv) and 4-dimethylaminopyridine (DMAP, 2 equiv) in N,N- 
dimethylformamide, providing a protected 17-keto cortistatin A precursor 108 in 60% 
yield over three steps on a 75-mg scale (8 steps from key intermediate 112 with 17% 
overall yield). 
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Conclusion 
 
In summary, we have developed a robust route to produce the key intermediate 
azido alchol 112 on gram scale by an efficient assembly of a readily available benzyl zinc 
reagent 116 and an enol triflate reagent 117 in eight steps (including Negishi cross-
coupling, Ring-closing-metathesis-then-epoxidation, hydrogenation, epoxide-opening, 
oxidative-dearomatization, hydrosilylation-bromination, nucleophilic-displacement, and 
CBS-reduction) (Figure 2.2). This key intermediate was subsequently transformed to 
cortistatin J precursor 109, cortistatin K precursor 110, cortistatin L precursor 111, and 
cortistatin A precursor 108 in three to eight steps. These precursors represent each of the 
four natural cortistatin ABC-ring substitution patterns, which were elaborated to final 
cortistatin natural products as described in Chapter 3. 
 
Figure 2.2 Summary of the Syntheses of Cortistatin Precursors from Key Intermediate 112. 
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Experimental Section 
 
General Experimental Procedures. All reactions were performed in round-
bottomed flasks fitted with rubber septa under a positive pressure of argon, unless 
otherwise noted. Air- and moisture-sensitive liquids were transferred via syringe or 
stainless steel cannula. Organic solutions were concentrated by rotary evaporation (house 
vacuum, ca. 25–40 Torr) at ambient temperature, unless otherwise noted. Analytical thin-
layer chromatography (TLC) was performed using glass plates pre-coated with silica gel 
(0.25 mm, 60 Å pore-size, 230–400 mesh, Merck KGA) impregnated with a fluorescent 
indicator (254 nm). TLC plates were visualized by exposure to ultraviolet light, then were 
stained with either an aqueous sulfuric acid solution of ceric ammonium molybdate 
(CAM) or acidic ethanolic p-anisaldehyde solution (p-anisaldehyde) then briefly heated 
on a hot plate. Flash-column chromatography was performed as described by Still et al.,37 
employing silica gel (60 Å, 32–63 μM, standard grade, Dynamic Adsorbents, Inc.). 
Materials. Commercial solvents and reagents were used as received with the 
following exceptions. Tetrahydrofuran, dichloromethane, benzene, toluene, dioxane, and 
ether were purified by the method of Pangborn et al. 38  N-Bromosuccinimide was 
recrystallized from water.  The molarity of n-butyllithium solutions was determined by 
titration against a standard solution of diphenylacetic acid in tetrahydrofuran (average of 
three determinations).39 
                                                 
37 Still, W. C.; Khan, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923–2925. 
38 Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics 1996, 
15, 1518–1520. 
39 Kofron, W. G.; Baclawski, L. M. J. Org. Chem. 1976, 41, 1879−1880. 
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Instrumentation. Proton magnetic resonance (1H NMR) spectra were recorded 
on Varian INOVA 500 (500 MHz) or 600 (600 MHz) NMR spectrometers at 23 °C. 
Proton chemical shifts are expressed in parts per million (ppm, δ scale) and are 
referenced to residual protium in the NMR solvent (CHCl3, δ 7.26; C6D5H, δ 7.15). Data 
are represented as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, 
q = quartet, m = multiplet and/or multiple resonances, br = broad, app = apparent), 
integration, and coupling constant (J) in Hertz. Carbon nuclear magnetic resonance 
spectra (13C NMR) were recorded on Varian INOVA 500 (126 MHz) NMR 
spectrometers at 23 °C. Carbon chemical shifts are expressed in parts per million (ppm, δ 
scale) and are referenced to the carbon resonances of the NMR solvent (CDCl3, δ 77.0; 
C6D6, δ 128.0). Infrared (IR) spectra were obtained using a Shimadzu 8400S FT-IR 
spectrometer and were referenced to a polystyrene standard. Data are represented as 
follows: frequency of absorption (cm–1), intensity of absorption (vs = very strong, s = 
strong, m = medium, w = weak, br = broad). High-resolution mass spectra were obtained 
at the Harvard University Mass Spectrometry Facility.  
 
(For clarity, intermediates that have not been assigned numbers in the text are numbered 
sequentially in the experimental section beginning with 154). 
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Triene 115. 
Note: Magnesium turnings used in this procedure were washed sequentially with 1 N 
aqueous hydrochloric acid solution (2 × 10 mL), 0.1 N aqueous hydrochloric acid 
solution (10 mL), water (6 × 10 mL), ethanol (3 × 10 mL), then ether (3 × 10 mL).  The 
washed turnings were dried under high vacuum for 12 h prior to use. 
To a flame-dried, 250-mL flask fitted with a reflux condenser and a stirring bar 
were added magnesium turnings (14.3 g, 587 mmol, 15 equiv) followed by ether (50 
mL).  The reaction flask was placed in a water bath at 23 ºC. 1,2-dibromoethane (4.05 
mL, 47.0 mmol, 1.2 equiv) was added dropwise over a period of 10 min.  After 30 min, 
visible gas evolution had ceased, and a solution of benzyl bromide 119 (17.4 g, 47.0 
mmol, 1.2 equiv) in ether (30 mL) was added.  After 30 min, the dark green reaction 
mixture was transferred via cannula to a flask containing a solution of zinc chloride (6.41 
g, 47.0 mmol, 1.2 equiv) in tetrahydrofuran (60 mL).  The transfer was quantitated with 
tetrahydrofuran (2 × 10 mL).  The resulting cloudy white mixture was allowed to stir at 
23 ºC for 40 min.  To a separate flame-dried, 1-L flask was added enol triflate 117 (17.3 
g, 39.2 mmol, 1 equiv)40 and N-methyl-2-pyrrolidinone (160 mL).  The resulting solution 
was degassed by sparging for 20 min with a slow stream of argon gas through a 20-gauge 
                                                 
40 Used as a 10:1 mixture of diastereomers (epimeric at C14) carried from α-methylene ketone 24; the 
major diastereomer is depicted in the equation above.  The minor diastereomer was separated after the 
Negishi coupling. 
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stainless steel needle.  Tris(dibenzylideneacetone)dipalladium (1.62 g, 1.76 mmol, 0.045 
equiv) and 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (2.90 g, 7.05 mmol, 0.18 
equiv) were added in sequence.  After 10 min, the organozinc reagent prepared in the 
paragraph above was transferred to the reaction flask via cannula.  The resulting cloudy 
orange suspension was sparged for 20 min with a slow stream of argon gas through a 20-
gauge stainless steel needle.  The flask was capped with a glass stopper under argon and 
the stopped flask was sealed with Teflon® tape and then Parafilm®. After sealing, the 
reaction flask was placed in an oil bath preheated to 70 ºC.  After 20 h, the oil bath was 
removed and the reaction flask was allowed to cool to 23 ºC.  The reaction mixture was 
partitioned between aqueous hydrochloric acid solution (1.0 N, 400 mL) and ether (1.5 
L).  The layers were separated.  The aqueous layer was extracted with ether (2 × 250 
mL).   The organic layers were combined.  The combined solution was washed 
sequentially with saturated aqueous sodium bicarbonate solution (400 mL), water (400 
mL), then saturated aqueous sodium chloride solution (400 mL) and the washed solution 
was dried over sodium sulfate.  The dried solution was filtered and the filtrate was 
concentrated.  The residue was filtered through silica (hexanes initially, grading to 10:1 
hexanes−ether) and the filtrate was concentrated.  The residue was purified by flash-
column chromatography (hexanes initially, grading to 20:1 hexanes−ether) to furnish a 
single diastereomer of coupling product 115 as a pale yellow oil (16.0 g, 70%). 
 
1H NMR:  
(500 MHz, CDCl3) 
7.35 (dd, 1H, J = 8.3, 2.5 Hz), 6.89 (dd, 1H, J = 17.3, 
11.0 Hz), 6.70 (dd, 1H, J = 8.5, 2.7 Hz), 6.61 (d, 1H, J = 
2.4 Hz), 6.45 (dd, 1H, J = 17.6, 11.2 Hz), 5.51 (dd, 1H, 
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J = 17.6, 1.5 Hz), 5.15 (dd, 1H, J = 11.2, 1.5 Hz), 5.09–
5.01 (m, 2H), 3.66 (app t, 1H, J = 8.1 Hz), 3.54 (d, 1H, J 
= 15.7 Hz), 3.42 (d, 1H, J = 15.6 Hz), 2.31–2.23 (m, 
1H), 2.08–1.96 (m, 3H), 1.94–1.85 (m, 1H), 1.69 (ddd, 
1H, J = 12.5, 6.3, 1.7 Hz), 1.59–1.52 (m, 1H), 1.49 (dd, 
1H, J = 12.2, 5.4 Hz), 1.28–1.16 (m, 4H), 1.07 (d, 18H, 
J = 7.3 Hz), 0.87 (s, 9H), 0.74 (s, 3H), 0.01 (s, 3H), 0.01 
(s, 3H). 
 
13C NMR :  
(126 MHz, CDCl3) 
155.9, 139.2, 134.5, 134.2, 133.1, 132.9, 130.0, 126.6, 
119.6, 117.9, 115.1, 113.3, 80.2, 44.8, 43.5, 35.8, 33.7, 
31.5, 29.1, 25.9, 24.5, 18.1, 18.0, 12.7, 11.1, −4.5, −4.8; 
FTIR (neat), cm−1 2945 (m), 2891 (m), 1603 (m), 1491 
(m), 1258 (s). 
 
FTIR, cm–1: 
 (thin film) 
2945 (m), 2891 (m), 1603 (m), 1491 (m), 1258 (s). 
 
 
HRMS:  
(ESI) 
Calcd for (C36H60O2Si2+H)+                           581.4205,  
Found                                                              581.4183. 
 
TLC 
(10:1 hexanes–ethyl acetate)
Rf = 0.90 (UV, p-anisaldehyde) 
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Allylic Alcohol 123. 
Note: Dichloromethane used in this procedure was degassed just prior to use by sparging 
for 20 min with a slow stream of argon gas through a 20-gauge stainless steel needle. 
To a flame-dried, 250-mL flask fitted with a reflux condenser and a stirring bar 
were added sequentially coupling product 115 (11.2 g, 19.2 mmol, 1 equiv), 
dichloromethane (96 mL), and the 2nd generation Grubbs catalyst (407 mg, 0.480 mmol, 
0.025 equiv).  The reaction flask was placed in an oil bath preheated to 40 ºC.  After 5 h, 
the oil bath was removed and the reaction flask was allowed to cool to 23 ºC.  The 
reaction mixture was transferred to a 3-L flask and dichloromethane (1.2 L) was added.  
The reaction flask was placed in an ice bath, and a solution of dimethyldioxirane in 
acetone (0.060 M, 480 mL, 28.8 mmol, 1.5 equiv) was then added.  After 1 h, hexanes 
(700 mL) were added and the diluted product solution was dried over sodium sulfate.  
The dried solution was filtered and the filtrate was concentrated.  The black oily residue 
(vinyl epoxide 121) was transformed in the following step directly without purification. 
Benzene (5 mL) was added to the oily residue prepared above and volatiles were 
removed in vacuo through a 16-gauge needle in order to effect azeotropic drying.  A 
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second portion of benzene (5 mL) was added, and the volatiles were again removed.  
Benzene (64 mL) was added to the concentrate.  To the resulting solution was added 
sodium bicarbonate (2.42 g, 28.8 mmol, 1.5 equiv), followed by Wilkinson’s catalyst 
(2.67 g, 2.88 mmol, 0.15 equiv).  The reaction flask was placed in a hydrogenation vessel 
and the vessel was pressurized to 500 psi with hydrogen.  The reaction mixture was 
stirred vigorously.  After 20 h, the pressure was released.  Solids were removed by 
filtration through a pad of Celite, washing with ethyl acetate (3 × 30 mL).  The filtrates 
were combined and the combined organic solution was concentrated.  The residue was 
purified by flash-column chromatography on triethylamine-deactivated silica gel (20:1 
hexanes−ethyl acetate initially, grading to 10:1 hexanes−ethyl acetate) to furnish epoxide 
122 as a yellow oil (7.67 g, >80% purity by 1H NMR analysis).   
A solution of n-butyllithium in hexanes (2.50 M, 10.7 mL, 26.8 mmol, 2 equiv) 
was added dropwise to a solution of diethylamine (3.48 mL, 33.6 mmol, 2.5 equiv) in 
tetrahydrofuran (60 mL) at −78 ºC.  After 15 min, the cooling bath was exchanged for an 
ice bath and the reaction flask was allowed to warm to 0 ºC.  After 15 min, the ice-cold 
solution was transferred by cannula to a solution of epoxide 122 (7.67 g, 13.4 mmol, 1 
equiv) in tetrahydrofuran (200 mL) cooled to −15 ºC in an ice-salt bath.  After 20 min, 
saturated aqueous sodium bicarbonate solution (10 mL) was added.  The product solution 
was concentrated to remove the bulk of solvent.  The concentrate was partitioned 
between water (100 mL) and 1:1 ether−hexanes (300 mL).  The layers were separated.  
The aqueous layer was extracted with ether (2 × 50 mL).  The organic layers were 
combined.  The combined solution was washed with saturated aqueous sodium chloride 
solution (100 mL) and the washed solution was dried over sodium sulfate.  The dried 
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solution was filtered and the filtrate was concentrated.  The residue was purified by flash-
column chromatography on triethylamine-deactivated silica gel (20:1 hexanes−ethyl 
acetate initially, grading to 10:1 hexanes−ethyl acetate, then 5:1 hexanes−ethyl acetate) to 
provide allylic alcohol 123 as a pale yellow foam (5.37 g, 50% three).   
 
1H NMR:  
(500 MHz, CDCl3) 
7.00 (d, 1H, J = 8.0 Hz), 6.71 (d, 1H, J = 2.5 Hz), 6.65 
(dd, 1H, J = 8.0, 2.5 Hz), 6.31 (s, 1H), 3.66 (app t, 1H, J = 
8.6 Hz), 2.84–2.68 (m, 3H), 2.44–2.35 (m, 1H), 2.19–2.11 
(m, 1H), 2.07 (s, 1H), 2.04–1.96 (m, 2H), 1.96–1.89 (m, 
1H), 1.70–1.59 (m, 3H), 1.58–1.50 (m, 1H), 1.48–1.38 
(m, 1H), 1.29–1.19 (m, 3H), 1.09 (d, 18H, J = 7.6 Hz), 
0.87 (s, 9H), 0.73 (s, 3H), 0.02 (s, 3H), 0.01 (s, 3H). 
 
13C NMR :  
(126 MHz, CDCl3) 
154.4, 145.7, 137.4, 133.7, 129.8, 127.4, 121.8, 118.2, 
82.5, 74.9, 52.8, 42.6, 39.4, 36.3, 31.2, 30.8, 29.6, 25.8, 
19.9, 18.0, 17.9, 13.8, 12.6, −4.4, −4.8. 
 
FTIR, cm–1:  (thin film) 3414 (br), 2949 (s), 2866 (m), 1462 (m), 1281 (s). 
 
HRMS:  
(ESI) 
Calcd for (C34H58O3Si2+Na)+           593.3817 
 Found                                               593.3803 
 
TLC                                      Rf = 0.38 (UV, p-anisaldehyde) 
(5:1 hexanes–ethyl acetate) 
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Cyclohexatrienone 74. 
A solution of tetra-n-butylammonium fluoride in tetrahydrofuran (1.0 M, 10.3 
mL, 10.3 mmol, 1.1 equiv) was added to an ice-cooled solution of allylic alcohol 123 
(5.33 g, 9.33 mmol, 1 equiv) in dichloromethane (75 mL).  After 15 min, 1,1,1,3,3,3-
hexafluoro-2-propanol (50 mL) was added, followed by 2,6-lutidine (4.35 mL, 37.4 
mmol, 4 equiv).   A solution of [bis(trifluoroacetoxy)iodo]benzene (7.23 g, 16.8 mmol, 
1.8 equiv) in dichloromethane (25 mL) was then added by cannula over 10 min, forming 
a bright red solution.  After 30 min, the bright red reaction mixture was concentrated to 
remove the bulk of solvent. The residue was partitioned between aqueous hydrochloric 
acid solution (0.5 N, 50 mL) and ethyl acetate (300 mL).  The layers were separated.  The 
aqueous layer was extracted with ether (3 × 70 mL).  The organic layers were combined.  
The combined solution was washed with saturated aqueous sodium chloride solution (70 
mL) and the washed solution was dried over sodium sulfate.  The dried solution was 
filtered and the filtrate was concentrated. The residue was purified by flash-column 
chromatography on triethylamine-deactivated silica gel (15:1 hexanes−ethyl acetate 
initially, grading to 7:1 hexanes−ethyl acetate, then 5:1 hexanes−ethyl acetate, two 
purifications were necessary to obtain product of >95% purity by 1H NMR analysis), 
affording cyclohexatrienone 74 as a pale yellow solid (1.98 g, 50%).   
 
1H NMR:  6.43 (d, 1H, J = 9.8 Hz), 6.20 (dd, 1H, J = 10.0, 1.7 Hz), 
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(500 MHz, CDCl3) 5.93 (s, 1H), 5.49 (d, 1H, J = 2.0 Hz), 3.37 (app t, 1H, J 
= 8.1 Hz), 2.12–2.02 (m, 1H), 1.93 (dd, 1H, J = 17.0, 
3.4 Hz), 1.85 (dd, 1H, J = 11.5, 7.5 Hz), 1.80–1.72 (m, 
1H), 1.71–1.60 (m, 3H), 1.57 (ddd, 1H, J = 13.1, 6.3, 
1.6 Hz), 1.51–1.41 (m, 3H), 1.20–1.13 (m, 1H), 0.98 (s, 
9H), 0.89 (app td, 1H, J = 12.9, 4.9 Hz), 0.70 (s, 3H), 
0.01 (s, 3H), 0.00 (s, 3H). 
 
13C NMR :  
(126 MHz, CDCl3) 
185.7, 157.4, 154.4, 146.6, 129.9, 119.8, 119.1, 86.2, 
81.7, 75.3, 47.7, 43.9, 37.3, 36.2, 30.8, 29.1, 28.9, 26.0, 
19.7, 18.3, 11.0, −4.3, −4.7. 
 
FTIR, cm–1: 
 (thin film) 
2955 (s), 2857 (m), 1661 (vs), 1611 (s), 1354 (m), 1257 
(s). 
 
HRMS:  
(ESI) 
Calcd for (C25H36O3Si+H)+                   413.2507 
Found                                                    413.2505 
 
TLC 
(4:1 hexanes–ethyl acetate) 
Rf = 0.40 (UV, p-anisaldehyde) 
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Bromo Ketone 125. 
Note: Toluene used in this procedure was degassed using the freeze-pump-thaw method 
(4 iterations).  Triethylsilane was filtered through a pipette packed with neutral alumina 
just prior to use. 
To a flame-dried flask charged with cyclohexatrienone 74 (1.96 g, 4.74 mmol, 1 
equiv) was added toluene (2 mL).  Volatiles were removed in vacuo through a 20-gauge 
needle in order to effect azeotropic drying.  A second portion of toluene (2 mL) was 
added, and the volatiles were again removed. Triethylsilane (1.52 mL, 9.50 mmol, 2 
equiv) was added to the concentrate followed by a solution of Wilkinson’s catalyst (220 
mg, 0.238 mmol, 0.05 equiv) in toluene (96 mL), the latter added via cannula. The 
reaction flask was then placed in an oil bath preheated to 50 ºC.  After 4 h, the oil bath 
was removed and the reaction flask was allowed to cool to 23 ºC.  Pyridine (16 mL) was 
added.  After 12 h, the reaction flask was cooled to −78 ºC and a solution of N-
bromosuccinimide (1.69 g, 9.48 mmol, 2.0 equiv) in tetrahydrofuran (10 mL) was added 
by cannula.  After 1 h, the cooling bath was removed and the reaction flask was allowed 
to warm to 23 ºC. After 0.5 h, the reaction mixture was partitioned between saturated 
aqueous sodium thiosulfate solution (50 mL) and ethyl acetate (250 mL). The layers were 
separated. The aqueous layer was extracted with ethyl acetate (3 × 50 mL). The organic 
layers were combined.  The combined solution was washed with saturated aqueous 
sodium chloride solution (80 mL) and the washed solution was dried over sodium sulfate.  
The dried solution was filtered and the filtrate was concentrated. The residue was purified 
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by flash-column chromatography on silica gel (20:1 hexanes–ethyl acetate initially, 
grading to 8:1 hexanes–ethyl acetate) to provide diastereomerically pure bromo ketone 
125  as a white solid (1.63 g, 70%).   
 
1H NMR:  
(500 MHz, CDCl3) 
5.92 (d, 1H, J = 2.3 Hz), 5.61 (s, 1H), 4.59 (ddd, 1H, J = 
4.6, 2.3, 1.1 Hz), 3.64 (app t, 1H, J = 8.2 Hz), 2.93 (dd, 
1H, J = 15.0, 4.7 Hz), 2.59–2.36 (m, 3H), 2.31 (ddd, 1H, 
J = 13.4, 9.4, 6.0 Hz), 2.09 (app td, 1H, J = 11.4, 5.8 
Hz), 2.04–1.94 (m, 1H), 1.90 (dd, 1H, J = 10.6, 8.8 Hz), 
1.86–1.73 (m, 2H), 1.69–1.48 (m, 4H), 1.23 (ddd, 1H, J 
= 12.9, 4.5 Hz), 0.89 (s, 9H), 0.84 (s, 3H), 0.02 (s, 6H). 
 
13C NMR :  
(126 MHz, CDCl3) 
191.2, 160.3, 158.9, 119.4, 116.5, 83.4, 81.4, 76.0, 47.7, 
44.7, 43.9, 41.1, 37.2, 36.1, 30.6, 29.9, 29.3, 25.8, 19.4, 
18.1, 10.9, –4.4, –4.9. 
 
FTIR, cm–1: 
 (thin film) 
2953 (m), 2856 (m), 1668 (s), 1618 (s), 1250 (m). 
 
 
HRMS:  
(ESI) 
Calcd for (C25H37BrO3Si+H)+                    493.1768 
Found                                                         493.1768 
 
TLC 
(5:1 hexanes–ethyl acetate) 
Rf = 0.50 (UV, p-anisaldehyde) 
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Keto Enamine 127. 
Sodium azide (26.0 mg, 0.406 mmol, 10 equiv) was added to a solution of bromo 
ketone 125 (20.0 mg, 0.041 mmol, 1 equiv) in N,N-dimethylformamide (1.0 mL) at 23 
ºC. After 12 h, the reaction mixture was partitioned between half saturated aqueous 
sodium chloride solution (10 mL) and ether (15 mL). The layers were separated. The 
aqueous layer was extracted with ether (3 × 10 mL). The organic layers were combined.  
The combined solution was washed with water (10 mL) and then saturated aqueous 
sodium chloride solution (10 mL) and the washed solution was dried over sodium sulfate.  
The dried solution was filtered and the filtrate was concentrated. The residue was purified 
by flash-column chromatography on silica gel (10:1 hexanes–ethyl acetate initially, 
grading to 4:1 hexanes–ethyl acetate) to provide keto enamine 127 as a yellow solid (14.9 
mg, 85%). 
 
1H NMR:  
(500 MHz, C6D6) 
5.94 (s, 1H), 5.51 (s, 1H), 5.36 (s, 1H), 3.48 (br. s., 2H), 
3.38 (t, 1H, J = 8.1 Hz), 2.11 (app td, 1H, J = 15.5, 3.0 
Hz), 1.96 (dd, 1H, J = 16.9, 4.6 Hz), 1.90 (dd, 1H, J = 
12.2, 7.0 Hz), 1.84 (ddd, 1H, J = 14.0, 10.5, 2.6 Hz), 
1.80–1.75 (m, 1H), 1.75–1.67 (m, 3H), 1.62–1.55 (m, 
2H), 1.52 (dd, 1H, J = 12.0, 4.9 Hz), 1.48–1.42 (m, 1H), 
1.17 (ddd, 1H, J = 12.5, 9.2, 2.7 Hz), 0.98 (s, 9H), 0.93 
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(app td, 1H, J = 12.9, 4.8 Hz), 0.74 (s, 3H), 0.01 (d, 6H, 
J = 2.5 Hz); 
 
13C NMR :  
(126 MHz, C6D6) 
181.5, 158.8, 154.1, 138.7, 118.6, 116.7, 111.4, 84.3, 
80.8, 75.4, 46.9, 42.9, 36.5, 35.2, 29.8, 28.1, 27.0, 25.0, 
18.7, 17.3, 10.1, -5.3, -5.7; 
 
FTIR, cm–1: 
 (thin film) 
3468 (br), 3362 (br), 2955 (s), 2926 (s), 2857 (m), 1641 
(m), 1616 (s), 1464 (m), 1250 (m). 
 
 
HRMS:  
(ESI) 
Calcd for (C25H38NO3Si+H)+                     428.2615 
Found                                                         428.2631 
 
TLC 
(2:1 hexanes–ethyl acetate) 
Rf = 0.47 (UV, p-anisaldehyde) 
 
 
 
 
 
 59 
 
O
CH3
OTBS
H
O
Br
1. TMGA, CH3CN, THF, 23 °C
2. (R)-CBS catalyst
TMG, catecholborane
PhCH3, 40 °C
85%, 15 : 1 dr
O
CH3
OTBS
H
HO
N3
125 112
2
 
Azido Alcohol 112. 
Tetramethylguanidinium azide (960 mg, 6.08 mmol, 2 equiv) was added to a 
solution of bromo ketone 125 (1.50 g, 3.04 mmol, 1 equiv) in a mixture of acetonitrile 
(60 mL) and tetrahydrofuran (30 mL). After 12 h, the solution was concentrated to 
remove the bulk of solvent. Ethyl acetate (100 mL) and ether (50 mL) were added.  
Solids were removed by filtration, washing with ether (3 × 50 mL). The filtrates were 
combined and the combined solution was concentrated.   
Toluene (2 mL) was added, and volatiles were removed in vacuo through a 20-
gauge needle in order to effect azeotropic drying. A second portion of toluene (2 mL) was 
added, and the volatiles were again removed. Toluene (60 mL) was added to the 
concentrate. Tetramethylguanidine (382 µl, 3.04 mmol, 1 equiv) and a solution of (R)-
tetrahydro-1-methyl-3,3,-diphenyl-1H,3H-pyrrolo[1,2-c][1,3,2]oxazaborole catalyst in 
toluene (1.0 M, 608 µl, 0.608 mmol, 0.2 equiv) were added in sequence. The reaction 
flask was then cooled to −40 ºC.  A solution of catecholborane in toluene (1.0 M, 6.08 
mL, 6.08 mmol, 2 equiv) was added dropwise over 5 min. After 2 h, excess 
catecholborane was quenched by the addition of methanol (2 mL).  The cooling bath was 
removed and the reaction flask was allowed to warm to 23 ºC.  The reaction mixture was 
then partitioned between aqueous sodium hydroxide solution (1.0 N, 15 mL) and ethyl 
acetate (120 mL). The layers were separated. The organic layer was washed with aqueous 
sodium hydroxide solution (1.0 N, 3 × 15 mL).  The aqueous layers were combined. The 
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combined aqueous solution was extracted with ethyl acetate (3 × 30 mL).  The combined 
organic layers were washed with saturated aqueous sodium chloride solution (30 mL) and 
the washed solution was dried over sodium sulfate.  The dried solution was filtered and 
the filtrate was concentrated.  The residue was purified by flash-column chromatography 
on silica gel (9:1 hexanes–ether, grading to 3:1 hexanes–ether) to furnish azido alcohol 
112 as a white foam (1.18 g, 85%, a 15:1 mixture of diastereomers).41  
 
 
1H NMR:  
(500 MHz, CDCl3) 
5.69 (d, 1H, J = 2.3 Hz), 5.14 (d, 1H, J = 2.3 Hz), 4.24 
(app td, 1H, J = 5.4, 2.5 Hz), 3.60 (app t, 1H, J = 8.5 
Hz), 3.49 (ddd, 1H, J = 12.7, 8.6, 3.9 Hz), 2.52–2.37 (m, 
1H), 2.34–2.23 (m, 1H), 2.18 (d, 1H, J = 5.0 Hz), 2.13–
2.00 (m, 4H), 2.00–1.89 (m, 2H), 1.89–1.77 (m, 2H), 
1.73 (ddd, 1H, J = 12.5, 5.6, 1.6 Hz), 1.68–1.55 (m, 
2H), 1.55–1.43 (m, 1H), 1.13 (app td, 1H, J = 13.2, 4.8 
Hz), 0.87 (s, 9H), 0.79 (s, 3H), 0.01 (s, 6H). 
 
13C NMR :  
(126 MHz, CDCl3) 
148.6, 142.0, 118.5, 118.4, 83.9, 81.6, 78.0, 72.4, 63.4, 
47.8, 43.9, 38.3, 38.3, 36.3, 32.5, 30.5, 28.6, 25.8, 19.6, 
18.0, 10.8, –4.5, –4.9. 
 
                                                 
41 The product obtained in this procedure is a 15:1 mixture of diastereomers (epimeric at C2); the major 
diastereomer is depicted in the equation above.  The minor diastereomer was removed at different points in 
the syntheses of the cortistatins, as detailed in the procedures that follow.   
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FTIR, cm–1: 
 (thin film) 
3431 (br), 2953 (m), 2857 (m), 2102 (vs), 1251 (s). 
 
 
HRMS:  
(ESI) 
Calcd for (C25H39N3O3Si+Na)+               480.2653 
Found                                                      480.2651. 
 
TLC 
(3:1 hexanes–ethyl acetate) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rf = 0.34 (UV, p-anisaldehyde) 
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Dimethylamino Alcohol 133 (Cortistatin J and K Series). 
A solution of azido alcohol 11241 (80 mg, 175 µmol, 1 equiv) in a mixture of 
tetrahydrofuran (5 mL) and aqueous sodium hydroxide solution (1.0 N, 1 mL) was 
degassed by sparging for 20 min with a slow stream of argon gas through a 20-gauge 
stainless steel needle.  To the degassed solution was added a solution of 
trimethylphosphine in tetrahydrofuran (1.0 M, 525 µL, 525 µmol, 3 equiv).  After 2 h, 
methanol (6 mL) was added, followed by aqueous hydrochloric acid solution (1.0 N, 1 
mL) then acetic acid (200 µL, 3.50 mmol, 20 equiv).  Formalin (37 wt %, 710 µL, 8.75 
mmol, 50 equiv) and a solution of sodium cyanoborohydride (110 mg, 1.75 mmol, 10 
equiv) in methanol (1 mL) were added in sequence.  After 1 h, the reaction mixture was 
concentrated to remove the bulk of solvent. The concentrate was partitioned between 
aqueous sodium hydroxide solution (1.0 N, 20 mL) and dichloromethane (30 mL).  The 
layers were separated. The aqueous layer was extracted with dichloromethane (4 × 20 
mL).  The organic layers were combined.  The combined solution was washed with 
saturated aqueous sodium chloride solution (15 mL) and the washed solution was dried 
over sodium sulfate.  The dried solution was filtered and the filtrate was concentrated. 
The residue was purified by flash-column chromatography on Davisil® silica gel (ethyl 
acetate initially, grading to 5:1 ethyl acetate–methanol, then 1:1 ethyl acetate–methanol) 
to furnish diastereomerically pure dimethylamino alcohol 133 (cortistatin J and K series) 
as a white solid (68 mg, 85%).   
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1H NMR:  
(500 MHz, CDCl3) 
5.70 (d, 1H, J = 2.1 Hz), 5.29 (d, 1H, J = 1.5 Hz), 4.22 
(d, 1H, J = 9.2 Hz), 3.59 (app t, 1H, J = 8.5 Hz), 3.48 
(br s, 1H), 2.59 (ddd, 1H, J = 12.5, 9.4, 2.5 Hz), 2.49–
2.37 (m, 1H), 2.30 (s, 6H), 2.29–2.20 (m, 1H), 2.12–
1.89 (m, 3H), 1.89–1.75 (m, 5H), 1.71 (dd, 1H, J = 12.5, 
4.0 Hz), 1.67–1.54 (m, 2H), 1.54–1.43 (m, 1H), 1.12 
(app td, 1H, J = 13.0, 4.6 Hz), 0.87 (s, 9H), 0.79 (s, 3H), 
0.01 (s, 6H). 
 
13C NMR :  
(126 MHz, CDCl3) 
δ147.3, 141.0, 119.9, 119.1, 83.7, 81.6, 79.5, 67.6, 66.2, 
48.0, 43.9, 40.4, 38.4, 36.4, 32.5, 30.6, 30.3, 28.6, 25.8, 
19.6, 18.0, 10.9, –4.5, –4.9. 
 
FTIR, cm–1: 
 (thin film) 
3431 (br), 2955 (s), 2859 (m), 1462 (m), 1250 (s), 1134 
(s), 1044 (s). 
 
HRMS:  
(ESI) 
Calcd for (C27H45NO3Si+H)+                       460.3242 
 Found                                                          460.3259. 
 
TLC 
(methanol) 
Rf  = 0.32 (UV, p-anisaldehyde) 
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Dimethylamino Ketone 109 (Cortistatin J Series). 
Concentrated aqueous hydrochloric acid solution (37 wt %, 2.15 mL, 26.1 mmol, 
300 equiv) was added to a solution of dimethylamino alcohol (cortistatin J and K series) 
133 (40 mg, 87.0 µmol, 1 equiv) in chloroform (4 mL).  The resulting biphasic mixture 
was stirred vigorously. After 20 min, the reaction flask was placed in an ice bath and 
saturated aqueous sodium carbonate solution (20 mL) was added dropwise over 10 min 
(CAUTION: gas evolution).  The layers were separated.  The aqueous layer was 
extracted with dichloromethane (4 × 20 mL).  The organic layers were combined.  The 
combined solution was washed with saturated aqueous sodium chloride solution (15 mL) 
and the washed solution was dried over sodium sulfate.  The dried solution was filtered 
and the filtrate was concentrated. The residue was purified by flash-column 
chromatography on Davisil® silica gel (ethyl acetate initially, grading to 5:1 ethyl 
acetate–methanol, then 1:1 ethyl acetate–methanol) to furnish trienyl alcohol 134 
(cortistatin J series) as a white solid (25 mg, 87%) which was transformed in the 
following step directly. 
Dess-Martin periodinane (97 mg, 229 µmol, 3 equiv) was added to an ice-cooled 
solution of the trienyl alcohol 134 prepared above (25 mg, 76.3 µmol, 1 equiv) in 
dichloromethane (3.5 mL).  After 10 min, the ice bath was removed and the reaction flask 
was allowed to warm to 23 ºC. After 2 h, ethyl acetate (10 mL) was added, followed by a 
mixture of water (4 mL), saturated aqueous sodium thiosulfate solution (4 mL), and 
saturated aqueous sodium bicarbonate solution (2 mL).  The resulting biphasic mixture 
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was stirred vigorously until both layers were clear. The layers were separated.  The 
aqueous layer was extracted with ethyl acetate (3 × 10 mL).  The organic layers were 
combined.  The combined solution was washed with saturated aqueous sodium chloride 
solution (10 mL) and the washed solution was dried over sodium sulfate.  The dried 
solution was filtered and the filtrate was concentrated.  The residue was purified by flash-
column chromatography on Davisil® silica gel (ethyl acetate initially, grading to 5:1 
ethyl acetate–methanol, then 1:1 ethyl acetate–methanol) to furnish dimethylamino 
ketone 109 (cortistatin J series) as a white solid (22 mg, 77% over two steps).   
 
 
1H NMR:  
(500 MHz, CDCl3) 
6.09 (dd, 1H, J = 9.7, 2.6 Hz), 5.83 (d, 1H, J = 9.7 Hz), 
5.82 (s, 1H), 5.43 (dd, 1H, J = 5.0, 3.0 Hz), 3.44 (d, 1H, 
J = 11.0 Hz), 2.52 (dd, 1H, J = 18.8, 8.7 Hz), 2.44 (dd, 
1H, J = 12.6, 5.5 Hz), 2.31 (s, 6H), 2.29–2.26 (m, 1H), 
2.26–2.19 (m, 3H), 2.19–2.14 (m, 1H), 2.08 (ddd, 1H, J 
= 11.0, 9.0, 2.2 Hz), 1.99 (app t, 1H, J = 12.0 Hz), 1.95–
1.87 (m, 2H), 1.85–1.77 (m, 1H), 1.76–1.69 (m, 1H), 
0.95 (s, 3H). 
 
13C NMR :  
(126 MHz, CDCl3) 
220.5, 141.1, 140.1, 132.5, 127.2, 121.0, 120.8, 81.9, 
79.2, 60.4, 47.9, 47.3, 40.5, 38.0, 35.9, 34.2, 31.4, 31.0, 
18.9, 17.1. 
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FTIR, cm–1: 
 (thin film) 
2967 (s), 2864 (m), 1744 (vs), 1454 (m), 1153 (m), 1078 
(m). 
 
HRMS:  
(ESI) 
Calcd for (C21H27NO2+H)+                      326.2115 
Ffound                                                      326.2119. 
 
TLC 
(methanol) 
Rf  = 0.32 (UV, p-anisaldehyde) 
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Triene 135. 
Methanesulfonyl chloride (3.3 µL, 41.3 µmol, 2 equiv) was added to an ice-
cooled solution of the dimethylamino alcohol 133 (9.5 mg, 20.7 µmol, 1 equiv) and 
triethylamine (9.0 µL, 62.0 µmol, 3 equiv) in dichloromethane (0.50 mL).  After 40 min, 
saturated aqueous sodium bicarbonate solution (0.20 mL) was added.  The reaction 
mixture was then partitioned between saturated aqueous sodium bicarbonate solution (10 
mL) and dichloromethane (20 mL).  The layers were separated.  The aqueous layer was 
extracted with dichloromethane (3 × 10 mL).  The organic layers were combined.  The 
combined solution was washed with saturated aqueous sodium chloride solution (10 mL).  
The washed solution was dried over sodium sulfate.  The dried solution was filtered and 
the filtrate was concentrated. The residue was purified by flash-column chromatography 
on Davisil® silica gel (10:1 ethyl acetate–methanol initially, grading to 5:1 ethyl acetate–
methanol, then 2:1 ethyl acetate–methanol) to afford triene 135 as a pale yellow solid (6.8 
mg, 75%).  
 
1H NMR:  
(500 MHz, CDCl3) 
6.10 (d, 1H, J = 10.0 Hz), 5.83 (s, 1H), 5.78 (d, 1H, J = 
9.6 Hz), 5.49–5.32 (m, 1H), 3.77 (app t, 1H, J = 8.7 Hz), 
3.47 (br d, 1H, J = 10.0 Hz), 2.33 (s, 6H), 2.25 (app t, 
1H, J = 12.0 Hz), 2.21–2.09 (m, 2H), 2.09–1.92 (m, 
4H), 1.88 (dd, 1H, J = 11.0, 4.6 Hz), 1.83–1.60 (m, 4H), 
1.60–1.47 (m, 1H), 0.89 (s, 9H), 0.77 (s, 3H), 0.03 (s, 
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6H). 
 
13C NMR :  
(126 MHz, CDCl3) 
141.0, 139.4, 131.3, 127.7, 122.7, 121.5, 82.4, 81.7, 
78.8, 60.5, 46.4, 43.5, 40.4, 39.6, 38.1, 30.9, 30.7, 30.6, 
25.8, 19.5, 18.1, 13.4, −4.4, −4.8. 
 
FTIR, cm–1: 
 (thin film) 
2957 (s), 2859 (m), 1620 (s), 1572 (s), 1514 (m), 1462 
(m), 1248 (s). 
 
HRMS:  
(ESI) 
Calcd for (C27H43NO2Si+H)+                    442.3136  
Found                                                         442.3139 
 
TLC 
(methanol) 
Rf  = 0.45 (UV, p-anisaldehyde) 
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Acetate 137 (Cortistatin K Series). 
Scandium trifluoromethanesulfonate (2.68 mg, 5.44 µmol, 0.05 equiv) was added 
to an ice-cooled solution of dimethylamino alcohol 133 (cortistatin J and K series) (50 
mg, 109 µmol, 1 equiv) and acetic anhydride (205 µL, 2.175 µmol, 20.0 equiv) in a 
mixture of acetonitrile (1.0 mL) and dichloromethane (1.0 mL).  After 1 h, saturated 
aqueous sodium bicarbonate solution (200 µL) was added and the resulting biphasic 
mixture was concentrated to remove the bulk of solvent.  The concentrate was partitioned 
between ethyl acetate (30 mL) and saturated aqueous potassium carbonate solution (10 
mL). The layers were separated.  The organic layer was washed with saturated aqueous 
potassium carbonate solution (10 mL).  The aqueous layers were combined.  The 
combined aqueous solution was extracted with ethyl acetate (2 × 10 mL).  The combined 
organic layers were washed with saturated aqueous sodium chloride solution (10 mL) and 
the washed solution was dried over sodium sulfate.  The dried solution was filtered and 
the filtrate was concentrated to provide acetate 137 (cortistatin K series) as an off-white 
solid (51 mg, 93%).   
  
1H NMR:  
(500 MHz, CDCl3) 
5.67 (d, 1H, J = 2.0 Hz), 5.55 (d, 1H, J = 8.8 Hz), 5.09 
(d, 1H, J = 2.4 Hz), 3.60 (app t, 1H, J = 8.3 Hz), 2.89 
(ddd, 1H, J = 12.7, 9.3, 3.4 Hz), 2.49–2.39 (m, 1H), 
2.29 (s, 6H), 2.30 (s, 6H), 2.30–2.25 (m, 1H), 2.07 (s, 
3H), 2.06–1.99 (m, 2H), 1.98–1.79 (m, 6H), 1.75–1.69 
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(m, 1H), 1.68–1.55 (m, 2H), 1.54–1.45 (m, 1H), 1.14 
(app td, 1H, J = 13.2, 4.9 Hz), 0.90–0.85 (m, 9H), 0.79 
(s, 3H), 0.01 (s, 6H). 
 
13C NMR :  
(126 MHz, CDCl3) 
171.0, 148.4, 143.1, 118.6, 116.7, 83.5, 81.6, 78.8, 70.2, 
62.4, 47.9, 43.9, 40.6, 37.6, 36.3, 32.6, 32.3, 30.5, 28.5, 
25.8, 21.6, 19.6, 18.0, 10.9, −4.5, −4.9. 
FTIR, cm–1: 
 (thin film) 
2953 (m), 2858 (m), 1734 (m), 1369 (m), 1238 (s). 
 
 
HRMS:  
(ESI) 
Calcd for (C29H47NO4Si+H)+                     502.3347 
 Found                                                         502.3327 
 
TLC 
(methanol) 
Rf  = 0.69 (UV, p-anisaldehyde) 
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tert-Butyldimethylsilyl Ether 139 (Cortistatin K Series). 
Note: Tetrahydrofuran used in this procedure was degassed by sparging for 20 min with a 
slow stream of argon gas through a 22-gauge stainless steel needle prior to use. Raney 
nickel was prepared according to the procedure of Baran and coworkers.42 
A solution of lithium borohydride in tetrahydrofuran (1.0 M, 1.0 mL, 1.0 mmol, 
10 equiv) was added dropwise to a solution of acetate 133 (cortistatin K series) (50 mg, 
99.6 µmol, 1 equiv) and tetrakis(triphenylphosphine)palladium(0) (23 mg, 19.9 µmol, 0.2 
equiv) in tetrahydrofuran (4 mL).  After 1 h, methanol (10 mL) was added, followed by a 
slurry of Raney nickel in water (4 drops, ca. 0.2 mL).  After 16 h, the reaction mixture 
was filtered through a pad of Celite, washing with methanol (3 × 10 mL).  The filtrates 
were combined and the combined organic solution was concentrated.  The residue was 
purified by flash-column chromatography on Davisil® silica gel (ethyl acetate initially, 
grading to 5:1 ethyl acetate–methanol, then 1:1 ethyl acetate–methanol) to furnish tert-
butyldimethylsilyl ether 139 (cortistatin K series) as a pale yellow solid (39 mg, 90%).   
 
1H NMR:  
(500 MHz, CDCl3) 
5.69 (d, 1H, J = 2.0 Hz), 5.26–5.20 (m, 1H), 3.59 (app t, 
1H, J = 8.3 Hz), 2.77–2.65 (m, 1H), 2.52–2.37 (m, 1H), 
2.33 (s, 6H), 2.30 (s, 1H), 2.27–2.20 (m, 2H), 2.19–2.07 
(m, 1H), 2.07–1.89 (m, 4H), 1.89–1.76 (m, 3H), 1.76–
                                                 
42 Shi, J.; Shigehisa, H.; Guerrero, C. A.; Shenvi, R. A.; Li, C. C.; Baran, P. S. Angew. Chem., Int. Ed. 
2009, 48, 4328−4331. 
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1.68 (m, 1H), 1.68–1.54 (m, 2H), 1.54–1.42 (m, 1H), 
1.12 (app td, 1H, J = 13.1, 4.6 Hz), 0.88 (s, 9H), 0.79 (s, 
3H), 0.01 (s, 6H). 
 
13C NMR :  
(126 MHz, CDCl3) 
145.4, 140.2, 119.4, 117.4, 83.3, 81.7, 79.2, 58.8, 48.0, 
43.9, 41.1, 38.8, 36.6, 36.5, 33.0, 30.6, 28.5, 28.2, 25.8, 
19.7, 18.1, 10.9, –4.5, –4.9. 
 
FTIR, cm–1: 
 (thin film) 
2955 (s), 2657 (m), 1738 (m), 1472 (m), 1252 (s). 
 
 
HRMS:  
(ESI) 
Calcd for (C27H45NO2Si+H)+                   444.3292 
Ffound                                                      444.3293. 
 
TLC 
(methanol) 
Rf = 0.31 (UV, p-anisaldehyde) 
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Dimethylamino Alcohol 154 (Cortistatin K Series). 
A solution of tetra-n-butylammonium fluoride in tetrahydrofuran (1.0 M, 250 µL, 
250 µmol, 3 equiv) was added to a solution of tert-butyldimethylsilyl ether 139 
(cortistatin K series) (37 mg, 83.4 µmol, 1 equiv) in tetrahydrofuran (2.1 mL).  The 
reaction flask was placed in an oil bath preheated to 65 ºC.  After 3 h, the oil bath was 
removed and the reaction flask was allowed to cool to 23 ºC.  The reaction mixture was 
then concentrated to remove the bulk of solvent.  The residue was purified by flash-
column chromatography on Davisil® silica gel (ethyl acetate initially, grading to 5:1 
ethyl acetate–methanol, then 2:1 ethyl acetate–methanol) to furnish dimethylamino 
alcohol 154 (cortistatin K series) as a white solid (24 mg, 87%).   
 
1H NMR:  
(400 MHz, CDCl3) 
5.70 (d, 1H, J = 1.8 Hz), 5.29–5.15 (m, 1H), 3.70 (app t, 
1H, J = 8.6 Hz), 2.79–2.62 (m, 1H), 2.45 (app t, 1H, J = 
13.5 Hz), 2.32 (s, 6H), 2.31–2.22 (m, 2H), 2.20–2.07 
(m, 2H), 2.06–1.93 (m, 4H), 1.93–1.74 (m, 5H), 1.74–
1.44 (m, 3H), 1.21 (ddd, 1H, J = 13.0, 4.5 Hz), 0.85 (s, 
3H). 
 
13C NMR :  
(126 MHz, CDCl3) 
145.0, 140.1, 119.6, 117.4, 83.1, 81.7, 79.2, 58.7, 48.4, 
43.5, 40.8, 38.8, 36.4, 36.1, 33.1, 30.1, 28.4, 27.9, 19.6, 
10.7. 
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FTIR, cm–1: 
 (thin film) 
3443 (br), 2955 (s), 2860 (m), 1738 (m), 1462 (m), 1254 
(s). 
 
HRMS:  
(ESI) 
Calcd for (C21H31NO2+H)+                           330.2428 
Found                                                            330.2438 
 
TLC 
(methanol) 
Rf  = 0.30 (UV, p-anisaldehyde) 
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Dimethylamino Ketone 110 (Cortistatin K Series). 
Dess-Martin periodinane (77 mg, 183 µmol, 3 equiv) was added to an ice-cooled 
solution of dimethylamino alcohol 154 (cortistatin K series) (20 mg, 61 µmol, 1 equiv) in 
dichloromethane (4 mL).  After 10 min, the ice bath was removed and the reaction flask 
was allowed to warm to 23 ºC.  After 2 h, ethyl acetate (10 mL) was added, followed by a 
mixture of water (4 mL), saturated aqueous sodium thiosulfate solution (4 mL), and 
saturated aqueous sodium bicarbonate solution (2 mL).  The resulting biphasic mixture 
was stirred vigorously until both layers were clear and colorless. The layers were 
separated.  The aqueous layer was extracted with ethyl acetate (3 × 10 mL).  The organic 
layers were combined.  The combined solution was washed with saturated aqueous 
sodium chloride solution (10 mL) and the washed solution was dried over sodium sulfate.  
The dried solution was filtered and the filtrate was concentrated.  The residue was 
purified by flash-column chromatography on Davisil® silica gel (ethyl acetate initially, 
grading to 5:1 ethyl acetate–methanol, then 2:1 ethyl acetate–methanol) to furnish 
dimethylamino ketone 110 (cortistatin K series) as a pale yellow solid (18 mg, 90%).   
 
1H NMR:  
(500 MHz, CDCl3) 
5.74 (d, 1H, J = 2.4 Hz), 5.34–5.27 (m, 1H), 2.66 (br s, 
1H), 2.51 (dd, 1H, J = 19.0, 9.0 Hz), 2.53–2.43 (m, 1H), 
2.41–2.35 (m, 1H), 2.32 (s, 6H), 2.31–2.23 (m, 1H), 
2.23–2.07 (m, 4H), 2.07–1.95 (m, 3H), 1.95–1.78 (m, 
 76 
 
5H), 1.39 (app td, 1H, J = 13.3, 5.1 Hz), 0.96 (s, 3H). 
 
13C NMR :  
(126 MHz, CDCl3) 
219.8, 143.8, 139.8, 120.4, 118.3, 82.8, 79.5, 58.7, 49.5, 
48.1, 41.1, 38.8, 36.6, 35.9, 34.3, 31.3, 28.1, 27.8, 18.8, 
14.0. 
 
FTIR, cm–1: 
 (thin film) 
2955 (s), 2857 (m), 1740 (vs), 1472 (m), 1252 (s). 
 
 
HRMS:  
(ESI) 
Calcd for (C21H29NO2+H)+                         328.2271 
Found                                                          328.2273. 
 
TLC 
(methanol) 
Rf  = 0.30 (UV, p-anisaldehyde) 
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Dienyl Diol 155 (Cortistatin L Series). 
Concentrated aqueous hydrofluoric acid solution (48 wt %, 573 µL, 15.9 mmol, 
152 equiv) was added dropwise to a polypropylene vessel containing an ice-cooled  
solution of azido alcohol 11241 (48 mg, 105 µmol, 1 equiv) in a mixture of 
tetrahydrofuran (0.9 mL) and acetonitrile (1.8 mL).  After 3 h, the product solution was 
poured into water (30 mL) containing dipotassium hydrogen phosphate (10 g).  The 
reaction vessel was rinsed with ethyl acetate (40 mL) and the rinse was transferred to the 
product mixture. The resulting biphasic mixture was stirred vigorously, then was 
transferred to a separatory funnel.  The layers were separated.  The aqueous layer was 
extracted with ethyl acetate (4 × 20 mL). The organic layers were combined.  The 
combined solution was washed sequentially with saturated aqueous sodium bicarbonate 
solution (30 mL) then saturated aqueous sodium chloride solution (2 × 30 mL) and the 
washed solution was dried over sodium sulfate.  The dried solution was filtered and the 
filtrate was concentrated.  The residue was purified by flash-column chromatography on 
silica gel (initially 20:1 benzene−acetone, grading to 10:1 benzene−acetone, then 5:1 
benzene−acetone, then 3:1 benzene−acetone) to furnish diastereomerically pure dienyl 
diol 155 (cortistatin L series) as a white powder (29.5 mg, 82%).   
 
1H NMR:  
(500 MHz, CDCl3) 
.71 (d, 1H, J = 2.3 Hz), 5.16 (s, 1H), 4.24 (d, 1H, J = 7.8 
Hz), 3.71 (dd, 1H, J = 8.7, 8.6 Hz), 3.50 (ddd, 1H, J = 
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12.6, 8.5, 3.7 Hz), 2.52–2.40 (m, 1H), 2.32 (ddd, 1H, J 
= 16.5, 4.6, 1.8 Hz), 2.19–2.00 (m, 5H), 2.00–1.84 (m, 
3H), 1.80 (ddd, 1H, J = 12.4, 5.5, 1.8 Hz), 1.73–1.46 
(m, 4H), 1.42 (br s, 1H), 1.22 (ddd, 1H, J = 12.8, 12.7, 
4.6 Hz), 0.84 (s, 3H). 
 
13C NMR :  
(126 MHz, CDCl3) 
148.1, 141.8, 118.8, 118.7, 83.6, 81.6, 78.1, 72.3, 63.4, 
48.3, 43.5, 38.3, 38.3, 35.9, 32.6, 30.1, 28.5, 19.5, 10.6. 
 
FTIR, cm–1: 
 (thin film) 
3383 (br), 2926 (m), 2100 (vs), 1255 (m). 
 
 
HRMS:  
(ESI) 
Calcd for (C19H25N3O3+Na)+                    366.1788  
Found                                                        366.1790. 
 
TLC 
(4:1 benzene-acetone) 
Rf  = 0.28 (UV, p-anisaldehyde) 
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Azido tert-Butyldimethylsilyl Ether 140 (Cortistatin L Series). 
A freshly-prepared solution of tert-butyldimethylsilyl chloride in tetrahydrofuran 
(1.0 M, 134 µL, 134 µmol, 2 equiv) was added dropwise to a solution of dienyl diol 155 
(cortistatin L series) (23 mg, 67.0 µmol, 1 equiv) and 1,8-diazabicyclo[5.4.0]undec-7-ene 
(100 µL, 670 µmol, 10 equiv) in tetrahydrofuran (0.5 mL).  After 24 h, a second portion 
of tert-butyldimethylsilyl chloride solution in tetrahydrofuran (1.0 M, 67 µL, 67 µmol, 1 
equiv) was added.  After an additional 36 h, the reaction mixture was partitioned between 
aqueous hydrochloric acid solution (1.0 N, 10 mL) and ethyl acetate (20 mL).  The layers 
were separated.  The aqueous layer was extracted with ethyl acetate (2 × 10 mL).  The 
organic layers were combined.  The combined solution was washed with saturated 
aqueous sodium chloride solution (10 mL) and the washed solution was dried over 
sodium sulfate.  The dried solution was filtered and the filtrate was concentrated.  The 
residue was purified by flash-column chromatography (10:1 hexanes−ethyl acetate 
initially, grading to 5:1 hexanes−ethyl acetate, then 2:1 hexanes−ethyl acetate) to furnish  
azido tert-butyldimethylsilyl ether 140 (cortistatin L series) as a colorless oil (28 mg, 
90%).   
 
1H NMR:  
(500 MHz, CDCl3) 
5.70 (s, 1H), 5.05 (s, 1H), 4.20 (d, 1H, J = 7.9 Hz), 3.71 
(app t, 1H, J = 8.6 Hz), 3.46 (ddd, 1H, J = 12.3, 8.1, 4.2 
Hz), 2.53–2.38 (m, 1H), 2.30 (dd, 1H, J = 16.3, 3.7 Hz), 
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2.18–2.06 (m, 2H), 2.05–1.96 (m, 2H), 1.96–1.91 (m, 
1H), 1.91–1.81 (m, 2H), 1.79 (dd, 1H, J = 12.3, 4.4 Hz), 
1.74–1.55 (m, 3H), 1.50 (app tdd, 1H, J = 12.4, 8.3, 3.7 
Hz), 1.41–1.34 (m, 1H), 1.21 (app td, 1H, J = 13.0, 4.7 
Hz), 0.91 (s, 9H), 0.83 (s, 3H), 0.17 (s, 3H), 0.12 (s, 
3H). 
 
13C NMR :  
(126 MHz, CDCl3) 
147.5, 140.7, 120.6, 118.9, 83.5, 81.6, 78.0, 73.3, 63.7, 
48.3, 43.5, 38.9, 38.2, 36.0, 32.6, 30.1, 28.5, 25.8, 19.5, 
18.0, 10.6, –4.5, –4.8. 
 
FTIR, cm–1: 
 (thin film) 
3421 (br), 2955 (s), 2857 (m), 2101 (vs), 1464 (m), 
1258 (s). 
 
HRMS:  
(ESI) 
Calcd for (C25H39N3O3Si+Na)+                     480.2653 
Found                                                            480.2640. 
 
TLC 
(2:1 hexanes–ethyl acetate) 
Rf = 0.39 (UV, p-anisaldehyde) 
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Dimethylamino Alcohol 143 (Cortistatin L Series). 
A solution of trimethylphosphine in tetrahydrofuran (1.0 M, 306 µL, 306 µmol, 5 
equiv) was added to a solution of azido tert-butyldimethylsilyl ether 140 (cortistatin L 
series) (28 mg, 61.2 µmol, 1 equiv) in tetrahydrofuran (3 mL).  After 24 h, formalin (37 
wt %, 480 µL, 6.12 mmol, 100 equiv) was added.  After 20 h, methanol (3 mL) was 
added, then acetic acid (70 µL, 1.22 mmol, 20 equiv) and, lastly, a solution of sodium 
cyanoborohydride (77 mg, 1.22 mmol, 20 equiv) in methanol (1 mL).  After 2 h, the 
reaction mixture was concentrated to remove the bulk of solvent.  The concentrate was 
partitioned between aqueous sodium hydroxide solution (1.0 N, 15 mL) and ethyl acetate 
(20 mL).  The layers were separated.  The aqueous layer was extracted with ethyl acetate 
(3 × 20 mL).  The organic layers were combined.  The combined solution was washed 
with saturated aqueous sodium chloride solution (15 mL) and the washed solution was 
dried over sodium sulfate.  The dried solution was filtered and the filtrate was 
concentrated. The residue was purified by flash-column chromatography on Davisil® 
silica gel (66:33:1 hexanes–ethyl acetate–triethylamine initially, grading to 50:49:1 
hexanes–ethyl acetate–triethylamine) to provide dimethylamino alcohol 143 (cortistatin L 
series) as a pale yellow solid (25 mg, 90%).  
 
1H NMR:  
(500 MHz, CDCl3) 
5.70 (d, 1H, J = 2.4 Hz), 5.10 (d, 1H, J = 2.0 Hz), 4.23 
(d, 1H, J = 8.3 Hz), 3.71 (app td, 1H, J = 8.4, 5.6 Hz), 
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2.67–2.51 (m, 1H), 2.51–2.38 (m, 1H), 2.36–2.28 (m, 
1H), 2.27 (s, 6H), 2.18–1.95 (m, 3H), 1.93–1.75 (m, 
3H), 1.74–1.59 (m, 2H), 1.58–1.44 (m, 2H), 1.38 (d, 1H, 
J = 5.4 Hz), 1.25–1.16 (m, 1H), 0.89 (s, 9H), 0.83 (s, 
3H), 0.08 (s, 3H), 0.07 (s, 3H). 
 
13C NMR :  
(126 MHz, CDCl3) 
146.6, 140.2, 122.9, 119.4, 83.2, 81.7, 79.3, 69.3, 65.7, 
48.4, 43.5, 41.0, 37.8, 36.1, 32.7, 32.5, 30.1, 28.4, 26.0, 
19.5, 18.3, 10.7, –4.1, –4.7. 
 
FTIR, cm–1: 
 (thin film) 
3431 (br), 2930 (s), 2857 (m), 1715 (m), 1472 (m), 1250 
(s). 
 
HRMS:  
(ESI) 
Calcd for (C27H45NO3Si+H)+                         460.3242 
Found                                                             460.3250 
 
TLC 
(50:49:1 hexanes–ethyl 
acetate–triethylamine) 
Rf  = 0.19  (UV, p-anisaldehyde) 
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Dimethylamino Ketone 111 (Cortistatin L Series). 
Dess-Martin periodinane (69 mg, 163 µmol, 3 equiv) was added to an ice-cooled 
solution of dimethylamino alcohol 143 (cortistatin L series) (25 mg, 54.4 µmol, 1 equiv) 
in dichloromethane (2.7 mL).  After 10 min, the ice bath was removed and the reaction 
flask was allowed to warm to 23 ºC.  After 2 h, ethyl acetate (10 mL) was added, 
followed by a mixture of water (4 mL), saturated aqueous sodium thiosulfate solution (4 
mL), and saturated aqueous sodium bicarbonate solution (2 mL).  The resulting biphasic 
mixture was stirred vigorously until both layers were clear.  The layers were separated.  
The aqueous layer was extracted with ethyl acetate (3 × 10 mL).  The organic layers were 
combined.  The combined solution was washed with saturated aqueous sodium chloride 
solution (10 mL) and the washed solution was dried over sodium sulfate.  The dried 
solution was filtered and the filtrate was concentrated.  The residue was purified by flash-
column chromatography on Davisil® silica gel (66:33:1 hexanes–ethyl acetate–
triethylamine initially, grading to 50:49:1 hexanes–ethyl acetate–triethylamine) to furnish 
dimethylamino ketone 111 (cortistatin L series) as a pale yellow oil (23 mg, 90%).   
 
1H NMR:  
(500 MHz, CDCl3) 
5.73 (d, 1H, J = 2.3 Hz), 5.14 (d, 1H, J = 2.5 Hz), 4.25 
(d, 1H, J = 8.2 Hz), 2.66–2.55 (m, 1H), 2.55–2.43 (m, 
2H), 2.42–2.33 (m, 1H), 2.28 (s, 6H), 2.24–2.06 (m, 
5H), 2.02 (dd, 1H, J = 12.0, 6.5 Hz), 1.96–1.78 (m, 5H), 
1.39 (app td, 1H, J = 13.2, 5.2 Hz), 0.97 (s, 3H), 0.89 (s, 
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9H), 0.08 (s, 3H), 0.08 (s, 3H). 
 
13C NMR :  
(126 MHz, CDCl3) 
219.7, 145.5, 139.9, 123.6, 120.1, 82.9, 79.6, 69.3, 65.7, 
49.4, 48.1, 41.0, 37.8, 35.8, 33.9, 32.4, 31.2, 27.8, 26.0, 
18.8, 18.3, 14.0, –4.1, –4.7. 
 
FTIR, cm–1: 
 (thin film) 
2934 (s), 2863 (m), 1740 (vs), 1460 (m), 1248 (s). 
 
 
HRMS:  
(ESI) 
Calcd for (C27H43NO3Si+H)+ 458.3085 
Found 458.3088. 
 
TLC 
(50:49:1 hexanes–ethyl 
acetate–triethylamine) 
Rf  = 0.24  (UV, p-anisaldehyde) 
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Azido Dienyl Diol 147. 
A solution of bromo dienyl bromide 146 (10 mg, 16.0 µmol, 1 equiv) and sodium 
azide (52 mg, 800 µmol, 50 equiv) in a mixture of N,N-dimethylformamide (0.8 mL) and 
aqueous potassium phosphate buffer solution (pH 7.0, 0.5 M, 0.20 mL) was degassed by 
sparging for 10 min with a slow stream of argon gas through a 22-gauge stainless steel 
needle. The reaction flask was capped with a glass stopper and the stopped flask was 
sealed with Teflon® tape and then Parafilm®.  After sealing, the reaction flask was 
placed in an oil bath preheated to 100 ºC. After 12 h, the oil bath was removed and the 
reaction flask was allowed to cool to 23 ºC. The reaction mixture was partitioned between 
half-saturated aqueous sodium chloride solution (10 mL) and 1:1 hexanes−ethyl acetate 
(20 mL). The layers were separated. The aqueous layer was extracted with 1:1 
hexanes−ethyl acetate (3 × 10 mL).  The organic layers were combined.  The combined 
solution was washed sequentially with water (10 mL) then saturated aqueous sodium 
chloride solution (2 × 10 mL).  The washed solution was dried over sodium sulfate.  The 
dried solution was filtered and the filtrate was concentrated.  The residue was purified by 
flash-column chromatography on Davisil® silica gel (10:1 hexanes−ethyl acetate 
initially, grading to 5:1 hexanes−ethyl acetate, then 2:1 hexanes−ethyl acetate) to furnish 
azido dienyl diol 147 as a white solid (4.5 mg, 60%).   
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1H NMR:  
(500 MHz, CDCl3) 
6.18 (d, 1H, J = 2.3 Hz), 5.46 (dd, 1H, J = 5.0, 2.3 Hz), 
4.07 (d, 1H, J = 8.2 Hz), 3.76 (app t, 1H, J = 8.7 Hz), 
3.48–3.26 (m, 2H), 2.25 (app t, 1H, J = 11.0 Hz), 2.19–
2.06 (m, 3H), 2.06–1.92 (m, 3H), 1.82–1.61 (m, 4H), 
1.61–1.44 (m, 2H), 0.88 (s, 9H), 0.74 (s, 3H), 0.03 (s, 3H), 
0.02 (s, 3H). 
 
13C NMR :  
(126 MHz, CDCl3) 
139.0, 138.6, 123.0, 119.9, 82.1, 81.6, 78.4, 78.2, 72.3, 
60.3, 46.2, 43.4, 39.8, 39.3, 37.5, 30.7, 25.8, 19.4, 18.0, 
13.3, −4.4, −4.8. 
 
FTIR, cm–1: 
 (thin film) 
3466 (br), 2955 (s), 2857 (m), 2099 (vs), 1472 (m), 
1362 (m), 1250 (s). 
 
 
HRMS:  
(ESI) 
Calcd for (C25H39N3O4Si+Na)+:                    496.2602 
Found:                                                            496.2619 
 
TLC 
(1:1 hexanes–ethyl acetate) 
Rf = 0.55 (UV, p-anisaldehyde) 
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Dimethylamino Diol 148. 
A solution of azido dienyl diol 147 (4.0 mg, 8.44 µmol, 1 equiv) in a mixture of 
tetrahydrofuran (1.0 mL) and aqueous sodium hydroxide solution (1.0 N, 0.50 mL) was 
degassed by sparging for 20 min with a slow stream of argon gas through a 22-gauge 
stainless steel needle.  To the degassed solution was added a solution of 
trimethylphosphine in tetrahydrofuran (1.0 M, 43 µL, 43 µmol, 5 equiv).  After 2 h, 
methanol (2 mL) was added, followed by aqueous hydrochloric acid solution (2.0 N, 0.25 
mL) then acetic acid (10 µL, 169 µmol, 20 equiv).  To the resulting solution were added 
sequentially formalin (37 wt %, 70 µL, 844 µmol, 100 equiv) and a solution of sodium 
cyanoborohydride (11 mg, 169 µmol, 20 equiv) in methanol (0.5 mL).  After 1 h, the 
reaction mixture was concentrated to remove the bulk of solvent. The concentrate was 
partitioned between aqueous sodium hydroxide solution (1.0 N, 10 mL) and 
dichloromethane (15 mL).  The layers were separated. The aqueous layer was extracted 
with dichloromethane (3 × 10 mL).  The organic layers were combined.  The combined 
solution was washed with saturated aqueous sodium chloride solution (10 mL) and the 
washed solution was dried over sodium sulfate.  The dried solution was filtered and the 
filtrate was concentrated.  The residue was purified by flash-column chromatography on 
Davisil® silica gel (10:1 ethyl acetate–methanol initially, grading to 1:1 ethyl acetate–
methanol) to furnish dimethylamino diol 148 as a white solid (3.2 mg, 80%).  
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1H NMR:  
(500 MHz, CDCl3) 
6.23 (s, 1H), 5.44 (br s, 1H), 4.09 (d, 1H, J = 9.3 Hz), 
3.76 (app t, 1H, J = 8.5 Hz), 3.33 (app t, 1H, J = 9.8 
Hz), 2.49 (app t, 1H, J = 10.0 Hz), 2.33 (s, 6H), 2.23 
(app t, 1H, J = 11.5 Hz), 2.20–2.07 (m, 2H), 2.04–1.92 
(m, 2H), 1.92–1.82 (m, 2H), 1.81–1.64 (m, 3H), 1.64–
1.47 (m, 3H), 0.88 (s, 9H), 0.74 (s, 3H), 0.03 (s, 3H), 
0.02 (s, 3H). 
 
13C NMR :  
(126 MHz, CDCl3) 
139.4, 139.3, 122.2, 119.6, 82.1, 81.7, 79.3, 74.1, 73.7, 
62.3, 46.3, 43.4, 40.0, 39.8, 39.3, 30.7, 30.6, 29.2, 25.8, 
19.4, 18.1, 13.2, −4.4, −4.8. 
 
FTIR, cm–1: 
 (thin film) 
3399 (br), 2955 (s), 2858 (m), 1472 (m), 1387 (m),  
1250 (s). 
 
HRMS:  
(ESI) 
Calcd for (C27H45NO4Si+H)+: 476.3191 
Found: 476.3199 
 
TLC 
(methanol) 
Rf = 0.24 (UV, p-anisaldehyde) 
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Dimethylamino Diacetate 41 (Shair’s Intermediate). 
 Acetic anhydride (16 µL, 168 µmol, 40 equiv) was added to a solution of 
dimethylamino diol 148 (2.0 mg, 4.20 µmol, 1 equiv) and 4-dimethylaminopyridine (2.0 
mg, 16.4 µmol, 4 equiv) in pyridine (0.21 mL).  After 24 h, the reaction mixture was 
partitioned between ethyl acetate (20 mL) and saturated aqueous sodium bicarbonate 
solution (10 mL).  The layers were separated.  The aqueous layer was extracted with 
ethyl acetate (3 × 10 mL). The organic layers were combined.  The combined solution 
was washed with saturated aqueous sodium chloride solution (10 mL) and the washed 
solution was dried over sodium sulfate.  The dried solution was filtered and the filtrate 
was concentrated.  The residue was purified by flash-column chromatography on 
Davisil® silica gel (5:1 hexanes−ethyl acetate initially, grading to 2:1 hexanes−ethyl 
acetate, then 1:1 hexanes−ethyl acetate) to furnish dimethylamino diacetate 41 as a pale 
yellow foam (1.2 mg, 50%). The 1H NMR data for 41 was identical to that reported by 
Shair and coworkers for this compound.34 
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Dimethylamino Ketone 108 (Cortistatin A Series). 
A solution of dienyl azido diol (cortistatin A series) 153 (70 mg, 0.196 mmol, 1 
equiv) in a mixture of tetrahydrofuran (6 mL) and aqueous sodium hydroxide solution 
(1.0 N, 3 mL) was degassed by sparging for 20 min with a slow stream of argon gas 
through a 20-gauge stainless steel needle.  To the degassed solution was added a solution 
of trimethylphosphine in tetrahydrofuran (1.0 M, 588 µL, 0.588 mmol, 3 equiv).  After 2 
h, methanol (9 mL) was added, followed by aqueous hydrochloric acid solution (3.0 N, 1 
mL) then acetic acid (224 µL, 3.92 mmol, 20 equiv).  To the resulting solution were 
added sequentially formalin (37 wt. %, 795 µL, 9.80 mmol, 50 equiv) and a solution of 
sodium cyanoborohydride (123 mg, 1.96 mmol, 10 equiv) in methanol (1 mL).  After 1 h, 
the reaction mixture was concentrated to remove the bulk of solvent. The concentrate was 
partitioned between aqueous sodium hydroxide solution (1.0 N, 20 mL) and 
dichloromethane (40 mL).  The layers were separated. The aqueous layer was extracted 
with dichloromethane (4 × 20 mL).  The organic layers were combined.  The combined 
solution was washed with saturated aqueous sodium chloride solution (30 mL) and the 
washed solution was dried over sodium sulfate.  The dried solution was filtered and the 
filtrate was concentrated.  The residue was purified by flash-column chromatography on 
Davisil® silica gel (4:1 ethyl acetate-methanol initially, grading to 2:1 ethyl acetate-
methanol) to afford dimethylamino keto diol 23 (cortistatin A series) as a white solid (59 
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mg, 84%). The characteristic data for 23 was identical to that reported by the Baran group 
and by the Shair group.34,43 
Chlorotriethylsilane (166 µL, 0.985 mmol, 6 equiv) was added dropwise to an ice-
cooled solution of the residue prepared above (59 mg, 0.164 mmol, 1 equiv), 
triethylamine (275 µL, 1.97 mmol, 12 equiv), and 4-dimethylaminopyridine (40.0 mg, 
0.328 mmol, 2 equiv) in N,N-dimethylformamide (2.0 mL).  After 30 min, the ice bath 
was removed and the reaction flask was allowed to warm to 23 ºC.  After 3 h, the reaction 
mixture was partitioned between ethyl acetate (30 mL) and a 1:1:1 mixture of water, 
saturated aqueous sodium bicarbonate solution, and saturated aqueous sodium chloride 
solution (15 mL).  The layers were separated.  The aqueous layer was extracted with 
ethyl acetate (4 × 15 mL).  The organic layers were combined.  The combined solution 
was washed with saturated aqueous sodium chloride solution (2 × 20 mL) and the washed 
solution was dried over sodium sulfate.  The dried solution was filtered and the filtrate 
was concentrated.  The residue was purified by flash-column chromatography on 
Davisil® silica gel (10:1 hexanes−ethyl acetate initially, grading to 4:1 hexanes−ethyl 
acetate) to afford dimethylamino ketone 108 (cortistatin A series) as a colorless oil (75 
mg, 77%).   
 
1H NMR:  
(500 MHz, CDCl3) 
6.02 (d, 1H, J = 2.0 Hz), 5.38 (dd, 1H, J = 4.9, 2.9 Hz), 
3.99 (d, 1H, J = 7.8 Hz), 3.50 (app t, 1H, J = 7.6 Hz), 
2.57–2.44 (m, 2H), 2.39 (dd, 1H, J = 12.7, 5.4 Hz), 2.22 
                                                 
43 (a) Shenvi, R. A.; Guerrero, C. A.; Shi, J.; Li, C.-C.; Baran, P. S. J. Am. Chem. Soc. 2008, 130, 
7241−7243;(b) Shi, J.; Manolikakes, G.; Yeh, C.-H.; Guerrero, C. A.; Shenvi, R. A.; Shigehisa, H.; Baran, 
P. S. J. Am. Chem. Soc. 2011, 133, 8014−8027. 
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(s, 6H), 2.30–2.17 (m, 5H), 2.16–2.10 (m, 1H), 1.95 
(app t, 1H, J = 12.7 Hz), 1.91–1.79 (m, 2H), 1.79–1.60 
(m, 2H), 0.98 (s, 3H), 0.97–0.92 (m, 18H), 0.69–0.58 
(m, 12H). 
 
13C NMR :  
(126 MHz, CDCl3) 
220.6, 143.1, 140.5, 120.4, 119.6, 81.2, 79.5, 75.9, 75.3, 
64.8, 47.9, 47.2, 41.3, 38.9, 35.9, 33.9, 31.6, 28.9, 18.9, 
17.0, 7.1, 7.0, 5.3, 5.1. 
FTIR, cm–1: 
 (thin film) 
2955 (s), 2876 (s), 1742 (s), 1622 (s), 1456 (m), 1238 
(m). 
 
HRMS:  
(ESI) 
Calcd for (C33H57NO4Si2+H)+               588.3899 
 Found                                                    588.3889. 
 
TLC 
(1:1 hexanes–ethyl acetate) 
Rf = 0.66 (UV, p-anisaldehyde) 
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Chapter 3 
Synthesis of Cortistatins A, J, K, and L, and Cortistatin Based Affinity Reagents 
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Introduction 
The previous chapter described an efficient synthesis of the key intermediate 112 
on gram scale and the conversion of this azido alcohol into cortistatin A, J, K, and L 
precursors, representing each of the four natural cortistatin ABC-ring substitution 
patterns. With these 17-keto precursors in hand, the next stage was to find a generally 
applicable way to introduce the C17 isoquinoline substituent, which is detailed in this 
chapter (Figure 3.1). 
 
Figure 3.1 Introduction of the 17-Isoquinolinyl Appendage. 
 
 
In the published syntheses of cortistatins, different strategies were employed to 
introduce the isoquinoline moiety (Figure 3.2). The Baran group1 and the Shair group2 
                                                 
1  (a) Shenvi, R. A.; Guerrero, C. A.; Shi, J.; Li, C.-C.; Baran, P. S. J. Am. Chem. Soc. 2008, 130, 
7241−7243; (b) Shi, J.; Manolikakes, G.; Yeh, C.-H.; Guerrero, C. A.; Shenvi, R. A.; Shigehisa, H.; Baran, 
P. S. J. Am. Chem. Soc. 2011, 133, 8014−8027. 
2 Lee, H. M.; Nieto-Oberhuber, C.; Shair, M. D. J. Am. Chem. Soc. 2008, 130, 16864−16866. 
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used similar strategies starting from cortistatinone 23. This ketone was first converted to 
a vinyl iodide via hydrazone iodination, and the vinyl iodide product was cross-coupled 
with 7-(trimethylstannyl)-isoquinoline to afford Δ16-cortistatin A (12). However, the final 
selective hydrogenation of the tri-substituted benzylic olefin in the presence of the diene 
moiety proved to be challenging. Baran and co-workers used Raney nickel reduction in 
heated methanol to provide cortistatin A in 25% yield with 50%  conversion on a 2.3-mg 
scale,1 while Shair and co-workers used diimide reduction and obtained cortistatin A with 
20% yield on a 1.0-mg scale.2  Meanwhile, the Nicolaou−Chen group,3  the Hirama 
group,4 and the Funk group5 introduced the isoquinoline ring early in their syntheses 
before functionalizing/forming the A-ring (see Chapter 1 for details). 
 
Figure 3.2 Literature Approaches to Introduce the 17-Isoquinolinyl Appendage.                   
 
                                                 
3 (a) Nicolaou, K. C.; Sun, Y. P.; Peng, X. S.; Polet, D.; Chen, D. Y. K. Angew. Chem., Int. Ed. 2008, 47, 
7310−7313; (b) Nicolaou, K. C.; Peng, X. S.; Sun, Y. P.; Polet, D.; Zou, B.; Lim, C. S.; Chen, D. Y. K. J. 
Am. Chem. Soc. 2009, 131, 10587−10597. 
4 Yamashita, S.; Iso, K.; Kitajima, K.; Himuro, M.; Hirama, M. J. Org. Chem. 2011, 76, 2408−2425. 
5 Nilson, M. G.; Funk, R. L.  J. Am. Chem. Soc. 2011, 133, 12451−12453. 
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In our synthetic plan, we wished to introduce the 17-isoquinolinyl appendage at 
the final stage of our synthesis in order to achieve maximum diversification of this 
important ring appendage with respect to analog preparation. Therefore, we imagined a 
different strategy by applying an organometallic isoquinoline addition to 17-keto 
cortistatin precursors (in which the organoletallic reagent would presumably attack from 
the less hindered bottom face), followed by deoxygenation of the newly formed tertiary 
C17 alcohol to produce the final products (Figure 3.3). 6   We speculate that in the 
deoxygenation process, e.g. a radical deoxygenation reaction, the hydrogen radical (or an 
equivalent) would also come from the less-hindered bottom face to provide the desired 
stereochemistry at C17. This approach proved to be quite general and was successfully 
employed in the synthesis of natural cortistatins A, J, K, and L, as well as unnatural 
cortistatin analogs and affinity probes as detailed in this chapter. 
 
Figure 3.3 Our Approach to Introduce the 17-Isoquinolinyl Appendage. 
 
 
 
                                                 
6 During our work, the Hirama group also used an organometallic isoquinoline addition-deoxygenation 
sequence to introduce the isoquinoline appendage, although at an earlier stage with an unfunctionalized A-
ring (ketone 30), see: Yamashita, S.; Kitajima, K.; Iso, K.; Hirama, M. Tetrahedron Lett. 2009, 50, 
3277−3279; see also ref 4. 
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A General Applicable Isoquinoline-Addition-Deoxygenation Sequence to Synthesize 
Cortistatins A, L, J and K 
 
The readily available 3-O-methyl estrone 156 was selected as a model system to 
study the organometallic isoquinoline addition (Scheme 3.1). 7-Iodoisoquinoline (157) 
was prepared by iodination of 7-trimethylstannylisoquinoline as detailed in the 
experimental section. It was found that when a solution of 7-iodoisoquinoline (157) in 
tetrahydrofuran at –78 ºC was treated with 1 equiv of n-butyllithium, it underwent 
lithium-halogen exchange to generate a dark red solution within 30 min; without any 
additives, this 7-lithioisoquinoline reagent did not add to the C17 ketone of 156, 
presumably because of the more rapid, competing enolization process. A number of 
additives were thus screened (entries 2−8). While additives like triethylamine (entries 2) 
or hexamethylphosphoramide (HMPA, entries 3) did not benefit the reaction, N,N,N’,N’- 
 
 Scheme 3.1 Isoquinoline Additions to an Estrone Model System. 
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tetramethylethylenediamine (TMEDA), a reagent used by Jaouen and co-workers to 
complex with differently substituted phenyllithium reagents to improve their addition to a 
similar 17-keto steroid system,7,8  was found to effectively promote the nucleophilic 
addition, in which 60% of the addition product 158 was obtained (as a single 
diastereomer) along with 35% of the starting ketone recovered (entry 4). 
This isoquinoline addition protocol was successfully applied to the natural 
cortistatin system (Scheme 3.2). After complexation to TMEDA (15 equiv), 7-lithio-
isoquinoline (5 equiv) added to 17-keto cortistatin precursors to provide the 
corresponding addition products 159, 160, 161, and 162 in 52–62% yield, along with 35– 
 
Scheme 3.2. Isoquinoline Additions to Cortistatin A, L, J, and K Precursors. 
 
                                                 
7 Foy, N.; Stephan, E.; Vessieres, A.; Salomon, E.; Heldt, J. M.; Huche, M. ; Jaouen, G. Chembiochem, 
2003, 4, 494–503. 
8  During our work, the Baran group also reported a similar reaction condition by lithiation of 7-
bromoisoquinoline and then complexation to TMEDA to enable its addition to 17-ketone  in a cortistatin 
system, see: Shi, J.; Shigehisa, H.; Guerrero, C. A.; Shenvi, R. A.; Li, C. C.; Baran, P. S. Angew. Chem., 
Int. Ed. 2009, 48, 4328−4331. 
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45% of the starting ketone recovered. The recovered ketones could be re-subjected to the 
isoquinoline addition condition, and after a typical 3-cycle procedure, >80% overall yield 
of the addition products could be obtained for the addition. 
Now that the isoquinoline addition was working, the next step would be removing 
the C17 hydroxyl group. Barton deoxygenation conditions were first tried (Scheme 
3.3a).9  In the model system, xanthate 163 was formed with excess potassium hydride and 
1-(methyldithiocarbonyl)imidazole in a modest yield (about 20% of elimination product 
was also obtained), and subsequent radical deoxygenation went on smoothly, affording 
the desired deoxygenated 17-(S) product 164 as a single diastereomer, in which the 
hydrogen radical presumably came from the less hindered bottom face as expected (the 
stereochemistry was proved by NOE studies). However, in every attempt to apply this 
and a number of other conditions to make the xanthate or other thiocarbonyl derivatives 
of the real cortistatin J system, no desired product could be formed. This was thought to 
be due to the more sensitive starting material as well as a more hindered C17 tertiary 
alcohol (likely because of the push from the C6,C7 carbon bridge to the C18 angular 
methyl group and then to the C17 alcohol, Scheme 3.3b). Many other conditions were 
screened (Scheme 3.3c). Several ionic hydrogenation 10  and metal boride reduction 
conditions11 resulted in the reduction of the isoquinoline ring first. A reported general 
zinc iodide-sodium cyanoborohydride mediated reduction of benzylic alcohols afforded 
                                                 
9  For a general review of Barton radical deoxygenation, see: Hartwig, W. Tetrahedron 1983, 39, 
2609−2645. 
10 (a) Kursanov, D. N.; Parnes, Z. N.; Loim, N. M. Synthesis 1974, 633–651;(b) Layton, M. E.; Morales, C. 
A.; Shair, M. D. J. Am. Chem. Soc. 2002, 124, 773–775. 
11 He, Y.; Pan, X.; Wang, S.; Zhao, H. Synth. Commun. 1989, 19, 3051–3054. 
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only returning starting material.12  Raney Nickel13,14 and photochemistry via acetates15 
were also unsuccessful in our hands. 
 
Scheme 3.3 Attempts to Remove C17 Hydroxyl Group with Barton Radical 
Deoxygenation and Other Conditions. 
 
 
Given the initial modest success in the model system, we decided to turn our 
attention back to the radical deoxygenation process, which is ideal with its mild reaction 
condition, orthogonality to all the functional groups, and a presumably stable radical 
                                                 
12 Lau C. K.; Dufresne, C.; Belanger, P. C.; Pietre, S.; Scheigetz, J. J. Org. Chem. 1986, 51, 3038–3043. 
13 Krafft, M. E.; Crooks, W. J., III; Zorc, B.; Milczanowski, S. E. J. Org. Chem. 1988, 53, 3158–3163. 
14 During our work, the Baran group reported a Raney Nickel mediated deoxygenation of the benzylic, 
tertiary alcohol, but giving the wrong stereochemistry at C17 position, see Ref 8. 
15 Deshayes, H.; Pete, J.; Portella C.; Scholler. D. J. Chem. Soc. Chem. Commun 1975, 439–440. 
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intermediate at the tertiary, benzylic C17 position. What we needed was to find an easily 
obtained activating group to activate the hindered C17 tertiary alcohol. Initial attempts 
with C17 alcohol derived oxalate 16  or phosphate 17  led to complex decomposition 
(Scheme 3.3c). After extensive literature search, we found that Jiang and co-workers 
reported a radical deoxygenation condition with readily available trifluoroacetates 
(Scheme 3.4).18  For instance, when trifluoroacetate 165 was heated with di-tert-butyl 
peroxide (1 equiv, as the radical initiator) in diphenylsilane as a solvent (as the hydrogen 
donor) at 130 ºC, a smooth radical deoxygenation occurred within 12 h to provide 
cumene (166) in excellent yield.  
 
Scheme 3.4 Jiang’s Radical Deoxygenation with Trifluoroacetates. 
 
 
This promising protocol was first applied to the estrone model system (Scheme 
3.5). The trifluoroacetate 167 was readily prepared by stirring tertiary alcohol 158 with 
trifluoroacetic anhydride (5 equiv) in the presence of pyridine (10 equiv) and 4-
dimethylaminopyridine (DMAP, 0.5 equiv) in dichloromethane at 0 ºC for 0.5 h in almost 
quantitative yield. However, when this trifluoroacetate 167 was subjected to the Jiang’s 
condition with di-tert-butyl peroxide (1−3 equiv) in diphenylsilane as a solvent at 130 ºC, 
                                                 
16 Lecomte, V.; Stephan, E.; Rager, M.-N.; Jaouen, G. J. Org.Chem. 2004, 69, 3216–3219. 
17 Zhang, L.; Koreeda, M. J. Am. Chem. Soc. 2004, 126, 13190–13191. 
18 (a) Jang, D. O.; Kim, J. G.; Cho, D. H.; Chung, C. M Tetrahedron Lett. 2001, 42, 1073–1075; (b) Kim, J. 
G.; Cho, D. H.; Jang, D. O. Tetrahedron Lett. 2004, 45, 3031–3033.   
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only the elimination product 168 was obtained.  It was speculated that the high 
temperature employed in this reaction might caused the exclusive elimination in our 
system. Therefore, azobisisobutyronitrile (AIBN, 1.5 equiv), a radical initiator that could 
be triggered at much lower temperature, 19  was employed with a commonly used 
hydrogen donor, tributyltin hydride (5 equiv) in heated benzene at 100 ºC in a sealed tube. 
To our delight, a clean radical deoxygenation proceeded and the starting trifluoroacetate 
was consumed within 1 h, affording the desired product 164 with 17-(S) configuration as 
a single diastereomer in 80% yield, along with less than 10% elimination product 168. It 
was found that the use of excess radical initiator and hydrogen donor was necessary for 
the reaction, otherwise leading to much more elimination product. The reaction 
temperature was also critical, as reaction at 120 ºC (1 h) resulted in more elimination 
 
Scheme 3.5 Deoxygenation with Trifluoroacetate 167 in an Estrone Model System. 
 
                                                 
19 The half  life (t1/2) of di-tert-butyl peroxide at 130 ºC is 6.4 h, at 100 ºC is 219 h; while the t1/2 of AIBN is 
0.13 h at 100 ºC, 1.0 h at 80 ºC; for a complete chart, see: Polymer Handbook, Eds. Brandrup, J; Immergut, 
E.H.; Grulke, E.A., 4th Edition, John Wiley, New York, 1999, II/2-69 or the Sigma-Aldrich online chart: 
“Applications: Free Radical Initiators”. 
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product (>40%) while reaction at 80 ºC (12 h) led to mostly the recovered starting 
trifluroacetate. 
The optimized reaction condition was successfully translated to the real cortistatin 
system (Scheme 3.6). The C17 tertiary alcohol of addition products 159, 160, 161, and 
162 were readily transformed to the corresponding trifluoroacetates using the previous 
condition with excess trifluoroacetic anhydride (5 equiv) in the presence of pyridine (10 
equiv) and 4-dimethylaminopyridine (DMAP, 0.5 equiv) in dichloromethane at 0 ºC; 
following radical deoxygenation with azobisisobutyronitrile (AIBN, 1.5 equiv) and 
excess tributyltin hydride (5−10 equiv) in benzene at 100 ºC for 1−2 h led to the desired 
deoxygenated products with the correct 17-(S) configuration in 60–70% yield over two 
steps (about 10% of the corresponding elimination products were also observed). In the 
cortistatin J and K series, deoxygenation led to these substances directly; while in the 
  
Scheme 3.6 Syntheses of Cortistatin A, L, J, and K. 
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cortistatin A and cortistatin L series, a final cleavage of the silyl ether protective group(s) 
with tetra-n-butylammonium fluoride (TBAF) at 23 ºC afforded the desired natural 
products in good yields. In all cases, spectroscopic data for the synthetic materials 
matched values reported for the natural products; and by employing this sequence, we 
were able to prepare 20 mg of cortistatin A in a single batch. 
In addition to spectroscopic characterization, synthetic cortistatins A, J, K, and L 
were evaluated for their ability to inhibit the growth of HUVECs in culture (Figure 3.4).  
My co-worker, Dr. Ge Zou measured the GI50 values after a 96-h incubation. It was found 
that for synthetic cortistatin A, we observed growth inhibition of HUVECs consistent 
with reported values,20   while measurements for synthetic cortistatin J more closely 
matched reports from the Nicolaou−Chen group3b than initial reports,21  and GI50 values 
for synthetic cortistatins K and L fell within the range of those originally reported to 
slightly higher.21 
 
Figure 3.4 GI50 Values of Natural and Synthetic Cortistans against HUVECs. 
 
                                                 
20 Aoki, S.; Watanabe, Y.; Sanagawa, M.; Setiawan, A.; Kotoku, N.; Kobayashi, M. J. Am. Chem. Soc. 
2006, 128, 3148−3149. 
21 Aoki, S.; Watanabe, Y.; Tanabe, D.; Setiawan, A.; Arai, M.; Kobayashi, M. Tetrahedron Lett. 2007, 48, 
4485−4488. 
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An Improved Synthesis of Cortistatin A      
 
During our work, the Hirama group reported an efficient cerium (III) chloride 
promoted isoquinoline addition to C17 ketone in a cortistatin system (Scheme 3.7).6  1-
Chloro-7-iodo isoquinoline (47) and n-butyllithium was added sequentially to a slurry of 
anhydrous cerium (III) chloride in tetrahydrofuran at –78 ºC to afford an isoquinoline 
derived organocerium reagent,22  which add to ketone 30 in almost quantitative yield. The 
authors found that incorporation of 1'-chloride in the isoquinoline was important to 
prevent the C1' addition in the reaction conditions; when 7-iodo-isoquinoline (157) was 
subjected to the same reaction condition, no addition product could be observed, which 
was in consistent with our own observations (Scheme 3.1, entry 8). 
 
Scheme 3.7 Hirama’s Isoquinoline Addition Condition with Cerium (III) Chloride.  
 
 
We thought applying Hirama’s condition in our fully functionalized cortistatin 
system would effect a more efficient isoquinoline addition; we also envisioned that we 
should be able to remove the C1' chloride in our radical deoxygenation step (Scheme 3.8). 
To our delight, Hirama’s organocerium reagent derived from 1-chloro-7-iodo 
isoquinoline (46) also effectively added to the C17 ketone in the cortistatin A precursor 
                                                 
22 Imamoto, T.; Takiyama, N.; Nakamura, K.; Hatajima, T.; Kamiya, Y. J. Am. Chem. Soc. 1989, 111, 
4392–4398. 
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108 to afford the addition product 169 in 85% yield. After trifluoroacetate formation, the 
subsequent radical deoxygenation with azobisisobutyronitrile (AIBN, 3 equiv) and excess 
tributyltin hydride (15 equiv) in benzene at 100 ºC also cleaved the C1' chloride as 
expected, providing protected cortistatin A 170 in 70% yield over two steps. The final 
deprotection with triethylamine trihydrofluoride23 furnished cortistatin A (1) in 95% yield 
on a 10.8-mg batch. 
 
Scheme 3.8 An Improved Synthesis of Cortistatin A. 
 
 
 
Synthesis of Cortistatin Probes and Their Use in Target Identification   
 
To date, the mechanism of action of the cortistatins on inhibition of HEVECs 
remained unclear. An objective of our research was the synthesis of cortistatin-based 
biological probes and their use to identify the biological target(s) of this class of natural 
                                                 
23 In the previous tetra-n-butylammonium fluoride (TBAF)-mediated deprotection procedure, TBAF was 
found to co-spot with the final natural product, which makes the purification step difficult. 
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products. After study the preliminary SAR data of cortistatins (see Chapter 1 for details), 
we identified C3 amino group as a suitable place to install an affinity isolation tag which 
is likely to be far away from the binding site as suggested by Nicolaou-Chen’s homology 
model.24  Therefore, synthesis of a cortistatin A based C3-primary amine 176 was carried 
out (Scheme 3.9). 
Our synthesis commenced from the azido transdiol 153 (prepared in 6 steps from 
key intermediate 112 as described in Chapter 2). The diol was bis-protected with 
chlorotriethylsilane to provide intermediate 171; TMEDA-mediated 7-lithioisoquinoline 
addition to the C17 ketone of 171 proceeded smoothly, affording tertiary alcohol 172 in 
50% yield, along with 30% of ketone 171 recovered. The subsequent reduction of the 
hindered C3 azide was not straightforward. After much experimentation, an optimized  
 
Scheme 3.9 Synthesis of a Cortistatin A Primary Amine 176. 
 
                                                 
24 Cee, V. J.; Chen, D. Y. K.; Lee, M. R.; Nicolaou, K. C. Angew. Chem., Int. Ed. 2009, 48, 8952−8957. 
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procedure was developed, in which azide 172 was first heated with excess anhydrous 
trimethylphosphine (5 equiv) in benzene at 55 ºC for 2 h to effect its complete conversion 
to an iminophosphine intermediate 173;25 without isolation, the reaction mixture was 
cooled in an ice-bath and sequentially treated with pyridine (20 equiv), DMAP (1 equiv), 
followed by trifluoroacetic anhydride (TFAA, 10 equiv), to furnish a trifluoroacetamide 
174 with the C17 alcohol also trifluoroacetylated in the same operation. Subsequent 
radical deoxygenation with azobisisobutyronitrile (AIBN, 1.5 equiv) and excess 
tributyltin hydride (8 equiv) in benzene at 100 ºC cleaved the C17 trifluoroacetate as 
expected, providing intermediate 175 in 60% yield over two steps. Finally, a global 
deprotection by stirring 175 in a 4:1 mixture of methanol and 1N aqueous sodium 
hydroxide afforded a cortistatin A C3 primary amine 176 in 80% yield. 
The isoquinoline addition to ketone 171 could be further improved by employing 
Hirama’s organocerium reagent (Scheme 3.10). Despite a potentially reactive azide group 
at C3, the organocerium reagent derived from 1-chloro-7-iodo isoquinoline (47) added to 
 
Scheme 3.10 Synthesis of Intermediate 175 Using Hirama’s Organocerium Reagent. 
 
                                                 
25 Addition of water with trimethlyphosphine led to complex decomposition of the starting material.  
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the C17 ketone exclusively at −78 ºC to give tertiary alcohol product 177 in 80% yield. 
The same Staudinger-trifluoroacetylation sequence afforded 178, and subsequent radical 
deoxygenation-dehalogenation with azobisisobutyronitrile (AIBN, 3 equiv) and excess 
tributyltin hydride (20 equiv) at 100 ºC proceeded uneventfully, providing the same 
intermediate 175 in 60% yield over two steps. 
 
Scheme 3.11 Preparation of Cortistatin A Based Affinity Reagents. 
 
 
The cortistatin A amine 176 was subsequently linked to sepharose beads with an 
activated N-hydroxysuccinimide (NHS) ester to provide an immobilized affinity isolation 
reagent 179; this amine was also converted to amide 180 containing a diazirine as a 
photo-cross-linker26  and a terminal alkyne as a cycloaddition partner,27  which could 
potentially be used for target identification studies in live cells (by Dr. Ge Zou, Scheme 
3.11).28  In addition, a cortistatin J derived C3 primary amine 186 (prepared using the 
                                                 
26 (a) Dilly, S. J.; Bell, M. J.; Clark, A. J.; Marsh, A.; Napier, R. M.; Sergeant, M. J.;A. J. Thompson and P. 
C. Taylor, Chem. Commun. 2007, 2808–2810; (b) Smith, D. P.; Anderson, J.; Plante, J.; Ashcroft, A. E.; 
Radford, S. E.; Wilson A. J.; Parker, M. J. Chem. Commun. 2008, 5728–5730. 
27 Kolb, H. C.; Finn, M. G.; Sharpless, K. B. Angew. Chem. Int. Ed. 2001, 40, 2004–2021. 
28 Shi, H.; Zhang, C.-J.; Chen, G. Y. J.; Yao, S. Q. J. Am. Chem. Soc. 2012, 134, 3001–3014.  
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same isoquinoline-addition-radical-deoxygenation sequence by Dr. Ge Zou) was also 
transformed to an immobilized affinity isolation reagent 181, and amides 182 and 183; an 
∆16, naphthalene-containing inactive competitor 184 was also synthesized (Figure 3.5). 
Interestingly, amides 180, 182 and 183 were all about 5−20 fold less active than the 
parent natural products even with a large substitution group at C3, indicating that the 
immobilized reagents 179 and 181 were also likely to be active; while naphthalene-
containing amide 184 was another 18 fold less active than the isoquinoline-containing 
amide 182.29   
 
Figure 3.5 Cortistatin J Based Affinity Isolation Reagents and Related Amides. 
 
 
The immobile affinity reagents 179 and 181 were subsequently used by Dr. Ge 
Zou in pull-down experiments in HUVEC and HEK293T cell lysates to identify the 
molecular target(s) of cortistatins as depicted in Figure 3.6. In theory, the cortistatin 
target protein(s) should be pulled down by an affinity reagent alone, or by the affinity 
                                                 
29 The C16,C17 double bond were not likely to be responsible for loss of much activity, as suggested by the 
good GI50 of Δ16-cortistatin A (12) identified by Baran and co-workers: Shi, J.; Shigehisa, H.; Guerrero, C. 
A.; Shenvi, R. A.; Li, C. C.; Baran, P. S. Angew. Chem., Int. Ed. 2009, 48, 4328−4331. 
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reagent in the presence of the negative competitor 184; but should not be pulled down 
when the active competitor cortistatin A (1) was added. By applying these principles, a 
55-kD, membrane kinase was identified as a putative cortistatin target after initial 
validation studies. Further validations of this protein target and in vivo pull-down 
experiments using affinity reagent 180 are currently underway. 
 
Figure 3.6 Pull-down Experiments with Cortistatin Based Affinity Isolation Reagents. 
 
 
 
Conclusion  
         
Our synthesis of cortistatin alkaloids are summarized in Figure 3.7. We developed 
a robust synthetic route to prepare gram quantities of key intermediate 112 starting from 
readily available benzylzinc reagent 116 and enol triflate 117. This key intermediate 112 
was then successfully diversified to different cortistatin 17-keto precursors 108, 109, 110, 
and 111, representing each of the four natural occurring cortistatin ABC-ring substitution 
 112 
 
patterns; 112 was also converted to ketones 171 and 185, which retained the C3 azido 
group as a handle for further functionalization. Subsequently, a general applicable, 
isoquinoline-addition-radical-deoxygenation sequence was developed to introduce the 
C17 isoquinoline substituent at the final stage of our synthesis. By applying this strategy, 
natural products cortistatin A (1), J (9), K (10), and L (11) were prepared, as well as a 
number of unnatural cortistatin analogs and cortistatin primary amines 176 and 186. 
These primary amines were used to prepare several biological probes. By employing 
these probes in pull-down experiments, we identified a 55-kD membrane kinase as a 
putative protein target of cortistatins. 
 
Figure 3.7 Summary of the Syntheses of Cortistatin Alkaloids.  
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Experimental Section 
 
General Experimental Procedures. All reactions were performed in round-
bottomed flasks fitted with rubber septa under a positive pressure of argon, unless 
otherwise noted. Air- and moisture-sensitive liquids were transferred via syringe or 
stainless steel cannula. Organic solutions were concentrated by rotary evaporation (house 
vacuum, ca. 25–40 Torr) at ambient temperature, unless otherwise noted. Analytical thin-
layer chromatography (TLC) was performed using glass plates pre-coated with silica gel 
(0.25 mm, 60 Å pore-size, 230–400 mesh, Merck KGA) impregnated with a fluorescent 
indicator (254 nm). TLC plates were visualized by exposure to ultraviolet light, then were 
stained with either an aqueous sulfuric acid solution of ceric ammonium molybdate 
(CAM) or acidic ethanolic p-anisaldehyde solution (p-anisaldehyde) then briefly heated 
on a hot plate. Flash-column chromatography was performed as described by Still et al.,30 
employing silica gel (60 Å, 32–63 μM, standard grade, Dynamic Adsorbents, Inc.). 
Materials. Commercial solvents and reagents were used as received with the 
following exceptions. Tetramethylethylenediamine (TMEDA) weas distilled from 
calcium hydride under an atmosphere of argon. Tetrahydrofuran, dichloromethane, 
benzene, toluene, dioxane, and ether were purified by the method of Pangborn et al.31 N-
Bromosuccinimide was recrystallized from water.  The molarity of n-butyllithium 
solutions was determined by titration against a standard solution of diphenylacetic acid in 
tetrahydrofuran (average of three determinations).32 
                                                 
30 Still, W. C.; Khan, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923–2925. 
31 Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics 1996, 
15, 1518–1520. 
32 Kofron, W. G.; Baclawski, L. M. J. Org. Chem. 1976, 41, 1879−1880. 
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Instrumentation. Proton magnetic resonance (1H NMR) spectra were recorded 
on Varian INOVA 500 (500 MHz) or 600 (600 MHz) NMR spectrometers at 23 °C. 
Proton chemical shifts are expressed in parts per million (ppm, δ scale) and are 
referenced to residual protium in the NMR solvent (CHCl3, δ 7.26; C6D5H, δ 7.15). Data 
are represented as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, 
q = quartet, m = multiplet and/or multiple resonances, br = broad, app = apparent), 
integration, and coupling constant (J) in Hertz. Carbon nuclear magnetic resonance 
spectra (13C NMR) were recorded on Varian INOVA 500 (126 MHz) NMR 
spectrometers at 23 °C. Carbon chemical shifts are expressed in parts per million (ppm, δ 
scale) and are referenced to the carbon resonances of the NMR solvent (CDCl3, δ 77.0; 
C6D6, δ 128.0). Infrared (IR) spectra were obtained using a Shimadzu 8400S FT-IR 
spectrometer and were referenced to a polystyrene standard. Data are represented as 
follows: frequency of absorption (cm–1), intensity of absorption (vs = very strong, s = 
strong, m = medium, w = weak, br = broad). High-resolution mass spectra were obtained 
at the Harvard University Mass Spectrometry Facility. High performance liquid 
chromatography purifications were performed using an Agilent Technologies 1200 Series 
preparative HPLC system.  Optical rotations were measured using a 2-mL cell with a 10-
cm path length on a Jasco DIP 370 digital polarimeter.  
 
(For clarity, intermediates that have not been assigned numbers in the text are numbered 
sequentially in the experimental section beginning with 187). 
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N
TfO
N
(CH3)3Sn
LiCl, Sn2(CH3)6
Pd(PPh3)4
dioxane, 100 °C
75%187 188  
7-Trimethylstannylisoquinoline (188). 
Hexamethylditin (1.20 mL, 5.73 mmol, 1.1 equiv) was added to a solution of 7-
isoquinolyl trifluoromethylsulfonate (187) 33  (1.44 g, 5.21 mmol, 1 equiv), lithium 
chloride (1.33 g, 31.3 mmol, 6 equiv), and tetrakis(triphenylphosphine)palladium(0) (600 
mg, 0.521 mmol, 0.1 equiv) in dioxane (10.4 mL).  The reaction mixture was degassed by 
sparging for 20 min with a slow stream of argon gas through a 22-gauge stainless steel.  
The flask was capped with a glass stopper under argon and the stopped flask was sealed 
with Teflon® tape and then Parafilm®.  After sealing, the reaction flask was placed in an 
oil bath preheated to 100 ºC.  After 5 h, the oil bath was removed and the reaction flask 
was allowed to cool to 23 ºC.  Solids were removed by filtration through a pad of Celite, 
washing with ethyl acetate (3 × 30 mL).  The filtrates were combined and the combined 
organic solution was concentrated. The residue was purified by flash-column 
chromatography (7:1 hexanes−ethyl acetate initially, grading to 5:1 hexanes−ethyl 
acetate, then 3:1 hexanes−ethyl acetate) to furnish 7-trimethylstannylisoquinoline (188) 
as a pale yellow solid (1.14 g, 75%).   
 
1H NMR:  
(500 MHz, CDCl3) 
9.23 (s, 1H), 8.50 (dd, 1H, J = 6.0, 0.9 Hz), 8.09 (m, 
1H), 7.81–7.74 (m, 2H), 7.60 (d, 1H, J = 6.0 Hz), 0.38 
                                                 
33 7-isoquinolyl trifluoromethylsulfonate (187) was prepared as reported: Denni-Dischert, D.; Marterer, W.; 
Baenziger, M.; Yusuff, N.; Batt, D.; Ramsey, T.; Geng, P.; Michael, W.; Wang, R. B.; Taplin, F., Jr.; 
Versace, R.; Cesarz, D.; Perez, L. B. Org. Process Res. Dev. 2006, 10, 70−77. 
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(m, 9H). 
 
13C NMR :  
(126 MHz, CDCl3) 
152.3, 142.9, 142.2, 136.8, 135.5, 128.3, 125.4, 120.3, –
9.5. 
 
FTIR, cm–1: 
 (thin film) 
3047 (m), 2982 (s), 2913 (m), 1618 (s), 1402 (m), 1337 
(m). 
 
HRMS:  
(ESI) 
Calcd for (C12H15NSn+H)+                  294.0299 
Found                                              294.0313. 
 
TLC 
(1:1 hexanes–ethyl acetate) 
Rf = 0.57 (UV) 
 
 117 
 
 
7-Iodoisoquinoline (157). 
Iodine (525 mg, 2.07 mmol, 1.1 equiv) was added to a solution of 7-
trimethylstannylisoquinoline (188) (550 mg, 1.88 mmol, 1 equiv) in chloroform (19 mL).  
After 1 h, a second portion of iodine (52.5 mg, 0.207 mmol, 0.11 equiv) was added.  
After 1 h, the reaction mixture was partitioned between saturated aqueous sodium 
thiosulfate solution (20 mL) and ethyl acetate (60 mL).  The layers were separated.  The 
aqueous layer was extracted with ethyl acetate (3 × 20 mL).  The organic layers were 
combined.  The combined solution was washed with saturated aqueous sodium chloride 
solution (30 mL) and the washed solution was dried over sodium sulfate.  The dried 
solution was filtered and the filtrate was concentrated.  The residue was purified by flash-
column chromatography (5:1 hexanes−ethyl acetate initially, grading to 3:1 
hexanes−ethyl acetate, then 2:1 hexanes−ethyl acetate) to afford 7-iodoisoquinoline (157) 
as a white solid (475 mg, 90%).   
 
1H NMR:  
(500 MHz, CDCl3) 
9.14 (s, 1H), 8.54 (d, 1H, J = 6.0 Hz), 8.33 (d, 1H, J = 
0.9 Hz), 7.90 (dd, 1H, J = 8.7, 1.8 Hz), 7.58 (d, 1H, J = 
6.0 Hz), 7.53 (d, 1H, J = 8.7 Hz). 
 
13C NMR :  
(126 MHz, CDCl3) 
151.2, 143.5, 138.8, 136.4, 134.3, 129.8, 128.0, 120.1, 
92.3. 
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FTIR, cm–1: 
 (thin film) 
3057 (m), 2916 (m), 2849 (m), 1562 (s), 1489 (s), 1204 
(s). 
 
HRMS:  
(ESI) 
Calcd for (C9H6IN+H)+                                    255.9618 
 Found                                                               255.9620 
 
TLC 
(1:1 hexanes–ethyl acetate) 
Rf = 0.42 (UV) 
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Isoquinolyl Estrone (164). 
A solution of n-butyllithium in hexanes (2.50 M, 81 µL, 0.202 mmol, 5 equiv) 
was added dropwise to a solution of 7-iodoisoquinoline (157) (51.6 mg, 0.202 mmol, 5 
equiv) in tetrahydrofuran (1.0 mL) at −78 ºC, producing a dark red solution.  After 30 
min, N,N,N’,N’-tetramethylethylenediamine (92 µL, 0.607 mmol, 15 equiv) was added.  
After 10 min, a solution of ketone 156 (11.5 mg, 0.0404 mmol, 1 equiv) in 
tetrahydrofuran (0.20 mL) was added via cannula. After 30 min, saturated aqueous 
sodium bicarbonate solution (1 mL) was added.  The cooling bath was removed and the 
reaction flask was allowed to warm to 23 ºC.  The reaction mixture was partitioned 
between half-saturated aqueous sodium bicarbonate solution (15 mL) and ethyl acetate 
(30 mL).  The layers were separated.  The aqueous layer was extracted with ethyl acetate 
(4 × 15 mL). The organic layers were combined.  The combined solution was washed 
with saturated aqueous sodium chloride solution (20 mL) and the washed solution was 
dried over sodium sulfate. The dried solution was filtered and the filtrate was 
concentrated.  The residue was purified by flash-column chromatography on silica gel 
(4:1 hexanes−ethyl acetate initially, grading to 2:1 hexanes−ethyl acetate, then 1:1 
hexanes−ethyl acetate) to afford isoquinolyl alcohol 158 (estrone series) as a white solid 
(10.0 mg, 60%), and, separately, recovered ketone 156 (4.0 mg, 35%).  
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Trifluoroacetic anhydride (17.0 µL, 121 µmol, 5 equiv) was added dropwise to an 
ice-cooled solution of isoquinolyl alcohol 158 (10.0 mg, 24.2 µmol, 1 equiv), pyridine 
(19.0 µL, 242 µmol, 10 equiv) and 4-dimethylaminopyridine (1.5 mg, 12.1 µmol, 0.5 
equiv) in dichloromethane (1.5 mL).  After 10 min, the ice bath was removed and the 
reaction flask was allowed to warm to 23 ºC.  After 20 min, the reaction mixture was 
partitioned between aqueous potassium phosphate buffer solution (pH 7.0, 0.2 M, 10 mL) 
and ethyl acetate (20 mL).  The layers were separated.  The aqueous layer was extracted 
with ethyl acetate (3 × 10 mL).  The organic layers were combined.  The combined 
solution was washed with saturated aqueous sodium chloride solution (10 mL) and the 
washed solution was dried over sodium sulfate.  The dried solution was filtered and the 
filtrate was concentrated.  The residue was purified by flash-column chromatography on 
silica gel (5:1 hexanes−ethyl acetate initially, grading to 3:1 hexanes−ethyl acetate) to 
provide the intermediate trifluoroacetate ester as a pale yellow oil.   
Benzene (ca. 1.0 mL) was added, and the resulting solution was transferred by 
cannula to a capped 10-mL microwave vessel (CEM Corporation, cat. #908035, cap 
affixed by crimping).  The vessel was placed in a water bath at 23 ºC and volatiles were 
removed in vacuo through a 22-gauge needle in order to effect azeotropic drying.  
Benzene (0.40 mL) was added to the oily residue.  To the resulting solution was added a 
solution of 2,2’-azobisisobutyronitrile (6.0 mg, 36 µmol, 1.5 equiv) in benzene (80 µL). 
The reaction mixture was degassed by sparging for 10 min with a slow stream of argon 
gas through a 22-gauge stainless steel needle.  Tributyltin hydride (33.0 µL, 121 µmol, 
5.0 equiv) was added. The vessel cap was sealed with Teflon® tape and then Parafilm®. 
After sealing, the vessel was placed in an oil bath preheated to 100 ºC. After 1 h, the oil 
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bath was removed and the reaction flask was allowed to cool to 23 ºC.  The reaction 
mixture was directly purified by flash-column chromatography on silica gel (8:1 
hexanes−ethyl acetate initially, grading to 4:1 hexanes−ethyl acetate, then 2:1 
hexanes−ethyl acetate) to furnish isoquinolyl estrone (164) as a white solid (7.7 mg, 80% 
over two steps).   
 
1H NMR:  
(500 MHz, CDCl3) 
9.23 (s, 1H), 8.48 (d, 1H, J = 5.9 Hz), 7.81 (s, 1H), 7.75 
(d, 1H, J = 8.8 Hz), 7.63 (d, 1H, J = 1.5 Hz), 7.62 (dd, 
1H, J = 10.6, 1.0 Hz), 7.20 (d, 1H, J = 8.8 Hz), 6.70 (dd, 
1H, J = 8.8, 2.4 Hz), 6.65 (s, 1H), 3.78 (s, 3H), 2.99 
(app t, 1H, J = 9.8 Hz), 2.94–2.85 (m, 2H), 2.36–2.26 
(m, 2H), 2.17–2.06 (m, 1H), 2.04–1.92 (m, 2H), 1.74 (d, 
1H, J = 12.2 Hz), 1.70–1.61 (m, 1H), 1.61–1.51 (m, 
2H), 1.50–1.40 (m, 2H), 1.36 (dd, 1H, J = 15.1, 7.3 Hz), 
1.32–1.28 (m, 1H), 0.92 (app t, 1H, J = 7.3 Hz), 0.54 (s, 
3H); 
 
13C NMR :  
(126 MHz, CDCl3) 
157.4, 152.3, 142.3, 140.7, 138.0, 134.6, 132.7, 132.4, 
128.6, 126.3, 126.1, 125.5, 120.1, 113.8, 111.4, 57.2, 
55.3, 55.2, 45.1, 44.0, 39.3, 37.8, 29.9, 27.8, 26.4, 26.2, 
24.3, 12.9; 
 
FTIR, cm–1: 2957 (s), 2926 (s), 2872 (m), 1454 (m), 1387 (m), 1370 
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 (thin film) (m). 
 
 
HRMS:  
(ESI) 
Calcd for (C28H31NO+H)+                          398.2478  
Found                                                          398.2468 
 
TLC 
(4:1 hexanes–ethyl acetate) 
Rf = 0.15 (UV, p-anisaldehyde) 
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Isoquinolyl Alcohol 159 (Cortistatin A Series). 
A solution of n-butyllithium in hexanes (2.50 M, 232 µL, 0.578 mmol, 5 equiv) 
was added dropwise to a solution of 7-iodoisoquinoline (157) (148 mg, 0.578 mmol, 5 
equiv) in tetrahydrofuran (4.5 mL) at −78 ºC, producing a dark red solution.  After 30 
min, N,N,N’,N’-tetramethylethylenediamine (261 µL, 1.74 mmol, 15 equiv) was added.  
After 10 min, a solution of bistriethylsilyl ether ketone 108 (68 mg, 0.116 mmol, 1 equiv) 
in tetrahydrofuran (0.7 mL) was added via cannula.  The flask containing dimethylamino 
ketone 108 (cortistatin A series) was rinsed with tetrahydrofuran (2 × 0.3 mL), and the 
rinses were added to the reaction mixture.  After 30 min, saturated aqueous sodium 
bicarbonate solution (1 mL) was added.  The cooling bath was removed and the reaction 
flask was allowed to warm to 23 ºC.  The reaction mixture was partitioned between half-
saturated aqueous sodium bicarbonate solution (15 mL) and ethyl acetate (30 mL).  The 
layers were separated.  The aqueous layer was extracted with ethyl acetate (4 × 15 mL). 
The organic layers were combined.  The combined solution was washed with saturated 
aqueous sodium chloride solution (20 mL) and the washed solution was dried over 
sodium sulfate. The dried solution was filtered and the filtrate was concentrated.  The 
residue was purified by flash-column chromatography on Davisil® silica gel (10:1 
hexanes−ethyl acetate initially, grading to 4:1 then 1:2 hexanes−ethyl acetate) to afford 
isoquinolyl alcohol 159 (cortistatin A series) as a pale yellow oil (52 mg, 62%), and, 
separately, recovered dimethylamino ketone 108 (cortistatin A series) (23 mg, 34%).  
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1H NMR:  
(500 MHz, CDCl3) 
9.21 (s, 1H), 8.48 (d, 1H, J = 6.0 Hz), 7.93 (br s, 1H), 7.86 
(d, 1H, J = 7.8 Hz), 7.75 (d, 1H, J = 8.2 Hz), 7.60 (d, 1H, J 
= 5.5 Hz), 5.90 (d, 1H, J = 1.8 Hz), 5.15 (dd, 1H, J = 5.0, 
2.3 Hz), 3.94 (d, 1H, J = 7.8 Hz), 3.41 (app t, 1H, J = 7.8 
Hz), 2.62 (ddd, 1H, J = 14.2, 9.6, 4.6 Hz), 2.50–2.39 (m, 
2H), 2.39–2.26 (m, 2H), 2.20 (s, 6H), 2.19–2.02 (m, 3H), 
1.95–1.72 (m, 4H), 1.67–1.57 (m, 2H), 1.17 (s, 3H), 0.95–
0.89 (m, 18H), 0.66–0.55 (m, 12H). 
 
13C NMR :  
(126 MHz, CDCl3) 
153.1, 145.7, 143.2, 142.6, 139.4, 135.0, 130.6, 128.3, 
125.8, 125.4, 121.1, 120.5, 120.2, 85.8, 82.1, 79.6, 76.3, 
75.5, 64.9, 47.9, 46.2, 41.5, 39.3, 38.9, 35.7, 31.6, 29.4, 
20.9, 17.6, 7.3, 7.2, 5.6, 5.3. 
 
FTIR, cm–1: 
 (thin film) 
3391 (br), 2924 (s), 2878 (m), 1782 (s), 1624 (s), 1458 (s), 
1244 (m). 
 
HRMS:  
(ESI) 
Calcd for (C42H64N2O4Si2+H)+                     717.4477 
Found                                                            717.4480 
 
TLC 
(1:2 hexanes–ethyl acetate) 
Rf = 0.13 (UV, p-anisaldehyde) 
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Cortistatin A Bis(triethylsilyl) Ether (170). 
Trifluoroacetic anhydride (48 µL, 348 µmol, 5 equiv) was added dropwise to an 
ice-cooled solution of isoquinolyl alcohol (cortistatin A series) 159 (50 mg, 69.6 µmol, 1 
equiv), pyridine (55 µL, 696 µmol, 10 equiv) and 4-dimethylaminopyridine (4.3 mg, 34.8 
µmol, 0.5 equiv) in dichloromethane (7 mL).  After 10 min, the ice bath was removed 
and the reaction flask was allowed to warm to 23 ºC.  After 20 min, the reaction mixture 
was partitioned between aqueous potassium phosphate buffer solution (pH 7.0, 0.2 M, 20 
mL) and ethyl acetate (30 mL).  The layers were separated.  The aqueous layer was 
extracted with ethyl acetate (3 × 20 mL).  The organic layers were combined.  The 
combined solution was washed with saturated aqueous sodium chloride solution (20 mL) 
and the washed solution was dried over sodium sulfate.  The dried solution was filtered 
and the filtrate was concentrated.  The residue was purified by flash-column 
chromatography on Davisil® silica gel (2:1 hexanes−ethyl acetate initially, grading to 1:1 
hexanes−ethyl acetate) to provide the intermediate trifluoroacetate ester as a pale yellow 
oil.   
Benzene (1 mL) was added to the oily residue and volatiles were removed in 
vacuo through a 22-gauge needle in order to effect azeotropic drying.  A second portion 
of benzene (1 mL) was added, and the volatiles were again removed.  Benzene (1.2 mL) 
was added to the concentrate.  To the resulting solution was added a solution of 2,2’-
azobisisobutyronitrile (34 mg, 209 µmol, 3 equiv) in benzene (0.5 mL) followed by 
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tributyltin hydride (150 µL, 557 µmol, 8 equiv).  The reaction mixture was degassed by 
sparging for 20 min with a slow stream of argon gas through a 22-gauge stainless steel 
needle.  The flask was capped with a glass stopper under argon and the stopped flask was 
sealed with Teflon® tape and then Parafilm®.  After sealing, the reaction flask was 
placed in an oil bath preheated to 100 ºC. After 2 h, the oil bath was removed and the 
reaction flask was allowed to cool to 23 ºC.  The product solution was concentrated. The 
residue was purified by flash-column chromatography on Davisil® silica gel (10:1 
hexanes−ethyl acetate initially, grading to 4:1 hexanes−ethyl acetate, then 2:1 
hexanes−ethyl acetate) to afford cortistatin A bis(triethylsilyl) ether (170) as a pale 
yellow oil (34 mg, 70% over two steps).   
 
1H NMR:  
(500 MHz, CDCl3) 
9.23 (s, 1H), 8.49 (d, 1H, J = 5.4 Hz), 7.79 (s, 1H), 7.76 
(d, 1H, J = 8.3 Hz), 7.63 (d, 1H, J = 5.4 Hz), 7.61–7.56 
(dd, 1H, J = 8.5, 1.5 Hz, 1H), 6.03 (d, 1H, J = 1.5 Hz), 
5.35 (dd, 1H, J = 4.9, 2.4 Hz), 3.99 (d, 1H, J = 7.8 Hz), 
3.50 (app t, 1H, J = 7.8 Hz), 3.14 (app t, 1H, J = 9.8 
Hz), 2.56–2.41 (m, 2H), 2.41–2.28 (m, 2H), 2.23 (s, 
6H), 2.28–2.21 (m, 1H), 2.21–2.14 (m, 2H), 2.12–1.99 
(m, 1H), 1.99–1.89 (m, 2H), 1.89–1.80 (m, 1H), 1.75–
1.68 (m, 1H), 1.68–1.59 (m, 2H), 1.01–0.87 (m, 18H), 
0.71–0.57 (m, 12H), 0.55 (s, 3H). 
 
13C NMR :  152.4, 142.7, 142.5, 140.6, 140.1, 134.7, 132.0, 128.6, 
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(126 MHz, CDCl3) 126.3, 125.8, 120.4, 120.2, 120.1, 81.4, 79.3, 76.1, 75.4, 
64.7, 57.0, 51.7, 44.8, 41.3, 40.1, 38.8, 30.8, 29.1, 26.5, 
20.6, 15.2, 7.1, 7.0, 5.3, 5.1. 
 
FTIR, cm–1: 
 (thin film) 
2957 (s), 2874 (m), 1622 (m), 1508 (s), 1452 (s), 1368 
(m). 
 
HRMS:  
(ESI) 
Calcd for (C42H64N2O3Si2+H)+                          699.4372 
 found                                                                 699.4355 
 
TLC 
(1:1 hexanes–ethyl acetate) 
Rf = 0.20 (UV, p-anisaldehyde) 
 
 128 
 
 
Cortistatin A (1). 
A solution of tetra-n-butylammonium fluoride in tetrahydrofuran (1.0 M, 291 µL, 
291 µmol, 6 equiv) was added to a solution of cortistatin A bis(triethylsilyl) ether (170) 
(34 mg, 48.5 µmol, 1 equiv) in tetrahydrofuran (2.4 mL) at 23 ºC.  After 20 min, the 
reaction mixture was partitioned between half-saturated aqueous sodium bicarbonate 
solution (20 mL) and dichloromethane (30 mL).  The layers were separated.  The aqueous 
layer was further extracted with dichloromethane (3 × 20 mL).  The organic layers were 
combined.  The combined solution was washed with saturated aqueous sodium chloride 
solution (20 mL) and the washed solution was dried over sodium sulfate.  The dried 
solution was filtered and the filtrate was concentrated.  The residue was purified by flash-
column chromatography on Davisil® silica gel (5:1 ethyl acetate−methanol initially, 
grading to 2:1 ethyl acetate−methanol, then 1:1 ethyl acetate−methanol).  Fractions 
containing cortistatin A (1) were collected and the pooled fractions were concentrated.  
The residue was further purified by flash-column chromatography on Sephadex® LH-20 
resin (methanol) to afford cortistatin A (1) as a white solid (20 mg, 87%, >85% purity by 
1H NMR analysis).  
 Further purification could be achieved by HPLC using an Agilent Eclipse XDB-
C8 column (9.4 mm × 250 mm, UV detection at 245 nm, solvent A: water containing 
0.1% formic acid, solvent B: acetonitrile containing 0.1% formic acid, gradient elution 
5→25% B over 60 min, flow rate: 3 mL/min). Fractions eluting at 28–31 min were 
collected and concentrated. To the residue was added saturated aqueous sodium 
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bicarbonate solution (10 mL). The aqueous solution was extracted with dichloromethane 
(4 × 10 mL).  The combined organic layers were washed with saturated aqueous sodium 
chloride solution (10 mL) and the washed solution was dried over sodium sulfate.  The 
dried solution was filtered and the filtrate was concentrated.  The residue was then 
purified by flash column chromatography on Sephadex® LH-20 resin (methanol) to 
afford cortistatin A (1) as a white solid.  In a typical HPLC purification sequence 
submission of a 2.0-mg sample provided 1.3 mg of cortistatin A (1) of >95% purity.   
 
1H NMR:  
(500 MHz, CDCl3) 
9.22 (br s, 1H), 8.49 (d, 1H, J = 5.4 Hz), 7.79 (s, 1H), 
7.76 (d, 1H, J = 8.8 Hz), 7.63 (d, 1H, J = 5.4 Hz), 7.59 
(dd, 1H, J = 8.5, 1.6 Hz), 6.25 (d, 1H, J = 2.4 Hz), 5.44 
(dd, 1H, J = 5.2, 2.2 Hz), 4.09 (d, 1H, J = 9.3 Hz), 3.33 
(app t, 1H, J = 9.8 Hz), 3.15 (app t, 1H, J = 9.9 Hz), 
2.51 (dd, 1H, J = 11.5, 8.5 Hz), 2.42 (ddd, 1H, J = 12.7, 
9.6, 3.1 Hz), 2.41–2.32 (m, 2H), 2.30 (s, 6H), 2.29–2.23 
(m, 1H), 2.22–2.14 (m, 2H), 2.10–2.01 (m, 1H), 1.96 
(dd, 1H, J = 17.6, 5.4 Hz), 1.95–1.89 (m, 1H), 1.89–
1.84 (m, 2H), 1.83–1.75 (m, 1H), 1.66 (app td, 1H, J = 
10.5, 8.5 Hz), 0.54 (s, 3H). 
 
13C NMR :  
(126 MHz, CDCl3) 
152.3, 142.6, 140.0, 139.9, 139.6, 134.7, 132.0, 128.6, 
126.3, 125.8, 121.4, 120.1, 119.4, 81.9, 79.5, 74.1, 73.7, 
62.2, 56.9, 51.7, 44.8, 40.1, 40.0, 39.7, 30.6, 29.0, 26.4, 
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20.5, 15.2. 
 
FTIR, cm–1: 
 (thin film) 
3464 (br), 2928 (s), 2860 (m), 1627 (m), 1450 (m), 1375 
(s), 1263 (s). 
 
HRMS:  
(ESI) 
Calcd for (C30H36N2O3+H)+                     473.2799 
 found                                                        473.2796 
 
 
TLC 
(methanol) 
Rf  = 0.20 (UV, p-anisaldehyde) 
 
 
Optical Rotation 
 
[α]D23 = +31.1º (c = 0.090 in methanol);  
lit.20: [α]D20 = +30.1º (c = 0.56 in methanol) 
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Isoquinolyl Alcohol 160 (Cortistatin L Series). 
A solution of n-butyllithium in hexanes (2.50 M, 62 µL, 153 µmol, 5 equiv) was 
added dropwise to a solution of 7-iodoisoquinoline (157) (39 mg, 153 µmol, 5 equiv) in 
tetrahydrofuran (1.5 mL) at −78 ºC, producing a dark red solution.  After 30 min, 
N,N,N’,N’-tetramethylethylenediamine (69 µL, 459 µmol, 15 equiv) was added.  After 10 
min, a solution of dimethylamino ketone 111 (cortistatin L series) (14 mg, 30.6 µmol, 1 
equiv) in tetrahydrofuran (0.3 mL) was added via cannula.  The flask containing 
dimethylamino ketone 111 (cortistatin L series) was rinsed with tetrahydrofuran (2 × 0.1 
mL), and the rinses were added to the reaction mixture.  After 30 min, saturated aqueous 
sodium bicarbonate solution (0.5 mL) was added.  The cooling bath was removed and the 
reaction flask was allowed to warm to 23 ºC.  The reaction mixture was partitioned 
between half-saturated aqueous sodium bicarbonate solution (10 mL) and ethyl acetate 
(10 mL).  The layers were separated.  The aqueous layer was extracted with ethyl acetate 
(4 × 10 mL).  The organic layers were combined.  The combined solution was washed 
with saturated aqueous sodium chloride solution (10 mL) and the washed solution was 
dried over sodium sulfate.  The dried solution was filtered and the filtrate was 
concentrated.  The residue was purified by flash-column chromatography on Davisil® 
silica gel (90:9:1 hexanes–acetone–triethylamine initially, grading to 80:19:1 then 
66:33:1 hexanes–acetone–triethylamine) to afford isoquinolyl alcohol 160 (cortistatin L 
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series) as a pale yellow solid (9.3 mg, 52%) and, separately, recovered dimethylamino 
ketone 111 (cortistatin L series) (5.6 mg, 40%).   
 
1H NMR:  
(500 MHz, CDCl3) 
9.22 (s, 1H), 8.50 (d, 1H, J = 5.9 Hz), 7.88 (br s, 1H), 7.83 (d, 1H, J = 
8.3 Hz), 7.74 (d, 1H, J = 8.3 Hz), 7.61 (d, 1H, J = 5.9 Hz), 5.51 (d, 
1H, J = 2.0 Hz), 5.02 (d, 1H, J = 2.4 Hz), 4.19 (d, 1H, J = 8.3 Hz), 
2.68–2.53 (m, 2H), 2.42–2.33 (m, 1H), 2.32–2.24 (m, 2H), 2.27 (s, 
6H), 2.21–1.97 (m, 5H), 1.96–1.76 (m, 4H), 1.55–1.49 (m, 1H), 1.21 
(s, 3H), 0.86 (s, 9H), 0.54 (app td, 1H, J = 13.2, 4.9 Hz), 0.05 (s, 3H), 
0.03 (s, 3H). 
 
13C NMR :  
(126 MHz, CDCl3) 
153.0, 146.0, 144.7, 143.1, 139.8, 134.8, 130.5, 127.9, 125.4, 125.3, 
123.3, 119.9, 119.3, 85.7, 83.7, 79.3, 69.2, 65.6, 47.7, 47.2, 41.0, 
38.5, 37.8, 33.2, 32.6, 28.4, 25.9, 25.9, 20.5, 18.3, 14.6, –4.2, –4.7. 
 
FTIR, cm–1: 
 (thin film) 
3264 (br), 2930 (s), 2857 (m), 1455 (m), 1250 (s). 
 
 
HRMS:  
(ESI) 
Calcd for (C36H50N2O3Si+H)+                 587.3664  
Found                                                       587.3652 
 
TLC                          Rf  = 0.35  (UV, p-anisaldehyde) 
(66:33:1 hexane–acetone–triethylamine) 
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Cortistatin L tert-Butyldimethylsilyl Ether (189). 
Trifluoroacetic anhydride (6.1 µL, 44 µmol, 5.0 equiv) was added dropwise to an 
ice-cooled solution of isoquinolyl alcohol (cortistatin L series) 160 (5.2 mg, 8.8 µmol, 1 
equiv), triethylamine (12 µL, 88 µmol, 10 equiv) and 4-dimethylaminopyridine (0.54 mg, 
4.4 µmol, 0.50 equiv) in dichloromethane (1.7 mL). After 5 min, the ice bath was 
removed and the reaction flask was allowed to warm to 23 ºC.  After 10 min, the reaction 
mixture was partitioned between aqueous potassium phosphate buffer solution (pH 7.0, 
0.2 M, 10 mL) and ethyl acetate (15 mL). The layers were separated. The aqueous layer 
was extracted with ethyl acetate (3 × 15 mL).  The organic layers were combined.  The 
combined solution was washed with saturated aqueous sodium chloride solution (10 mL) 
and the washed solution was dried over sodium sulfate.  The dried solution was filtered 
and the filtrate was concentrated.  The residue was purified by flash-column 
chromatography on Davisil® silica gel (88:11:1 hexanes–acetone–triethylamine) to 
provide the intermediate trifluoroacetate ester as a pale yellow oil.   
Benzene (ca. 1.5 mL) was added, and the resulting solution was transferred by 
cannula to a a capped10-mL microwave vessel (CEM Corporation, cat. #908035, cap 
affixed by crimping).  The vessel was placed in a water bath at 23 ºC and volatiles were 
removed in vacuo through a 22-gauge needle in order to effect azeotropic drying.  
Benzene (0.80 mL) was added to the oily residue.  To the resulting solution was added a 
solution of 2,2’-azobisisobutyronitrile (4.4 mg, 26 µmol, 3.0 equiv) in benzene (80 µL) 
followed by tributyltin hydride (14 µL, 52 µmol, 6.0 equiv). The reaction mixture was 
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degassed by sparging for 20 min with a slow stream of argon gas through a 22-gauge 
stainless steel needle.  The vessel cap was sealed with Teflon® tape and then Parafilm®.  
After sealing, the vessel was placed in an oil bath preheated to 100 ºC. After 1 h, the oil 
bath was removed and the reaction flask was allowed to cool to 23 ºC.  The reaction 
mixture was transferred by pipette to a round-bottom flask and the product solution was 
concentrated.  The residue was purified by flash-column chromatography on Davisil® 
silica gel (90:9:1 hexanes–acetone–triethylamine initially, grading to 80:19:1 hexanes–
acetone–triethylamine) to furnish cortistatin L tert-butyldimethylsilyl ether (189) as a 
pale yellow oil (4.0 mg, 80% over two steps).  
 
1H NMR:  
(500 MHz, CDCl3) 
9.22 (s, 1H), 8.48 (d, 1H, J = 5.9 Hz), 7.78 (s, 1H), 7.75 
(d, 1H, J = 9.0 Hz), 7.62 (d, 1H, J = 5.9 Hz), 7.57 (dd, 
1H, J = 8.8, 1.5 Hz), 5.72 (d, 1H, J = 1.5 Hz), 5.13 (d, 
1H, J = 2.4 Hz), 4.26 (d, 1H, J = 7.8 Hz), 3.00 (app t, 
1H, J = 10.0 Hz), 2.69–2.55 (m, 1H), 2.29 (s, 6H), 2.37–
2.23 (m, 3H), 2.20–2.03 (m, 3H), 2.03–1.93 (m, 1H), 
1.93–1.76 (m, 5H), 1.67–1.56 (m, 2H), 1.52 (app td, 1H, 
J = 12.7, 5.9 Hz), 0.90 (s, 9H), 0.60 (s, 3H), 0.09 (s, 
3H), 0.09 (s, 3H). 
 
 
13C NMR :  
(126 MHz, CDCl3) 
152.4, 146.6, 142.5, 140.2, 139.9, 134.7, 132.3, 128.6, 
126.4, 125.7, 123.0, 120.1, 119.4, 83.4, 79.3, 69.4, 65.8, 
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57.5, 53.5, 45.3, 41.0, 37.8, 37.2, 32.7, 32.5, 28.5, 26.0, 
26.0, 20.7, 18.3, 12.8, –4.1, –4.7. 
 
FTIR, cm–1: 
 (thin film) 
3393 (br), 2936 (m), 2857 (m), 1792 (m), 1724 (s), 1464 
(m), 1256 (m). 
 
HRMS:  
(ESI) 
Calcd for (C36H50N2O2Si+H)+                   571.3714 
Found                                                         571.3713 
 
TLC 
(66:33:1 hexanes–acetone–
triethylamine) 
Rf  = 0.55  (UV, p-anisaldehyde) 
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Cortistatin L (11). 
A solution of tetra-n-butylammonium fluoride in tetrahydrofuran (1.0 M, 62 µL, 
62 µmol, 10 equiv) was added to a solution of cortistatin L tert-butyldimethylsilyl ether 
189 (3.5 mg, 6.1 µmol, 1 equiv) in tetrahydrofuran (0.30 mL) at 23 ºC. After 5 h, the 
reaction mixture was partitioned between saturated aqueous sodium bicarbonate solution 
(5 mL) and ethyl acetate (10 mL). The layers were separated. The aqueous layer was 
further extracted with ethyl acetate (3 × 10 mL). The organic layers were combined.  The 
combined solution was washed with saturated aqueous sodium chloride solution (10 mL) 
and the washed solution was dried over sodium sulfate. The dried solution was filtered 
and the filtrate was concentrated. The residue was purified by flash-column 
chromatography on Davisil® silica gel (ethyl acetate initially, grading to 2:1 methanol–
ethyl acetate) to furnish cortistatin L (11) as a white solid (2.5 mg, 90%, >90% purity as 
judged by 1H NMR analysis).   
Further purification could be achieved by HPLC using an Agilent Eclipse XDB-
C8 column (9.4 mm × 250 mm, UV detection at 245 nm, solvent A: water containing 
0.1% formic acid, solvent B: acetonitrile containing 0.1% formic acid, gradient elution 
5→25% B over 60 min, flow rate: 3 mL/min). Fractions eluting at 27–30 min were 
collected and concentrated. To the residue was added saturated aqueous sodium 
bicarbonate solution (10 mL). The aqueous solution was extracted with dichloromethane 
(4 × 10 mL).  The combined organic layers were washed with saturated aqueous sodium 
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chloride solution (10 mL) and the washed solution was dried over sodium sulfate.  The 
dried solution was filtered and the filtrate was concentrated. The residue was purified by 
flash-column chromatography on Davisil® silica gel (1:1 methanol–ethyl acetate) to 
afford cortistatin L (11) as a white solid.  In a typical HPLC purification sequence 
submission of a 2.0-mg sample provided 1.0 mg of cortistatin L (11) of >95% purity.   
 
1H NMR:  
(600 MHz, CDCl3) 
9.22 (s, 1H), 8.48 (d, 1H, J = 5.6 Hz), 7.78 (s, 1H), 7.75 
(d, 1H, J = 8.5 Hz), 7.62 (d, 1H, J = 5.6 Hz), 7.50 (dd, 
1H, J = 8.5, 1.5 Hz), 5.75 (d, 1H, J = 1.8 Hz), 5.35 (d, 
1H, J = 2.1 Hz), 4.23 (d, 1H, J = 9.1 Hz), 3.13 (br s, 
1H), 3.00 (app t, 1H, J = 9.8 Hz), 2.59 (dd, 1H, J = 11.8, 
8.8 Hz), 2.31 (s, 6H), 2.41–2.28 (m, 3H), 2.28–2.22 (m, 
1H), 2.20–2.13 (m, 1H), 2.12–2.04 (m, 2H), 2.02–1.94 
(m, 1H), 1.94–1.89 (m, 1H), 1.89–1.76 (m, 4H), 1.62 
(dd, 1H, J = 12.5, 5.0 Hz), 1.51 (app td, 1H, J = 12.5, 
5.0 Hz), 0.60 (s, 3H). 
 
13C NMR :  
(126 MHz, CDCl3) 
152.4, 146.8, 142.6, 140.9, 139.8, 134.7, 132.2, 128.6, 
126.4, 125.7, 120.2, 120.1, 119.4, 83.7, 79.7, 67.8, 66.1, 
57.5, 53.5, 45.2, 40.5, 38.5, 37.2, 32.5, 30.2, 28.5, 25.9, 
20.7, 12.8. 
 
FTIR, cm–1: 3404 (br), 2932 (s), 2857 (m), 1792 (m), 1624 (s), 1456 
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 (thin film) (s), 1254 (m). 
 
HRMS:  
(ESI) 
Calcd for (C30H36N2O2+H)+                       457.2850 
Found                                                          457.2852 
 
TLC 
(methanol) 
 
Optical Rotation 
Rf  = 0.29 (UV, p-anisaldehyde) 
 
 
 [α]D23 = –23.8º (c = 0.021 in chloroform) 
lit.21: [α]D20 = –28.9º (c = 0.20 in chloroform) 
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Isoquinolyl Alcohol 161 (Cortistatin J Series). 
A solution of n-butyllithium in hexanes (2.50 M, 117 µL, 292 µmol, 5 equiv) was 
added dropwise to a solution of 7-iodoisoquinoline (157) (75 mg, 292 µmol, 5 equiv) in 
tetrahydrofuran (2.4 mL) at −78 ºC, producing a dark red solution.  After 30 min, 
N,N,N’,N’-tetramethylethylenediamine (132 µL, 876 µmol, 15 equiv) was added.  After 
10 min, a solution of dimethylamino ketone 109 (cortistatin J series) (19 mg, 58.4 µmol, 
1 equiv) in tetrahydrofuran (0.3 mL) was added via cannula.  The flask containing 
dimethylamino ketone 109 (cortistatin J series) was rinsed with tetrahydrofuran (2 × 0.1 
mL), and the rinses were added to the reaction mixture.  After 1 h, saturated aqueous 
sodium bicarbonate solution (0.5 mL) was added.  The cooling bath was removed and the 
reaction flask was allowed to warm to 23 ºC.  The reaction mixture was partitioned 
between half-saturated aqueous sodium bicarbonate solution (15 mL) and ethyl acetate 
(20 mL).  The layers were separated.  The aqueous layer was extracted with ethyl acetate 
(4 × 15 mL). The organic layers were combined.  The combined solution was washed 
with saturated aqueous sodium chloride solution (15 mL) and the washed solution was 
dried over sodium sulfate.  The dried solution was filtered and the filtrate was 
concentrated. The residue was purified by flash-column chromatography on Davisil® 
silica gel (ethyl acetate initially, grading to 5:1 ethyl acetate–methanol, then 2:1 ethyl 
acetate–methanol, then 1:1 ethyl acetate–methanol, then 1:2 ethyl acetate–methanol) to 
 140 
 
afford isoquinolyl alcohol 161 (cortistatin J series) as a pale yellow solid (16 mg, 60%) 
and, separately, recovered dimethylamino ketone 109 (cortistatin J series) (6.7 mg, 35%). 
   
1H NMR:  
(500 MHz, CDCl3) 
9.22 (s, 1H), 8.50 (d, 1H, J = 5.7 Hz), 7.94 (br s, 1H), 7.86 (d, 1H, 
J = 7.8 Hz), 7.75 (d, 1H, J = 8.7 Hz), 7.61 (d, 1H, J = 5.7 Hz), 
6.02 (dd, 1H, J = 9.8, 2.5 Hz), 5.76 (d, 1H, J = 9.8 Hz), 5.69 (s, 
1H), 5.22 (dd, 1H, J = 5.3, 2.7 Hz), 3.44 (d, 1H, J = 9.4 Hz), 2.63 
(ddd, 1H, J = 14.3, 9.7, 4.7 Hz), 2.52 (dd, 1H, J = 11.0, 8.9 Hz), 
2.45–2.36 (m, 1H), 2.33 (dd, 1H, J = 13.5, 6.0 Hz), 2.29 (s, 6H), 
2.23–2.06 (m, 3H), 2.06–2.00 (m, 1H), 2.00–1.80 (m, 4H), 1.69 
(app td, 1H, J = 11.0, 7.4 Hz), 1.63–1.53 (m, 1H), 1.19 (s, 3H). 
 
13C NMR :  
(126 MHz, CDCl3) 
152.9, 145.3, 143.1, 139.8, 139.4, 134.8, 131.9, 130.3, 128.0, 
127.3, 125.6, 125.2, 122.4, 120.9, 119.9, 85.5, 82.7, 78.9, 60.4, 
47.6, 45.8, 40.4, 38.9, 37.9, 35.7, 31.0, 30.9, 20.7, 17.4. 
 
FTIR, cm–1: 
 (thin film) 
3385 (br), 2942 (m), 1788 (m), 1624 (s), 1464 (m), 1157 (s). 
 
 
HRMS:  
(ESI) 
Calcd for (C30H34N2O2+H)+                     455.2692 
Found                                                          455.2707 
 
TLC 
(methanol) 
Rf  = 0.22 (UV, p-anisaldehyde) 
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Cortistatin J (9). 
Trifluoroacetic anhydride (6.1 µL, 44 µmol, 5.0 equiv) was added dropwise to an 
ice-cooled solution of isoquinolyl alcohol 161 (cortistatin J series) (4.0 mg, 8.8 µmol, 1 
equiv), pyridine (7.2 µL, 88 µmol, 10 equiv) and 4-dimethylaminopyridine (0.54 mg, 4.4 
µmol, 0.50 equiv) in dichloromethane (1.7 mL) at 0 ºC. After 5 min, the cooling bath was 
removed and the reaction flask was allowed to warm to 23 ºC. After 20 min, the reaction 
mixture was partitioned between aqueous potassium phosphate buffer solution (pH 7.0, 
0.2 M, 10 mL) and ethyl acetate (10 mL). The layers were separated. The aqueous layer 
was extracted with ethyl acetate (3 × 10 mL). The organic layers were combined.  The 
combined solution was washed with saturated aqueous sodium chloride solution (10 mL) 
and the washed solution was dried over sodium sulfate.  The dried solution was filtered 
and the filtrate was concentrated.  The residue was purified by flash-column 
chromatography on Davisil® silica gel (ethyl acetate initially, grading to 2:1 methanol–
ethyl acetate) to provide the intermediate trifluoroacetate ester as a pale yellow oil.   
Benzene (ca. 1.5 mL) was added, and the resulting solution was transferred by 
cannula to a capped 10-mL microwave vessel (CEM Corporation, cat. #908035, cap 
affixed by crimping).  The vessel was placed in a water bath at 23 ºC and volatiles were 
removed in vacuo through a 22-gauge needle in order to effect azeotropic drying.  
Benzene (0.80 mL) was added to the oily residue.  To the resulting solution was added a 
solution of 2,2’-azobisisobutyronitrile (4.4 mg, 26 µmol, 3.0 equiv) in benzene (80 µL) 
followed by tributyltin hydride (14 µL, 52 µmol, 6.0 equiv). The reaction mixture was 
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degassed by sparging for 20 min with a slow stream of argon gas through a 22-gauge 
stainless steel needle.  The vessel cap was sealed with Teflon® tape and then Parafilm®. 
After sealing, the vessel was placed in an oil bath preheated to 100 ºC. After 1 h, the oil 
bath was removed and the reaction flask was allowed to cool to 23 ºC.  The reaction 
mixture was transferred by pipette to a round-bottom flask and the product solution was 
concentrated.  The residue was purified by flash-column chromatography on Davisil® 
silica gel (ethyl acetate initially, grading to 2:1 methanol–ethyl acetate) to furnish 
cortistatin J (9) as a white solid (2.5 mg, 65% over two steps, >90% purity as judged by 
1H NMR analysis).   
Further purification could be achieved by HPLC using an Agilent Eclipse XDB-
C8 column (9.4 mm × 250 mm, UV detection at 245 nm, solvent A: water containing 
0.1% formic acid, solvent B: acetonitrile containing 0.1% formic acid, gradient elution 
5→25% B over 45 min, flow rate: 3 mL/min). Fractions eluting at 22–26 min were 
collected and concentrated. To the residue was added saturated aqueous sodium 
bicarbonate solution (10 mL). The aqueous solution was extracted with dichloromethane 
(4 × 10 mL).  The combined organic layers were washed with saturated aqueous sodium 
chloride solution (10 mL) and the washed solution was dried over sodium sulfate.  The 
dried solution was filtered and the filtrate was concentrated.  The residue was then 
purified by flash column chromatography on Davisil® silica gel (1:1 methanol–ethyl 
acetate) to afford cortistatin J (9) as a white solid.  In a typical HPLC purification 
sequence submission of a 2.0-mg sample provided 1.0 mg of cortistatin J (9) of >95% 
purity.   
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1H NMR:  
(500 MHz, CDCl3) 
9.23 (s, 1H), 8.49 (d, 1H, J = 5.9 Hz), 7.80 (s, 1H), 7.76 (d, 
1H, J = 8.8 Hz), 7.63 (d, 1H, J = 5.9 Hz), 7.59 (dd, 1H, J = 
8.3, 1.5 Hz), 6.09 (dd, 1H, J = 10.0, 2.7 Hz), 5.84 (s, 1H), 
5.81 (d, 1H, J = 9.8 Hz), 5.42 (dd, 1H, J = 5.1, 2.7 Hz), 3.45 
(d, 1H, J = 10.7 Hz), 3.17 (app t, 1H, J = 10.0 Hz), 2.56 (dd, 
1H, J = 11.5, 8.5 Hz), 2.41 (d, 1H, J = 19.0 Hz), 2.32 (s, 6H), 
2.36–2.26 (m, 2H), 2.25–2.14 (m, 1H), 2.12–1.96 (m, 4H), 
1.95–1.84 (m, 2H), 1.81–1.65 (m, 2H), 0.58 (s, 3H). 
 
13C NMR :  
(126 MHz, CDCl3) 
152.4, 142.6, 141.2, 140.0, 139.8, 134.7, 132.2, 132.0, 128.6, 
127.4, 126.3, 125.8, 121.8, 121.1, 120.1, 82.3, 79.0, 60.5, 
57.0, 51.7, 44.9, 40.6, 40.3, 38.0, 31.1, 30.5, 26.5, 20.6, 15.4. 
 
FTIR, cm–1: 
 (thin film) 
2933 (s), 1716 (s), 1647 (s), 1450 (m), 1366 (m), 1277 (s). 
 
 
HRMS:  
(ESI) 
Calcd for (C30H34N2O+H)+                               439.2744 
Found                                                                439.2743 
 
TLC (methanol) 
 
Rf  = 0.32 (UV, p-anisaldehyde) 
 
 
Optical Rotation 
 
[α]D23 = –51.7º (c = 0.041 in chloroform) 
lit. 21: [α]D20 = –54.0º (c = 0.26 in chloroform) 
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Isoquinolyl Alcohol 162 (Cortistatin K Series). 
A solution of n-butyllithium in hexanes (2.50 M, 92 µl, 229 µmol, 5 equiv) was 
added dropwise to a solution of 7-iodoisoquinoline (157) (59 mg, 229 µmol, 5 equiv) in 
tetrahydrofuran (1.8 mL) at −78 ºC, producing a dark red solution.  After 30 min, 
N,N,N’,N’-tetramethylethylenediamine (103 µL, 687 µmol, 15 equiv) was added.  After 
10 min, a solution of dimethylamino ketone 110 (cortistatin K series) (15 mg, 45.8 µmol, 
1 equiv) in tetrahydrofuran (0.3 mL) was added via cannula.  The flask containing 
dimethylamino ketone 110 (cortistatin K series) was rinsed with tetrahydrofuran (2 × 0.1 
mL), and the rinses were added to the reaction mixture.  After 1 h, saturated aqueous 
sodium bicarbonate solution (0.5 mL) was added.  The cooling bath was removed and the 
reaction flask was allowed to warm to 23 ºC.  The reaction mixture was partitioned 
between half-saturated aqueous sodium bicarbonate solution (15 mL) and ethyl acetate 
(20 mL).  The layers were separated.  The aqueous layer was extracted with ethyl acetate 
(4 × 15 mL). The organic layers were combined.  The combined solution was washed 
with saturated aqueous sodium chloride solution (15 mL) and the washed solution was 
dried over sodium sulfate.  The dried solution was filtered and the filtrate was 
concentrated.  The residue was purified by flash-column chromatography on Davisil® 
silica gel (ethyl acetate initially, grading to 5:1 ethyl acetate–methanol, then 2:1 then 1:1 
ethyl acetate–methanol) to afford isoquinolyl alcohol 162 (cortistatin K series) as a pale 
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yellow solid (11.5 mg, 55%), and separately, recovered dimethylamino ketone 110 
(cortistatin K series) (6.0 mg, 40%). 
 
1H NMR:  
(500 MHz, CDCl3) 
9.23 (s, 1H), 8.50 (d, 1H, J = 5.9 Hz), 7.89 (br s, 1H), 7.83 
(d, 1H, J = 8.5 Hz), 7.74 (d, 1H, J = 8.5 Hz), 7.60 (d, 1H, J 
= 5.6 Hz), 5.53 (d, 1H, J = 2.1 Hz), 5.17 (dd, 1H, J = 4.7, 
2.6 Hz), 2.70–2.57 (m, 2H), 2.47–2.34 (m, 1H), 2.30 (s, 6H), 
2.32–2.27 (m, 1H), 2.27–2.13 (m, 4H), 2.13–2.00 (m, 4H), 
2.00–1.82 (m, 4H), 1.55–1.50 (m, 1H), 1.21 (s, 3H), 0.54 
(app td, 1H, J = 13.2, 5.0 Hz). 
 
13C NMR :  
(126 MHz, CDCl3) 
153.0, 144.8, 144.4, 143.0, 139.7, 134.8, 130.5, 127.9, 
125.4, 119.9, 119.5, 118.0, 85.7, 83.6, 79.2, 58.7, 47.8, 47.2, 
41.0, 38.8, 38.5, 36.5, 33.6, 33.2, 28.3, 27.9, 20.6, 14.6. 
 
FTIR, cm–1: 
 (thin film) 
3234 (br), 2930 (s), 2859 (m), 1454 (m), 1279 (m). 
 
 
HRMS:  
(ESI) 
Calcd for (C30H36N2O2+H)+                    457.2850 
Found                                                       457.2856 
 
TLC 
(methanol) 
Rf  = 0.23 (UV, p-anisaldehyde) 
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Cortistatin K (10). 
Trifluoroacetic anhydride (6.1 µL, 44 µmol, 5 equiv) was added dropwise to an 
ice-cooled solution of isoquinolyl alcohol (cortistatin K series) 162 (4.0 mg, 8.8 µmol, 1 
equiv), pyridine (7.2 µL, 88 µmol, 10 equiv) and 4-dimethylaminopyridine (0.54 mg, 4.4 
µmol, 0.50 equiv) in dichloromethane (1.7 mL). After 5 min, the ice bath was removed 
and the reaction flask was allowed to warm to 23 ºC. After 20 min, the reaction mixture 
was partitioned between aqueous potassium phosphate buffer solution (pH 7.0, 0.2 M, 10 
mL) and ethyl acetate (10 mL). The layers were separated. The aqueous layer was 
extracted with ethyl acetate (3 × 10 mL). The organic layers were combined.  The 
combined solution was washed with saturated aqueous sodium chloride solution (10 mL) 
and the washed solution was dried over sodium sulfate.  The dried solution was filtered 
and the filtrate was concentrated.  The residue was purified by flash-column 
chromatography on Davisil® silica gel (ethyl acetate initially, grading to 1:1 methanol–
ethyl acetate) to provide the intermediate trifluoroacetate ester as a pale yellow oil.   
Benzene (ca. 1.0 mL) was added, and the resulting solution was transferred by 
cannula to a 10-mL microwave vessel (CEM Corporation, cat. #908035), to which a cap 
had been affixed by crimping.  The vessel was placed in a water bath at 23 ºC and 
volatiles were removed in vacuo through a 22-gauge needle in order to effect azeotropic 
drying.  Benzene (0.20 mL) was added to the oily residue.  To the resulting solution was 
added a solution of 2,2’-azobisisobutyronitrile (4.4 mg, 26 µmol, 3.0 equiv) in benzene 
(80 µL) followed by tributyltin hydride (19 µL, 70.1 µmol, 8.0 equiv). The reaction 
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mixture was degassed by sparging for 20 min with a slow stream of argon gas through a 
22-gauge stainless steel needle.  The vessel cap was sealed with Teflon® tape and then 
Parafilm®. After sealing, the vessel was placed in an oil bath preheated to 100 ºC. After 2 
h, the oil bath was removed and the reaction flask was allowed to cool to 23 ºC.  The 
reaction mixture was transferred by pipette to a round-bottom flask and the product 
solution was concentrated.  The residue was purified by flash-column chromatography on 
Davisil® silica gel (ethyl acetate initially, grading to 5:1 ethyl acetate–methanol, then 1:1 
ethyl acetate–methanol) to furnish cortistatin K (10) as a white solid (2.5 mg, 65% over 
two steps, >90% purity as judged by 1H NMR analysis).   
Further purification could be achieved by HPLC using an Agilent Eclipse XDB-
C8 column (9.4 mm × 250 mm, UV detection at 245 nm, solvent A: water containing 
0.1% formic acid, solvent B: acetonitrile containing 0.1% formic acid, gradient elution 
5→25% B over 45 min, flow rate: 3 mL/min). Fractions eluting at 20–25 min were 
collected and concentrated. To the residue was added saturated aqueous sodium 
bicarbonate solution (10 mL). The aqueous solution was extracted with dichloromethane 
(4 × 10 mL).  The combined organic layers were washed with saturated aqueous sodium 
chloride solution (10 mL) and the washed solution was dried over sodium sulfate.  The 
dried solution was filtered and the filtrate was concentrated.  The residue was then 
purified by flash column chromatography on Sephadex® LH-20 resin (methanol) to 
afford cortistatin K (10) as a white solid.  In a typical HPLC purification sequence 
submission of a 2.0-mg sample provided 1.2 mg of cortistatin K (10) of >95% purity.   
 
1H NMR:  9.22 (s, 1H), 8.48 (d, 1H, J = 5.9 Hz), 7.79 (s, 1H), 7.75 
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(500 MHz, CDCl3) (d, 1H, J = 8.8 Hz), 7.62 (d, 1H, J = 5.9 Hz), 7.58 (d, 
1H, J = 8.3 Hz), 5.74 (s, 1H), 5.27 (br s, 1H), 3.00 (app 
t, 1H, J = 9.8 Hz), 2.67 (app br s, 1H), 2.33 (s, 6H), 
2.45–2.23 (m, 5H), 2.22–2.06 (m, 3H), 2.05–1.97 (m, 
3H), 1.95–1.78 (m, 4H), 1.65–1.58 (m, 1H), 1.51 (app 
td, 1H, J = 12.9, 4.9 Hz), 0.60 (s, 3H). 
 
13C NMR :  
(100 MHz, CDCl3) 
δ 152.4, 144.9, 142.5, 140.2, 140.0, 134.7, 132.3, 128.7, 
126.4, 125.7, 120.1, 119.7, 117.7, 83.3, 79.3, 58.9, 57.5, 
53.5, 45.3, 41.1, 38.9, 37.2, 36.6, 33.1, 28.4, 28.3, 26.0, 
20.7, 12.8. 
 
FTIR, cm–1: 
 (thin film) 
2955 (s), 2930 (s), 2857 (m), 1599 (m), 1472 (m), 1371 
(s), 1254 (s). 
 
HRMS:  
(ESI) 
Calcd for (C30H36N2O+H)+                       441.2900 
Found                                                        441.2892 
 
TLC 
(methanol) 
Rf  = 0.30 (UV, p-anisaldehyde) 
 
 
Optical Rotation 
 
[α]D23 = –50.1º (c = 0.077 in chloroform);  
lit. 21: [α]D20 = –47.1º (c = 0.32 in chloroform) 
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1'-Chloro-Isoquinolyl Alcohol 169 (Cortistatin A Series). 
To a flame-dried, 10-mL Schlenk flask fitted with a stirring bar was added 
anhydrous cerium(III) chloride powder (101 mg, 408 µmol, 10 equiv) in glovebox. The 
reaction flask was placed under high vacuum (0.5 mmHg) and heated in an oil bath at 90 
ºC with vigorous stirring. After 2 h, the oil bath was removed. The reaction flask was 
back filled with Ar and cooled in an ice bath. Tetrahydrofuran (1.0 mL) was added. The 
cooling bath was removed and the reaction flask was allowed to warm to 23 ºC. The 
white suspension was stirred vigorously. After 16 h, a solution of 1-chloro-7-
iodoisoquinoline (47) (65 mg, 224 µmol, 5.5 equiv) in tetrahydrofuran (0.25 mL) was 
added.  The reaction flask was cooled to −78 ºC in a dry ice-acetone bath. A solution of 
n-butyllithium in hexanes (2.50 M, 82 µl, 204 µmol, 5 equiv) was added, producing a 
chartreuse suspension. After 30 min, a solution of dimethylamino ketone 108 (cortistatin 
A series) (24.0 mg, 40.8 µmol, 1 equiv) in tetrahydrofuran (0.25 mL) was added. After 30 
min, saturated aqueous ammonium chloride solution (1 mL) was added.  The cooling 
bath was removed and the reaction flask was allowed to warm to 23 ºC.  The reaction 
mixture was partitioned between half-saturated aqueous sodium bicarbonate solution (10 
mL) and ethyl acetate (15 mL).  The layers were separated.  The aqueous layer was 
extracted with ethyl acetate (4 × 10 mL). The organic layers were combined.  The 
combined solution was washed with saturated aqueous sodium chloride solution (10 mL) 
and the washed solution was dried over sodium sulfate.  The dried solution was filtered 
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and the filtrate was concentrated.  The residue was purified by flash-column 
chromatography on Davisil® silica gel (10:1 hexanes−ethyl acetate initially, grading to 
5:1 hexanes−ethyl acetate, then 2:1 hexanes−ethyl acetate, finally 1:1 hexanes−ethyl 
acetate) to afford 1'-chloro-isoquinolyl alcohol 169 (cortistatin A series) as a pale yellow 
foam (26.0 mg, 85%). 
 
1H NMR:  
(500 MHz, CDCl3) 
8.37 (br s, 1H), 8.26 (d, 1H, J = 6.0 Hz), 7.86 (br d, 1H, J = 
10.1 Hz), 7.77 (d, 1H, J = 9.2 Hz), 7.57 (d, 1H, J = 5.5 Hz), 
5.91 (s, 1H), 5.16 (dd, 1H, J = 4.8, 2.5 Hz), 3.93 (d, 1H, J = 
7.8 Hz), 3.40 (app t, 1H, J = 8.0 Hz), 2.63 (app td, 1H, J = 9.5, 
4.8 Hz), 2.48–2.40 (m, 1H), 2.39–2.27 (m, 2H), 2.20 (s, 6H), 
2.17–2.07 (m, 4H), 1.91 (dd, 1H, J = 17.9, 5.0 Hz), 1.87–1.74 
(m, 2H), 1.67–1.58 (m, 1H), 1.51 (d, 1H, J = 17.9 Hz), 1.29–
1.23 (m, 1H), 1.17 (s, 3H), 0.98–0.89 (m, 18H), 0.67–0.56 (m, 
12H); 
 
13C NMR :  
(126 MHz, CDCl3) 
151.8, 146.8, 142.5, 141.5, 139.1, 136.7, 131.0, 126.3, 126.2, 
124.0, 120.8, 120.2, 120.0, 85.7, 81.7, 79.3, 76.1, 75.3, 64.5, 
47.6, 46.0, 41.2, 39.1, 38.6, 35.5, 31.3, 29.1, 20.7, 17.3, 7.1, 
7.0, 5.3, 5.0; 
 
FTIR, cm–1: 
 (thin film) 
3327 (br), 2953 (s), 2876 (m), 1701 (s), 1456 (s), 1146 (s). 
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HRMS:  
(ESI) 
Calcd for (C42H63ClN2O4Si2+H)+                 750.4015  
Found                                                            750.4088 
 
TLC                                  Rf  = 0.21  (UV, p-anisaldehyde) 
(2:1 hexane–ethyl acetate) 
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Cortistatin A Bis(triethylsilyl) Ether (170). 
Trifluoroacetic anhydride (24.1 µL, 173 µmol, 5 equiv) was added dropwise to an 
ice-cooled solution of 1'-chloro-isoquinolyl alcohol 169 (26.0 mg, 35 µmol, 1 equiv), 
pyridine (28 µL, 346 µmol, 10 equiv) and 4-dimethylaminopyridine (2.1 mg, 17 µmol, 
0.5 equiv) in dichloromethane (3.5 mL).  After 30 min, the reaction mixture was 
partitioned between aqueous potassium phosphate buffer solution (pH 7.0, 0.2 M, 10 mL) 
and ethyl acetate (20 mL).  The layers were separated.  The aqueous layer was extracted 
with ethyl acetate (3 × 10 mL).  The organic layers were combined.  The combined 
solution was washed with saturated aqueous sodium chloride solution (10 mL) and the 
washed solution was dried over sodium sulfate.  The dried solution was filtered and the 
filtrate was concentrated.  The residue was purified by flash-column chromatography on 
Davisil® silica gel (4:1 hexanes−ethyl acetate initially, grading to 2:1 hexanes−ethyl 
acetate) to provide the intermediate trifluoroacetate ester as a pale yellow foam.   
Benzene (0.6 mL + 2 × 0.2 mL wash) was added, and the resulting solution was 
transferred by cannula to a flame-dried, 10-mL Schlenk flask fitted with a stirring bar. 
The reaction flask was placed in a water bath at 23 ºC and volatiles were removed in 
vacuo through a 22-gauge needle in order to effect azeotropic drying. The flask was back 
filled with Ar and added a solution of 2,2'-azobisisobutyronitrile (17.2 mg, 105 µmol, 3.0 
equiv) in benzene (0.7 mL). The reaction mixture was degassed by freeze-pump-thaw for 
four cycles. To the resulting solution was added tributyltin hydride (139 µL, 525 µmol, 
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15 equiv). The stopcock was closed and the reaction flask was placed in an oil bath 
preheated to 100 ºC. After 2 h, the oil bath was removed and the reaction flask was 
allowed to cool to 23 ºC.  The product solution was directly purified by flash-column 
chromatography on Davisil® silica gel (10:1 hexanes−ethyl acetate initially, grading to 
4:1 hexanes−ethyl acetate, then 2:1 hexanes−ethyl acetate) to afford cortistatin A 
bis(triethylsilyl) ether (170) as a pale yellow oil (17.1 mg, 70% over two steps). The 
spectral properties were identical to those previously reported. 
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Cortistatin A (1). 
Triethylamine trihydrofluoride (39.5 µL, 242 µmol, 10 equiv) was added to a 
solution of cortistatin A bis(triethylsilyl) ether (170) (17.0 mg, 24.2 µmol, 1 equiv) in 
tetrahydrofuran (1.0 mL) at 23 ºC.  After 30 min, the reaction mixture was partitioned 
between dichloromethane (20 mL) and a 1:1 mixture of saturated aqueous sodium 
chloride solution and saturated aqueous sodium bicarbonate solution (20 mL).  The layers 
were separated.  The aqueous layer was further extracted with dichloromethane (5 × 20 
mL).  The organic layers were combined.  The combined solution was dried over sodium 
sulfate.  The dried solution was filtered and the filtrate was concentrated.  The residue 
was purified by flash-column chromatography on Davisil® silica gel (50:1 ethyl 
acetate−methanol initially, grading to 2:1 ethyl acetate−methanol, then 1:1 ethyl 
acetate−methanol) to afford cortistatin A (1) as a white solid (10.8 mg, 95%, >90% purity 
by 1H NMR analysis). The spectral properties were identical to those previously reported. 
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Azido Ketone 171 (Cortistatin A Primary Amine Series). 
Chlorotriethylsilane (37 µL, 0.218 mmol, 6 equiv) was added dropwise to an ice-
cooled solution of azido diol (153) (13.0 mg, 0.036 mmol, 1 equiv), triethylamine (51 µL, 
0.364 mmol, 10 equiv), and 4-dimethylaminopyridine (8.9 mg, 0.073 mmol, 2 equiv) in 
N,N-dimethylformamide (1.0 mL).  After 10 min, the ice bath was removed and the 
reaction flask was allowed to warm to 23 ºC.  After 3 h, the reaction mixture was 
partitioned between ether (15 mL) and a 1:1:1 mixture of water, saturated aqueous 
sodium bicarbonate solution, and saturated aqueous sodium chloride solution (12 mL).  
The layers were separated.  The aqueous layer was extracted with ether (4 × 10 mL).  The 
organic layers were combined.  The combined solution was washed with water (15 mL) 
and saturated aqueous sodium chloride solution (2 × 15 mL) and the washed solution was 
dried over sodium sulfate.  The dried solution was filtered and the filtrate was 
concentrated.  The residue was purified by flash-column chromatography on Davisil® 
silica gel (10:1 hexanes−ethyl acetate) to afford azido ketone 171 (cortistatin A primary 
amine series) as a pale yellow oil (20 mg, 94%).   
 
1H NMR:  
(500 MHz, CDCl3) 
6.08 (d, 1H, J = 1.8 Hz), 5.43 (dd, 1H, J = 4.5, 2.9 Hz),
3.97 (d, 1H, J = 8.7 Hz), 3.41 (t, 1H, J = 8.5 Hz), 3.33
(ddd, 1H, J = 12.1, 8.0, 4.3 Hz), 2.52 (dd, 1H, J = 19.2, 8.7
Hz), 2.38 (dd, 1H, J = 12.7, 5.8 Hz), 2.28–2.18 (m, 4H),
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2.18–2.09 (m, 3H), 1.97 (t, 1H, J = 12.6 Hz), 1.92–1.82
(m, 1H), 1.78–1.69 (m, 2H), 1.03–0.95 (m, 18H), 0.93 (s,
3H), 0.76–0.63 (m, 12H); 
 
 
13C NMR :  
(126 MHz, CDCl3) 
220.4, 141.8, 139.7, 120.5, 119.7, 81.3, 78.8, 78.5, 73.9, 
62.6, 47.7, 47.2, 39.3, 37.4, 35.9, 33.9, 31.6, 18.9, 16.9, 
7.0, 5.2, 5.0; 
 
FTIR, cm–1: 
 (thin film) 
2957 (s), 2878 (m), 2106 (vs), 1741 (vs), 1641 (m), 1460 
(m), 1150 (s). 
 
 
HRMS:  
(ESI) 
Calcd for (C31H51N3O4Si2+Na)+                 608.3310  
Found                                                           608.3306 
 
TLC                                          Rf  = 0.50  (UV, p-anisaldehyde) 
(4:1 hexane–ethyl acetate) 
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Isoquinolyl Alcohol 172 (Cortistatin A Primary Amine Series). 
A solution of n-butyllithium in hexanes (2.50 M, 68 µL, 0.171 mmol, 5 equiv) 
was added dropwise to a solution of 7-iodoisoquinoline (157) (43.5 mg, 0.171 mmol, 5 
equiv) in tetrahydrofuran (2 mL) at −78 ºC, producing a dark red solution.  After 30 min, 
N,N,N’,N’-tetramethylethylenediamine (79 µL, 0.512 mmol, 15 equiv) was added.  After 
10 min, a solution of bistriethylsilyl ether ketone 171 (20 mg, 0.034 mmol, 1 equiv) in 
tetrahydrofuran (0.5 mL) was added via cannula.  The flask containing 171 was rinsed 
with tetrahydrofuran (2 × 0.2 mL), and the rinses were added to the reaction mixture.  
After 30 min, saturated aqueous sodium bicarbonate solution (1 mL) was added.  The 
cooling bath was removed and the reaction flask was allowed to warm to 23 ºC.  The 
reaction mixture was partitioned between half-saturated aqueous sodium bicarbonate 
solution (10 mL) and ethyl acetate (15 mL).  The layers were separated.  The aqueous 
layer was extracted with ethyl acetate (4 × 10 mL). The organic layers were combined.  
The combined solution was washed with saturated aqueous sodium chloride solution (10 
mL) and the washed solution was dried over sodium sulfate. The dried solution was 
filtered and the filtrate was concentrated.  The residue was purified by flash-column 
chromatography on Davisil® silica gel (10:1 hexanes−ethyl acetate initially, grading to 
4:1 hexanes−ethyl acetate, then 1:1 hexanes−ethyl acetate) to afford isoquinolyl alcohol 
172 (cortistatin A primary amine series) as a pale yellow oil (12.2 mg, 50%), and, 
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separately, recovered azido ketone 171 (cortistatin A primary amine series) (6.0 mg, 
30%).  
 
1H NMR:  
(500 MHz, CDCl3) 
9.23 (s, 1H), 8.50 (d, 1H, J = 5.9 Hz), 7.93 (br s, 1H), 7.85
(dd, 1H, J = 7.3, 2.9 Hz), 7.76 (d, 1H, J = 8.8 Hz), 7.61 (d,
1H, J = 5.9 Hz), 5.96 (d, 1H, J = 1.5 Hz), 5.20 (dd, 1H, J =
4.9, 2.4 Hz), 3.92 (d, 1H, J = 7.8 Hz), 3.34–3.24 (m, 2H),
2.63 (ddd, 1H, J = 14.0, 9.6, 4.6 Hz), 2.45 (dd, 1H, J =
11.0, 9.0 Hz), 2.39 (app t, 1H, J = 11.2 Hz), 2.31 (app td,
1H, J = 13.6, 5.6 Hz), 2.20–2.04 (m, 4H), 1.95–1.87 (m,
2H), 1.77 (app dt, 1H, J = 12.7, 8.3 Hz), 1.69 (dd, 1H, J =
19.0, 10.3 Hz), 1.55 (d, 1H, J = 18.1 Hz), 1.21 (t, 1H, J =
7.1 Hz), 1.16 (s, 3H), 0.98–0.91 (m, 18H), 0.71–0.59 (m,
12H); 
 
13C NMR :  
(126 MHz, CDCl3) 
152.9, 145.2, 143.1, 141.2, 138.3, 134.8, 130.2, 128.0, 
125.7, 125.2, 121.9, 119.9, 119.7, 85.6, 81.9, 78.7, 78.3, 
73.8, 62.6, 47.5, 45.8, 39.2, 39.0, 37.9, 35.4, 31.3, 20.7, 
17.2, 7.0, 7.0, 5.1, 5.0; 
 
FTIR, cm–1: 
 (thin film) 
3956 (br), 2955 (s), 2104 (s), 1641 (vs), 1390 (s), 1375 
(s), 1250 (vs). 
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HRMS:  
(ESI) 
Calcd for (C40H58N4O4Si2+H)+                 715.4069  
Found                                                        715.5050 
 
TLC                                          Rf  = 0.18  (UV, p-anisaldehyde) 
(2:1 hexane–ethyl acetate) 
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O
CH3
HN3
TESO
OTES
N
OH
1. P(CH3)3; TFAA, Py, DMAP
2. Bu3SnH, AIBN, PhH, 100°C
60% (two steps)
O
CH3
HHN
TESO
OTES
N
O CF3172 175  
Trifluoroacetamide 175 (Cortistatin A Primary Amine Series). 
A solution of trimethylphosphine in toluene (1.0 M, 35 µL, 35 µmol, 5 equiv) was 
added to a solution of azido isoquinolyl alcohol 172 (cortistatin A primary amine series) 
(5.0 mg, 7.0 µmol, 1 equiv) in benzene (1.5 mL).  The reaction flask was placed in an oil 
bath pre-heated to 55ºC. After 1.5 h, the reaction flask was cooled in an ice bath. Pyridine 
(11 µL, 140 µmol, 20 equiv) and 4-dimethylaminopyridine (0.85 mg, 7.0 µmol, 1 equiv) 
were added followed by trifluoroacetic anhydride (9.7 µL, 70 µmol, 10 equiv). After 30 
min, the reaction mixture was partitioned between aqueous potassium phosphate buffer 
solution (pH 7.0, 0.2 M, 10 mL) and ethyl acetate (10 mL).  The layers were separated.  
The aqueous layer was extracted with ethyl acetate (3 × 10 mL).  The organic layers were 
combined.  The combined solution was washed with saturated aqueous sodium chloride 
solution (10 mL) and the washed solution was dried over sodium sulfate.  The dried 
solution was filtered and the filtrate was concentrated.  The residue was purified by flash-
column chromatography on Davisil® silica gel (10:1 hexanes−ethyl acetate initially, 
grading to 4:1 hexanes−ethyl acetate) to provide the intermediate trifluoroacetate ester as 
a colorless oil.   
Benzene (0.6 mL+ 2 × 0.2 mL wash) was added, and the resulting solution was 
transferred by cannula to a 10-mL microwave vessel (CEM Corporation, cat. #908035), 
to which a cap had been affixed by crimping.  The vessel was placed in a water bath at 23 
ºC and volatiles were removed in vacuo through a 22-gauge needle in order to effect 
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azeotropic drying.  Benzene (0.65 mL) was added to the oily residue.  To the resulting 
solution was added a solution of 2,2’-azobisisobutyronitrile (3.4 mg, 21 µmol, 3.0 equiv) 
in benzene (50 µL). The reaction mixture was degassed by sparging for 20 min with a 
slow stream of argon gas through a 22-gauge stainless steel needle. Tributyltin hydride 
(15 µL, 56 µmol, 8.0 equiv) was then added.  The vessel cap was sealed with Teflon® 
tape and then Parafilm®. After sealing, the vessel was placed in an oil bath preheated to 
100 ºC. After 1 h, the oil bath was removed and the reaction flask was allowed to cool to 
23 ºC.  The reaction mixture was directly purified by flash-column chromatography on 
Davisil® silica gel (10:1 hexanes−ethyl acetate initially, grading to 4:1 hexanes−ethyl 
acetate) to furnish trifluoroacetamide 175 (cortistatin A primary amine series) as a pale 
yellow oil (3.2 mg, 60% over two steps). 
 
1H NMR:  
(500 MHz, CDCl3) 
9.23 (s, 1H), 8.50 (d, 1H, J = 5.9 Hz), 8.06 (d, 1H, J = 
6.8 Hz), 7.80 (s, 1H), 7.77 (d, 1H, J = 8.3 Hz), 7.63 (d, 
1H, J = 5.9 Hz), 7.59 (d, 1H, J = 8.3 Hz), 6.07 (s, 1H), 
5.40 (d, 1H, J = 2.9 Hz), 4.15 (d, 1H, J = 5.9 Hz), 3.85 
(br d, 1H, J = 3.4 Hz), 3.59 (d, 1H, J = 5.4 Hz), 3.18 (app 
t, 1H, J = 10.0 Hz), 2.42 (dd, 1H, J = 11.7, 8.3 Hz), 
2.38–2.32 (m, 2H), 2.28–2.17 (m, 2H), 2.12 (t, 1H, J = 
10.0 Hz), 2.02 (dd, 1H, J = 8.8, 4.4 Hz), 1.95 (dd, 1H, J 
= 17.6, 5.4 Hz), 1.87–1.79 (m, 2H), 1.75–1.67 (m, 1H), 
1.32–1.24 (m, 2H), 1.02–0.93 (m, 18H), 0.75 (q, 6H, J = 
7.8 Hz), 0.63 (q, 6H, J = 7.8 Hz), 0.56 (s, 3H); 
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13C NMR :  
(126 MHz, CDCl3) 
156.2 (q, J = 35.7 Hz), 152.3, 142.5, 141.5, 140.0, 139.7, 
134.7, 132.0, 128.1, 126.3, 125.9, 121.5, 120.2, 120.0, 
84.3, 80.7, 79.9, 75.3, 56.8, 53.3, 51.9, 44.5, 40.0, 38.1, 
30.6, 29.7, 29.3, 26.4, 20.6, 15.3, 7.0, 6.9, 4.8; 
 
19F NMR :  
(470 MHz, CDCl3) 
−76.7 (s); 
 
 
FTIR, cm–1: 
 (thin film) 
3315 (br), 2955 (s), 2928 (vs), 1724 (vs), 1458 (m), 1379 
(m), 1279 (m). 
 
HRMS:  
(ESI) 
Calcd for (C42H59F3N2O4Si2+H)+                 769.4038  
Found                                                             769.4054 
 
TLC                                          Rf  = 0.14 (UV, p-anisaldehyde) 
(4:1 hexane–ethyl acetate) 
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1'-Chloro-Isoquinolyl Alcohol 177 (Cortistatin A Primary Amine Series). 
To a flame-dried, 10-mL Schlenk flask fitted with a stirring bar was added 
anhydrous cerium(III) chloride powder (56.8 mg, 230 µmol, 10 equiv) in glovebox. The 
reaction flask was placed under high vacuum (0.5 mmHg) and heated in an oil bath at 90 
ºC with vigorous stirring. After 2 h, the oil bath was removed. The reaction flask was 
back filled with Ar and cooled in an ice bath. Tetrahydrofuran (1.0 mL) was added. The 
cooling bath was removed and the reaction flask was allowed to warm to 23 ºC. The 
white suspension was stirred vigorously. After 16 h, a solution of 1-chloro-7-
iodoisoquinoline (47) (36.7 mg, 127 µmol, 5.5 equiv) in tetrahydrofuran (0.2 mL) was 
added.  The reaction flask was cooled to −78 ºC in a dry ice-acetone bath. A solution of 
n-butyllithium in hexanes (1.60 M, 72 µl, 115 µmol, 5 equiv) was added, producing a 
chartreuse suspension. After 30 min, a solution of dimethylamino ketone 171 (cortistatin 
A primary amine series) (13.5 mg, 23 µmol, 1 equiv) in tetrahydrofuran (0.2 mL) was 
added. After 30 min, saturated aqueous ammonium chloride solution (1 mL) was added.  
The cooling bath was removed and the reaction flask was allowed to warm to 23 ºC.  The 
reaction mixture was partitioned between half-saturated aqueous sodium bicarbonate 
solution (10 mL) and ethyl acetate (15 mL).  The layers were separated.  The aqueous 
layer was extracted with ethyl acetate (4 × 10 mL). The organic layers were combined.  
The combined solution was washed with saturated aqueous sodium chloride solution (10 
mL) and the washed solution was dried over sodium sulfate.  The dried solution was 
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filtered and the filtrate was concentrated.  The residue was purified by flash-column 
chromatography on Davisil® silica gel (10:1 hexanes−ethyl acetate initially, grading to 
5:1 hexanes−ethyl acetate, then 2:1 hexanes−ethyl acetate) to afford 1'-chloro-isoquinolyl 
alcohol 177 (cortistatin A primary amine series) as a pale yellow oil (13.8 mg, 80%). 
 
1H NMR:  
(500 MHz, CDCl3) 
8.35 (br s, 1H), 8.26 (d, 1H, J = 6.0 Hz), 7.86 (d, 1H, J 
= 9.2 Hz), 7.78 (d, 1H, J = 8.7 Hz), 7.57 (d, 1H, J = 5.5 
Hz), 5.96 (s, 1H), 5.20 (dd, 1H, J = 5.0, 2.7 Hz), 3.92 (d, 
1H, J = 7.8 Hz), 3.33–3.27 (m, 2H), 2.64 (ddd, 1H, J = 
14.1, 9.5, 4.3 Hz), 2.46–2.35 (m, 2H), 2.32 (td, 1H, J = 
13.4, 6.8 Hz), 2.20–2.09 (m, 3H), 1.96–1.88 (m, 2H), 
1.81–1.74 (m, 1H), 1.69 (dd, 1H, J = 18.8, 10.1 Hz), 
1.51 (d, 1H, J = 17.4 Hz), 1.28–1.23 (m, 1H), 1.17 (s, 
3H), 1.00–0.91 (m, 18H), 0.72–0.58 (m, 12H); 
 
13C NMR :  
(126 MHz, CDCl3) 
151.9, 146.7, 141.6, 141.3, 138.3, 136.7, 130.9, 126.3, 
126.2, 124.0, 121.8, 120.2, 119.6, 85.6, 81.8, 78.7, 78.3, 
73.8, 62.6, 47.5, 45.9, 39.2, 39.0, 37.8, 35.4, 31.3, 20.7, 
17.3, 7.0, 7.0, 5.1, 5.0; 
 
FTIR, cm–1: 
 (thin film) 
3343 (br), 2955 (m), 2934 (m), 2104 (s), 1604 (s), 1454 
(s). 
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HRMS:  
(ESI) 
Calcd for (C40H57ClN4O4Si2+H)+                 749.3680  
Found                                                             749.3670 
 
TLC                                        
(2:1 hexane–ethyl acetate) 
Rf  = 0.45 (UV, p-anisaldehyde) 
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1. P(CH3)3; TFAA, Py, DMAP
2. Bu3SnH, AIBN, PhH, 100°C
61% (two steps)
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Trifluoroacetamide 175 (Cortistatin A Primary Amine Series). 
A solution of trimethylphosphine in toluene (1.0 M, 77 µL, 77 µmol, 5 equiv) was 
added to a solution of 1'-chloro-isoquinolyl alcohol 177 (cortistatin A primary amine 
series) (11.5 mg, 15 µmol, 1 equiv) in benzene (3.0 mL).  The reaction flask was placed 
in an oil bath pre-heated to 55ºC. After 1.5 h, the reaction flask was cooled in an ice bath. 
Pyridine (25 µL, 307 µmol, 20 equiv) and 4-dimethylaminopyridine (1.9 mg, 15 µmol, 1 
equiv) were added followed by trifluoroacetic anhydride (21 µL, 153 µmol, 10 equiv). 
After 30 min, the reaction mixture was partitioned between aqueous potassium phosphate 
buffer solution (pH 7.0, 0.2 M, 15 mL) and ethyl acetate (15 mL).  The layers were 
separated.  The aqueous layer was extracted with ethyl acetate (3 × 15 mL).  The organic 
layers were combined.  The combined solution was washed with saturated aqueous 
sodium chloride solution (10 mL) and the washed solution was dried over sodium sulfate.  
The dried solution was filtered and the filtrate was concentrated.  The residue was 
purified by flash-column chromatography on Davisil® silica gel (10:1 hexanes−ethyl 
acetate initially, grading to 4:1 hexanes−ethyl acetate) to provide the intermediate 
trifluoroacetate ester as a pale yellow solid.   
Benzene (0.6 mL+ 2 × 0.2 mL wash) was added, and the resulting solution was 
transferred by cannula to a 10-mL microwave vessel (CEM Corporation, cat. #908035), 
to which a cap had been affixed by crimping.  The vessel was placed in a water bath at 23 
ºC and volatiles were removed in vacuo through a 22-gauge needle in order to effect 
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azeotropic drying.  Benzene (0.70 mL) was added to the oily residue.  To the resulting 
solution was added a solution of 2,2'-azobisisobutyronitrile (7.4 mg, 45 µmol, 3.0 equiv) 
in benzene (50 µL). The reaction mixture was degassed by sparging for 10 min with a 
slow stream of argon gas through a 22-gauge stainless steel needle. Tributyltin hydride 
(81 µL, 300 µmol, 20 equiv) was then added.  The vessel cap was sealed with Teflon® 
tape and then Parafilm®. After sealing, the vessel was placed in an oil bath preheated to 
100 ºC. After 1.5 h, the oil bath was removed and the reaction flask was allowed to cool 
to 23 ºC.  The reaction mixture was directly purified by flash-column chromatography on 
Davisil® silica gel (40:1 hexanes−ethyl acetate initially, grading to 10:1 hexanes−ethyl 
acetate, then 4:1 hexanes−ethyl acetate) to furnish trifluoroacetamide 175 (cortistatin A 
primary amine series) as a pale yellow oil (7.0 mg, 61% over two steps). The spectral 
properties were identical to those previously reported. 
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Cortistatin A Primary Amine (176). 
Aqueous sodium hydroxide solution (1.0 N, 0.20 mL) was added to a solution of 
trifluoroacetamide 175 (cortistatin A primary amine series) (2.1 mg, 2.7 µmol, 1 equiv) in 
methanol (0.80 mL) at 23 ºC.  After 12 h, the reaction mixture was partitioned between a 
mixture of saturated aqueous sodium chloride solution (10 mL) and dichloromethane (10 
mL).  The layers were separated.  The aqueous layer was further extracted with 
dichloromethane (5 × 10 mL).  The organic layers were combined.  The combined 
solution was dried over sodium sulfate.  The dried solution was filtered and the filtrate 
was concentrated.  The residue was directly used in subsequent steps without further 
purification (a pale yellow solid, 1.1 mg, 90%, >90% purity by 1H NMR analysis). 
 
1H NMR:  
(500 MHz, CDCl3) 
9.22 (s, 1H), 8.49 (d, 1H, J = 5.9 Hz), 7.79 (s, 1H), 7.76 
(d, 1H, J = 8.3 Hz), 7.63 (d, 1H, J = 5.4 Hz), 7.58 (d, 
1H, J = 8.3 Hz), 6.19 (s, 1H), 5.43 (d, 1H, J = 2.9 Hz), 
4.05 (d, 1H, J = 8.8 Hz), 3.20–3.09 (m, 2H), 2.72 (br 
ddd, 1H, J = 12.6, 9.6, 2.5 Hz), 2.51 (dd, 2H, J = 11.2, 
8.8 Hz), 2.43–2.32 (m, 3H), 2.28 (app t, 2H, J = 11.2 
Hz), 2.23–2.15 (m, 3H), 2.03 (dd, 2H, J = 12.7, 3.4 Hz), 
1.97 (dd, 2H, J = 17.6, 5.4 Hz), 1.91–1.83 (m, 3H), 1.77 
(app dt, 2H, J = 12.6, 8.1 Hz), 1.69 (dd, 2H, J = 17.6, 
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9.3 Hz), 0.54 (s, 3H); 
  
FTIR, cm–1: 
 (thin film) 
3350 (br), 2953 (s), 2928 (s), 2857 (m), 1699 (s), 1254 
(s), 1038 (m). 
 
HRMS:  
(ESI) 
Calcd for (C28H32N2O3+H)+                         445.2486  
Found                                                            445.2482 
 
TLC 
(methanol) 
Rf  = 0.14 (UV, p-anisaldehyde) 
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Chapter 4 
A Versatile Synthesis of Substituted Isoquinolines 
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Introduction   
 
The previous two chapters detailed an efficient and general approach towards the 
cortistatin family of natural products. In addition to natural cortistatins, our synthetic 
strategy should allow us to prepare a diverse array of cortistatin analogs. As described in 
Chapter 1, the isoquinoline substituent is known to be essential to the biological activity 
of the cortistatins. Therefore, we are particularly interested in preparing cortistatin 
analogs with differentially substituted isoquinolines, requiring a versatile methodology to 
synthesize differently substituted isoquinolines (Figure 4.1). 
  
Figure 4.1 Diverse Cortistatin Derivatives by Isoquinoline Modification. 
 
 
Isoquinoline was first isolated by Hoogewerf and van Dorp from coal tar in 1885 
and its structure was elucidated in the subsequent year.1 Since then, isoquinolines have 
been recognized as one of the most important class of heterocycles: medicinally 
important isoquinolines include papaverine (used for multiple indications to improve 
blood flow), 2  fasudil (approved for the treatment of cerebral vasospasm in Japan),3 
                                                 
1 Hoogewerff, S.; van Dorp, W. A., J. Chem. Soc., Abstr. 1886, 50, 478–479. 
2 Poch, G.; Kukovetz, W. R. Life Science 1971, 10, 133–144. 
3 (a) Asano, T.; Suzuki, T.; Tsuchiya, M.; Satoh, S.; Ikegaki, I.; Shibuya, M.; Suzuki, Y.; Hidaka, H.; Br. J. 
Pharmacol 1989, 98, 1091–1100. (b) Ono-Saito, N.; Niki, I.; Hidaka, H. Phamacol. Ther. 1999, 82, 123–
131. 
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BMS-650032 4   and MK-1220 5   (candidates for the treatment of hepatitis C), and 
numerous dihydro-, tetrahydro-, as well as decahydro isoquinoline derivatives.6 
 
Figure 4.2 Synthetic Approaches to Isoquinolines.               
 
 
The literature approaches to construct this important class of heterocyclic rings 
are briefly summarized in Figure 4.2. Traditional methods to the synthesis of 
isoquinolines include the Pormeranz-Fitsch,7  the Bischler-Napieralski,8  and the Pictet-
Spengler reactions;9  however, their substrate scope is often limited due to the use of 
strong acids and elevated temperatures in the reaction condition. In recent years, Larock 
and co-workers have pioneered transition-metal-catalyzed annulation reactions to 
                                                 
4 Pasquinelli, C.; Eley, T.; Villegas, C.; Sandy, K.; Mathias E.;, Wendelburg, P.; Liao, S.; McPhee, F.; 
Scola, P. M.; Sun, L. Q.; Marbury, T. C.; Lawitz, E.; Goldwater, R.; Rodriguez-Torres, M.; DeMicco, M. P.; 
Ababa, M.; Wright, D.; Charlton, M.; Kraft, W. K.; Lopez-Talavera, J. C.;  Grasela, D. M. Hepatology 
2009, 50, 411A. 
5 Rudd, M. T.; McCauley, J. A.; Butcher, J. W.; Romano, J. J.; McIntyre, C. J.; Nguyen, K. T.; Gilbert, K. 
F.; Bush, K. J.; Holloway, M. K.; Swestock, J.; Wan, B.; Carroll, S. S.; Dimuzio, J. M.; Graham, D. J.; 
Ludmerer, S. W.; Stahlhut, M. W.; Fandozzi, C. M.; Trainor, N.; Olsen, D. B.; Vacca, J. P.; Liverton, N. J. 
ACS Med. Chem. Lett. 2011, 2, 207–212. 
6 For a general review, see Bentley, K. W. In The Isoquinoline Alkaloids, CRC Press, 1998. 
7 W. J. Gensler, In Organic Reactions, Vol. 6 (Eds: R. Adams), Wiley, New York, 1951, pp. 191–206. 
8 W. M. Whaley, T. R. Govindachari, In Organic Reactions, Vol. 6 (Ed: R. Adams), Wiley, New York, 
1951, pp. 74–150. 
9 Whaley, W. M.; Govindachari. T. R. In Organic Reactions, Vol. 6 (Ed: R. Adams), Wiley, New York, 
1951, pp. 151-190. 
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construct isoquinoline rings from o-iodoaldimines and alkynes.10,11  People have also 
used electrophilic cyclization reactions,12  aryne annulation,13  ring expansion,14  and 
numerous other methods15  to synthesize isoquinoline rings. 
Despite the large number of known methods, however, literature routes to many 
of the isoquinoline structures we envisioned were either lengthy or impractical. Thus we 
decided to develop a new, versatile synthesis of substituted isoquinolines. Two important 
precedents informed our present work.  The first was the Poindexter synthesis of 3-
substituted isoquinoline (191) by deprotonation of N,2-dimethylbenzamide (190) and 
subsequent addition of the resulting o-tolylbenzamide dianions to nitriles followed by 
aqueous ammonium chloride workup (Scheme 4.1).16  The second was the Forth method 
to prepare o-substituted benzaldehyde derivative (193) by metalation and subsequent 
alkylation of o-tolualdehyde tert-butylimines (192).17,18  We imagined that trapping the 
                                                 
10 For early examples of using stoichiometric, transition-metal-mediated annulation reactions to construct 
isoquinolines, see: (a) Maassarani, F.; Pfeffer, M.; Le Borgne, G. J. Chem. Soc., Chem. Commun. 1987, 
565–567; (b) Wu, G.; Geib, S.; Rheingold, A. L.; Heck, R. F. J. Org. Chem. 1988, 53, 3238–3241; (c) 
Girling, I. R.; Widdowson, D. A. Tetrahedron Lett. 1982, 23, 4281–4284. 
11 For selected examples of using transition-metal-catalyzed annulation reactions to construct isoquinolines, 
see: (a) Roesch, K. R.; Zhang, H.; Larock, R. C. J. Org. Chem. 1998, 63, 5306–5307; (b) Roesch, K. R.; 
Zhang, H.; Larock, R. C. Org. Lett. 1999, 1, 553–556; (c) Roesch, K. R.; Zhang, H.; Larock, R. C. J. Org. 
Chem. 2001, 66, 8042–8051; (d) Dai, G.; Zhang, H.; Larock, R. C. Org. Lett. 2001, 3, 4035–4038; (e) Dai, 
G.; Zhang, H.; Larock, R. C. J. Org. Chem. 2002, 67, 7042–7047; (f) Huang, Q.; Larock, R. C. 
Tetrahedron Lett. 2002, 43, 3557–3560; (g) Dai, G.; Zhang, H.; Larock, R. C. J. Org. Chem. 2003, 68, 
920–928; (h) Huang, Q.; Larock, R. C. J. Org. Chem. 2003, 68, 980–988; (i) Guimond, N.; Fagnou, K. J. 
Am. Chem. Soc. 2009, 131, 12050–12051; (j) Guimond, N.; Gorelsky, S. I.; Fagnou, K. J. Am. Chem. Soc. 
2011, 133, 6449–6457. 
12 For selected examples of using electrophilic cyclization reactions to construct isoquinolines, see: (a) 
Huang, Q.; Hunter, J. A.; Larock, R. C. Org. Lett. 2001, 3, 2973–2976; (b) Huang, Q.; Hunter, J. A.; 
Larock, R. C. J. Org. Chem. 2002, 67, 3437–3444; (c) Fischer, D.; Tomeba, H.; Pahadi, N. K.; Patil, N. T.; 
Yomamoto, Y.; Angew. Chem. Int. Ed. 2007, 46, 4764–4766; (d) Fischer, D.; Tomeba, H.; Pahadi, N. K.; 
Patil, N. T.; Huo, Z.; Yomamoto, Y.; J. Am. Chem. Soc. 2008, 130, 15720–15725 
13 Gilmore, C. D.; Allan, K. M.; Stoltz, B, M. J. Am. Chem. Soc. 2008, 130, 1558–1559. 
14 Chiba, S.; Xu, Y.; Wang, Y. J. Am. Chem. Soc. 2009, 131, 12886–12887. 
15 For selected examples of other methods, see: (a)Wang, B.; Lu, B.; Jiang. Y.; Zhang, Y.; Ma, D. Org. 
Lett. 2008, 10, 2761–2763. (b) Sha, F.; Huang, X. Angew. Chem. Int. Ed. 2009, 48, 3458–3461; (c) Yang, 
Y.-Y.; Shou, W.-G.; Chen, Z.-B.; Hong, D.; Wang, Y.-G. J. Org. Chem. 2008, 73, 3928 – 3930. 
16 Poindexter, G.. S. J. Org. Chem. 1982, 47, 3787–3788. 
17 Forth, M. A.; Mitchell, M. B.; Smith, S. A. C.; Gombatz, K.; Snyder, L. J. Org. Chem. 1994, 59, 2616–
2619. 
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metalated o-tolualdehyde tert-butylimine anions with nitriles might provide a direct route 
to 3-substituted isoquinolines. As detailed in this chapter, the chemistry proved to be 
much more versatile than we initially imagined, by virtue of transformations that ensue 
subsequent to addition of the nitrile.19   
 
Scheme 4.1 Literature Precedents and Our Approach to Construct Isoquinoline Rings. 
 
             
 
A Versatile Synthesis of Substituted Isoquinolines 
 
Initial experiments were conducted in a simple system with the readily available 
o-tolualdehyde tert-butylimine (192, Scheme 4.2). The Forth’s condition17 was applied, 
in which n-butyllithium (1.05 equiv) was added slowly to an ice-cooled solution of o-
                                                                                                                                                 
18 N-Cyclohexyl aldimines have also been used to direct ortho-metalation: (a) Ziegler, F. E.; Fowler, K. W. 
J. Org. Chem. 1976, 41, 1564–1566; (b) Flippin, L. A.; Muchowski, J. M.; Carter, D. S. J. Org. Chem. 
1993, 58, 2463–2467; (c) Forth, M. A.; Mitchell, M. B.; Smith, S. A. C.; Gombatz, K.; Snyder, L. J. Org. 
Chem. 1994, 59, 2616–2619. 
19 Si, C.; Myers, A. G. Angew. Chem. Int. Ed. 2011, 50, 10409–10413. 
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tolualdehyde tert-butylimine (192, 1 equiv) in the presence of a catalytic amount of 
tetramethylpiperidine (TMP, 0.10 equiv) in tetrahydrofuran (0.5 M) over 40 min, 
generating the o-tolyl anion as a deep purple solution. This deep purple solution was then 
cannulated to benzonitrile (1.5 equiv) at −78 ºC, forming a dark red solution within 3 
min.  Upon warming to 23 °C, the reaction mixture became dark brown.  Aqueous work-
up with ammonium chloride followed by chromatography purification provided 3-
phenylisoquinoline (194) in 42% yield and, separately, 3,3'-diphenyl-1,1'-biisoquinoline 
(195), in 35% yield.  This by-product probably arose by base-induced dimerization of 3-
phenylisoquinoline followed by oxidation, 20   suggesting that formation of the 
isoquinoline ring had occurred prior to quenching with ammonium chloride. By adopting 
a different quenching protocol, addition of excess trifluoroacetic acid at –78 °C then 
warming to 23 °C, formation of 195 was avoided and 3-phenylisoquinoline (194) could 
be isolated in 80% yield.  
 
Scheme 4.2 Initial Studies to Synthesize 3-Substituted Isoquinoline. 
   
                                                 
20 Clarke, J. E.; McNamara, S.; Meth-Cohn, O. Tetrahedron Lett. 1974, 27, 2373–2376. 
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Mechanistically, we considered that after the initial metalation, the deep purple 
anion 196 would add to benzonitrile, affording an imido anion 197, which subsequently 
cyclized to give a tert-butylamido anion 198. However, neither 197 nor 198 seemed 
likely to account for the dark red color that we observed upon addition of anion 196 to 
benzonitrile.  We speculated that the tert-butylamido anion 198 might react further by 
intra- or intermolecular proton transfer to form an extended eneamido anion 199, and this 
did appear to be a reasonable candidate to account for the red color we observed. 21 To 
test this hypothesis, methyl iodide (2 equiv) was added to the deep red solution shortly 
after its formation at –78 °C, producing an orange solution within minutes.  Addition of 
trifluoroacetic acid (excess) after 30 min, also at –78 °C, followed by warming, aqueous 
workup, and chromatography purification provided 4-methyl-3-phenyl-isoquinoline (200) 
in 80% yield.22,23 
 
Scheme 4.3 Synthesis of 4-Methyl-3-phenylisoquinoline (200) and a Plausible Mechanism. 
 
                                                 
21 An alternative sequencing of steps is feasible; e.g., tautomerization of intermediate 197 may occur prior 
to ring closure to form 199.  
22 Addition of alkyllithium reagents to C1 of isoquinolines is known to produce an adduct that can be 
trapped at C4, see: (a) Alexakis, A.; Amiot, F. Tetrahedron: Asymmetry 2002, 13, 2117–2122. b) Louërat, 
F. ; Fort, Y. ; Mamane, V.  Tetrahedron Lett. 2009, 50, 5716–5718. 
23 3,4-dihydro-l(2H)-isoquinolones have been synthesized by the condensation of N,N-diethyl-o-toluamide 
anions with aldimines. Lithiation (and subsequent trapping) of the benzylic position was reported in this 
study: Clark, R. D.; Jahangir  J. Org. Chem. 1987, 52, 5378–5382. 
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As illustrated in Table 4.1, a wide range of substituted isoquinolines could be 
synthesized by the direct condensation of o-tolualdehyde tert-butylimine anions with 
different nitriles followed by electrophilic trapping at C4.  The Forth protocol17 was 
found to be quite general for the metalation of different o-tolualdehyde tert-butylimines, 
except for the halogenated ones, in which lithium diisopropylamide (LDA, 1.05 equiv) 
was found to be superior and led to higher yields (entries 2, 6 and 8). Entries 1–4 
demonstrated the use of aliphatic nitriles as substrates and showed that a variety of alkyl 
halides were suitable for C4 alkylation, including ethyl iodide (entry 1), n-butyl iodide 
(entry 2), allyl bromide (entry 3), and benzyl bromide (entry 4).  Although a number of 
potentially enolizable aliphatic nitriles were successfully employed, thus far, acetonitrile 
has not proven to be a viable coupling partner, likely because enolization was more rapid 
than addition to the nitrile.24  Entries 5–9 illustrated that N,N-dialkylcyanamides were 
also effective substrates for the condensation, and the subsequent C4 trapping could be 
successfully achieved not only with alkylation reagents like para-bromobenzyl bromide 
(entry 5) and methyl iodide (to afford a hindered 4,5-dimethylisoquinoline structure, 
entry 7), but also with Mander’s reagent to introduce a C4 carbomethoxy group (entry 
6),25 and with N-fluorobenzenesulfonimide to produce isoquinolines with C4 fluorine 
(entries 8 and 9). Entries 10–13 exemplified couplings with arylnitriles and trapping 
reactions for the introduction of C4 heteroatoms other than fluorine, including chlorine 
(using hexachloroethane, entry 10), oxygen [using oxodiperoxymolybdenum 
(pyridine)(hexamethylphosphoric triamide),  MoOPH,  entry 11],26  sulfur (using methyl  
                                                 
24 Poindexter had also noted that acetonitrile was not a suitable substrate in his method for isoquinolone 
formation, see: Ref 16. 
25 S. R. Crabtree, W. L. Alex Chu, L. N. Mander, Synlett 1990, 169–170. 
26 Vedejs, E.; Engler, D. A.; Telschow, J. E. J. Org. Chem. 1978, 43, 188–196. 
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Table 4.1 Synthesis of a Wide Range of Substituted Isoquinolines by Condensation of 
Lithiated o-Tolualdehyde tert-Butylimines with Nitriles Followed by Trapping at C4 with 
Various Electrophiles.[a]  
      
Entry  Imine   Nitrile Electrophile Product Yield[b] 
1 
 
EtI 
 
52 
2[c]  n-BuI 
 
50 
3[d]   
 
60 
4 
 
BnBr 
 
50 
5[d] 
  
 
52 
6[c] 
  
 
66 
7[d] 
 
CH3I 
 
54 
8[c] 
 
NFSI 
 
74 
9 
 
NFSI 
 
60 
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Table 4.1 (Continued)   
  
10[e]  
 
C2Cl6 
 
 
54 
11[f] 
 
MoOPH 
 
40 
12[d] 
NC
OCH3
CH3SSCH3 
N
CH3S
TMS
OCH3
 
68 
13[d] 
 
 
 
55 
 
[a] For transformations with enolizable nitriles as substrates (entries 1–4) the nitriles were used as the 
limiting reagent (1 equiv) and the tert-butylaldimines were used in excess (1.25 equiv); in most other cases 
the tert-butylaldimine was used as the limiting reagent (1 equiv) and the nitrile was used in excess (1.25–
1.5 equiv).  Metalation of the tert-butylaldimine was achieved by the method of Forth et al.17  [b] Isolated 
yields based on the limiting reagent. In the fluorinations of entries 8 and 9 the fluorinating agent N-
fluorobenzene-sulfonimide (NFSI) was used as the limiting reagent (the tert-butylaldimine was used in 
excess, 1.25 equiv).  [c] With the halogenated tert-butylaldimine substrates of entries 2, 6, and 8, lithium 
diisopropylamide (LDA, 1.05 equiv) was used for metalation in lieu of TMP-n-BuLi.  [d] 
Hexamethylphosphoramide (HMPA, 2 equiv) was added prior to the addition of the electrophile.  [e] 
Electrophilic trapping with hexachloroethane was conducted by addition of the reaction mixture by cannula 
to a large excess of the electrophile (4 equiv) at –78 °C.  [f] Potassium hexamethyldisilazide (KHMDS, 1 
equiv) was added just prior to addition of MoOPH (1.5 equiv).  
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disulfide, entry 12), and nitrogen (using diethylazodicarboxylate, entry 13). In the latter 
two instances we found that the efficiencies of C4 trapping were enhanced in the 
presence of the additive hexamethylphosphoramide (HMPA, 2 equiv).  This additive also 
proved to enhance the yield of C4-alkylation products in the cases of entries 3, 5, and 7, 
which we believe was due to acceleration of an otherwise slow proton-transfer reaction 
that formed the eneamido anion intermediate.27 
4-Chloroisoquinolines, 1-tert-butylamino isoquinolines, or 4,4'-biisoquinolines 
were obtained selectively by modification of the protocol after trapping with 
hexachloroethane (Scheme 4.4).  After metalation and condensation with benzonitrile, the 
putative eneamido anion 199 was quenched by addition to an excess of hexachloroethane 
(4 equiv) at –78 °C.  Work-up under standard acidic conditions, with excess  
 
 
Scheme 4.4 Selective Preparation of Isoquinolines by Variation of Reaction Conditions.  
 
                                                 
27 In the absence of HMPA C4-unsubstituted isoquinolines were formed as major by-products in each of 
these cases; In the cases of entries 3, 5, and 7, where proton transfer to form the eneamide intermediate is 
believed to be slow, addition of HMPA caused a noticeable darkening of the red or orange solutions. 
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trifluoroacetic acid, led to the expected 4-chloroisoquinoline product 202 (also see Table 
4.1, entry 10).  Interestingly, using an alternative basic work-up procedure with excess 
diethylamine, elimination of hydrogen chloride in intermediate 201 occurred, providing 
1-tert-butylamino isoquinoline derivative 203, which proved valuable for subsequent 
diversification of C1. Also, upon addition of substoichiometric amount of the electrophile 
(0.4 equiv, added slowly) to the eneamido anion 199, a 4,4'-biisoquinoline derivative 205 
was formed as the primary product,28  which likely arose from the dimerization product 
204 formed between the remaining 4-lithiated isoquinolinyl intermediate 199 and the 
newly formed 4-choloro isoquinolinyl intermediate 201. 
With tert-butylaldimine substrates containing a second ortho directing group, such 
as a 3-fluoro substituent, it was possible to assemble substituted isoquinolines from as 
many as four components in sequence in a single operation (Scheme 4.5).  For example, 
metalation of 3-fluoro-5-(trimethylsilyl)benzaldehyde tert-butylimine (206) with lithium 
 
Scheme 4.5 One-pot Synthesis of Isoquinolines from Aldimines with a Second o-
Directing Group. 
 
 
                                                 
28 For an example where an isoquinolinyl dimer was formed by a similar mechanism, see: Ref 22b. 
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2,2,6,6-tetramethylpiperidide (LTMP, 1.05 equiv) initially formed an o-lithio 
intermediate that was trapped with methyl iodide (0.90 equiv);  subsequent deprotonation 
of the methylated product in the same pot with lithium diisopropylamide (LDA, 1.05 
equiv) at −40 ºC formed a dark red solution of the presumed o-tolyl anion; addition of 
benzonitrile, followed by C4-trapping with a second equivalent of methyl iodide afforded 
5-fluoro-4-methyl-3-phenyl-7-(trimethylsilyl)isoquinoline (207) in 45% yield.  A second 
example featured a simpler, three-component assembly by condensation of the presumed 
o-tolyl anion with N,N-bis(p-methoxybenzyl)cyanamide to provide isoquinoline 208 in 
55% yield, which proved to be a highly versatile intermediate for further elaboration (see 
below). 
Some of the isoquinolines prepared above could be further derivatized to highly 
halogenated structures (Scheme 4.6).  For example, treatment isoquinoline 209 (prepared 
in Table 4.1, entry 9) with iodine monochloride in dichloromethane at 0 °C afforded 
product of 7-iododesilylation;29 subsequent addition of trifluoroacetic acid (neat) led to 
cleavage of the p-methoxybenzyl groups, providing 3-amino-4-fluoro-7-iodoisoquinoline 
(210) in 75% yield. Diazotization of the latter product 210 in the presence of fluoride and 
chloride sources gave rise to the corresponding 3-fluoroisoquinoline 211 and 3-
chloroisoquinoline 212 in good yields. Application of the same sequence to isoquinoline 
208 (prepared in Scheme 4.5) proceeded with chlorination at C4 followed by a slower 7-
iododesilylation reaction during initial treatment with iodine monochloride;30 subsequent 
deprotection provided a 3-aminoisoquinoline 213, which was further transformed to 
polyhalogenated isoquinolines 214 and 215.  Lastly, 1-tert-butylaminoisoquinoline 
                                                 
29 Stock, L. M.; Spector, A. R.  J. Org. Chem. 1963, 28, 3272–3274. 
30 Iodine monochloride chlorinates in polycyclic aromatic compounds, see: Turner, D. E.; O'Malley, R. F.; 
Sardella, D. J.; Barinelli, L. S.; Kaul, P. J. Org. Chem. 1994, 59, 7335–7340. 
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derivatives 217, prepared by a modified basic work-up (see Scheme 4.4), was 
transformed directly into 1-fluoroisoquinoline 218 by dealkylative diazotization in the 
presence of fluoride ions,31 which we anticipate should allow for further diversification of 
position C1 by standard nucleophilic aromatic substitution reactions. These isoquinolines 
with a halogen-handle at C7 should find applications in the synthesis of cortistatin 
analogs, which is the currently ongoing in our laboratory.   
 
Scheme 4.6 Preparation of Poly-halogenated Isoquinolines. 
 
                                                 
31 In contrast, the transformation of isoquinolones to 1-fluoroisoquinolines can be low yielding, see: Zhu, 
G.-D.; Gong, J.; Claiborne, A.; Woods, K. W.; Gandhi, V. B.; Thomas, S.; Luo, Y.; Liu, X.; Shi, Y.; Guan, 
R.; Magnone, S. R.; Klinghofer, V.; Johnson, E. F.; Bouska, J.; Shoemaker, A.; Oleksijew, A.; Stoll, V. S.; 
Jong, R. D.; Oltersdorf, T.; Li, Q.; Rosenberg, S. H.; Giranda, V. L. Bioorg. Med. Chem. Lett. 2006, 16, 
3150–3155. 
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Conclusion    
  
 
In summary, we have developed a versatile synthesis of substituted isoquinolines, 
in which lithiated o-tolualdehyde tert-butylimines were condensed with a wide range of 
nitriles to form eneamido anion intermediates that were trapped in situ with various 
electrophiles, affording a diverse array of highly substituted isoquinolines, many of 
which were difficult to access by known methods (Figure 4.4). Further substitutional 
diversification can be achieved by modification of the work-up conditions and by 
subsequent transformations. This method should be useful for the preparation of many 
biological active isoquinolines, especially for the synthesis of cortistatin analogs with 
isoquinoline modifications.  
 
Figure 4.4 Summary of Our Synthetic Approach to Substituted Isoquinolines.  
 
 
185 
 
Experimental Section    
 
General Experimental Procedures. All reactions were performed in round-
bottom flasks fitted with rubber septa under a positive pressure of argon, unless otherwise 
noted. Air- and moisture-sensitive liquids were transferred via syringe or stainless steel 
cannula. Organic solutions were concentrated by rotary evaporation (house vacuum, ca. 
25–40 Torr) at ambient temperature, unless otherwise noted. Analytical thin-layer 
chromatography (TLC) was performed using glass plates pre-coated with silica gel (0.25 
mm, 60 Å pore-size, 230–400 mesh, Merck KGA) impregnated with a fluorescent 
indicator (254 nm). TLC plates were visualized by exposure to ultraviolet light, then were 
stained with either an aqueous sulfuric acid solution of ceric ammonium molybdate 
(CAM) or acidic ethanolic p-anisaldehyde solution (p-anisaldehyde) followed by brief 
heating on a hot plate. Flash-column chromatography was performed as described by Still 
et al.,32 employing silica gel (60 Å, 32–63 μM, standard grade, Dynamic Adsorbents, 
Inc.). 
Materials. Commercial solvents and reagents were used as received with the 
following exceptions. 2,2,6,6-Tetramethylpiperidine, diisopropylamine, benzonitrile, 
isobutyronitrile, diethylamine, trimethylsilyl chloride, and hexamethylphosphoramide 
were distilled from calcium hydride under an atmosphere of argon or dinitrogen. 
Tetrahydrofuran was purified by the method of Pangborn et al. 33  N-
fluorobenzenesulfonimide was recrystallized from ether. Iodomethane, iodoethane, 1-
iodobutane, allyl bromide, benzyl bromide, and dimethyl disulfide were passed through 
                                                 
32 W. C. Still, M. Khan, A. Mitra, J. Org. Chem. 1978, 43, 2923–2925. 
33 A. B. Pangborn, M. A. Giardello, R. H. Grubbs, R. K. Rosen, F. J. Timmers, Organometallics 1996, 15, 
1518–1520. 
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basic alumina immediately prior to use. 2-Methoxyl-6-methylbenzaldehyde 34  and 
oxodiperoxymolybdenum(pyridine)(hexamethylphosphoric triamide) (MoOPH) 35  were 
prepared according to literature procedures. The molarity of n-butyllithium solutions was 
determined by titration against a standard solution of diphenylacetic acid in 
tetrahydrofuran (average of three determinations).36 
Instrumentation. Proton magnetic resonance (1H NMR) spectra were recorded 
on Varian INOVA 400 (400 MHz), 500 (500 MHz) or 600 (600 MHz) NMR 
spectrometers at 23 °C. Proton chemical shifts are expressed in parts per million (ppm, δ 
scale) and are referenced to residual protium in the NMR solvent (CHCl3, δ 7.26). Data 
are represented as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, 
q = quartet, m = multiplet and/or multiple resonances, br = broad, app = apparent), 
integration, and coupling constant (J) in Hertz. Carbon nuclear magnetic resonance 
spectra (13C NMR) were recorded on Varian INOVA 500 (126 MHz) NMR 
spectrometers at 23 °C. Carbon chemical shifts are expressed in parts per million (ppm, δ 
scale) and are referenced to the carbon resonances of the NMR solvent (CDCl3, δ 77.0; 
C6D6, δ 128.0). Fluorine nuclear magnetic resonance spectra (19F NMR) were recorded 
on Varian INOVA 500 (470 MHz) NMR spectrometers at 23 °C. Infrared (IR) spectra 
were obtained using a Shimadzu 8400S FT-IR spectrometer and were referenced to a 
polystyrene standard. Data are represented as follows: frequency of absorption (cm–1), 
intensity of absorption (vs = very strong, s = strong, m = medium, w = weak, br = broad). 
High-resolution mass spectra were obtained at the Harvard University Mass Spectrometry 
                                                 
34 F. M. Hauser,S. R. Ellenberger, Synthesis 1987, 723−724. 
35 E. Vedejs, D. A. Engler, J. E. Telschow, J. Org. Chem. 1978, 43, 188–196. 
36 W. G. Kofron, L. M. Baclawski, J. Org. Chem. 1976, 41, 1879−1880. 
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Facility. Melting points were measured using a Thomas Hoover uni-melt apparatus 
(6427F10) and were uncorrected. 
 
(For clarity, intermediates that have not been assigned numbers in the text are numbered 
sequentially in the Supporting Information beginning with 219.) 
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2-Methyl-5-(trimethylsilyl)benzaldehyde (222) 
A solution of borane-tetrahydrofuran in tetrahydrofuran (1.0 M, 123 mL, 123 
mmol, 1.2 equiv) was added dropwise to a solution of 5-bromo-2-methylbenzoic acid 
(219, 22.0 g, 102 mmol, 1 equiv) in ether (120 mL) (CAUTION: gas evolution). After 1 
h, the reaction flask was placed in an oil bath preheated to 50 ºC. After 2 h, the oil bath 
was removed and the reaction flask was allowed to cool to 23 ºC. Methanol (20 mL) was 
added dropwise (gas evolution) and the product solution was concentrated to remove the 
bulk of solvent. The residue was purified by flash-column chromatography (10:1 initially, 
grading to 5:1 hexanes–ethyl acetate) to provide 220 as a white solid (19.5 g, 95%). 
A solution of n-butyllithium in hexanes (2.50 M, 77.6 mL, 194 mmol, 2.0 equiv) 
was added dropwise to a cooled solution of 220, (19.5 g, 97 mmol, 1 equiv) in 
tetrahydrofuran (200 mL) at –78 ºC. After 40 min, chlorotrimethylsilane (25.8 mL, 204 
mmol, 2.1 equiv) was added. After 30 min, the cooling bath was removed and the 
reaction flask was allowed to warm to 23 ºC. After 30 min, aqueous hydrochloric acid 
solution (4.0 N, 50 mL) was added. The product solution was concentrated to remove the 
bulk of solvent. The concentrate was partitioned between water (100 mL) and 2:1 
hexanes−ethyl acetate (300 mL). The layers were separated. The aqueous layer was 
extracted with 2:1 hexanes−ethyl acetate (2 × 100 mL). The organic layers were 
combined. The combined solution was washed sequentially with water (100 mL), 
saturated aqueous sodium bicarbonate solution (100 mL), and saturated aqueous sodium 
chloride solution (100 mL). The washed solution was dried over sodium sulfate. The 
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dried solution was filtered and the filtrate was concentrated. The residue was purified by 
flash-column chromatography (40:1 initially, grading to 20:1 then 10:1 hexanes–ethyl 
acetate), furnishing 221 as a colorless oil (13.2 g, 70%). 
Pyridinium chlorochromate (22.0 g, 102 mmol, 1.5 equiv) was added to an ice-
cooled solution of 221, (13.2 g, 67.9 mmol, 1 equiv) in dichloromethane (120 mL). After 
30 min, the cooling bath was removed. After 1 h, the reaction mixture was filtered 
through silica, washing with dichloromethane (3 × 100 mL). The filtrate was 
concentrated. The residue was purified by flash-column chromatography (20:1 
hexanes−ethyl acetate) to furnish 2-methyl-5-(trimethylsilyl)benzaldehyde (222) as a 
colorless oil (12.1 g, 93%).  
 
1H NMR:  
(400 MHz, CDCl3) 
10.30 (s, 1H), 7.93 (d, 1H, J = 1.5 Hz), 7.62 (dd, 1H, J = 7.3, 1.5 Hz), 
7.25 (d, 1H, J = 7.3 Hz), 2.67 (s, 3H), 0.30 (s, 9H). 
 
13C NMR :  
(100 MHz, CDCl3) 
193.3, 141.1, 138.5, 138.4, 137.2, 133.4, 131.2, 19.6, –1.2. 
 
 
FTIR, cm–1: (thin film) 2957 (m), 1697 (vs), 1595 (m), 1265 (m), 1250 (s). 
 
HRMS:  
(ESI) 
Calcd for (C11H16OSi+H)+                                193.1043 
Found                                                      193.1051 
 
TLC                                   Rf  = 0.49 (UV) 
(9:1 hexanes–ethyl acetate) 
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3-Fluoro-5-(trimethylsilyl)benzaldehyde (224)37 
1,3-Dibromo-5-fluorobenzene (223, 2.52 mL, 20 mmol, 1 equiv) was added 
dropwise to a cooled solution of n-butyllithium (2.50 M in hexanes, 8.0 mL, 20 mmol, 1 
equiv) in ether (40 mL) at –78 ºC. After 40 min, chlorotrimethylsilane (2.54 mL, 20 
mmol, 1 equiv) was added, followed by the addition of tetrahydrofuran (40 mL). After 40 
min, a second portion of n-butyllithium (2.50 M in hexanes, 8.8 mL, 22 mmol, 1.1 equiv) 
was added. After 30 min, N,N-dimethylformamide (4.65 mL, 60 mmol, 3 equiv) was 
added. After 40 min, the cooling bath was removed and the reaction flask was allowed to 
warm to 23 ºC. After 1 h, the product solution was concentrated to remove the bulk of 
solvent. The concentrate was partitioned between 2:1 hexanes−ethyl acetate (150 mL) 
and saturated aqueous sodium bicarbonate solution (50 mL). The layers were separated. 
The organic layer was washed with saturated aqueous sodium chloride solution (50 mL). 
The washed solution was dried over sodium sulfate. The dried solution was filtered and 
the filtrate was concentrated. The residue was purified by flash-column chromatography 
(100:1 hexanes–ethyl acetate initially, grading to 40:1 hexanes–ethyl acetate, then 20:1 
hexanes–ethyl acetate), furnishing 3-fluoro-5-(trimethylsilyl)benzaldehyde (224) as a 
yellow oil (3.14 g, 80%).  
 
1H NMR:  10.02 (dd, 1H, J = 1.8, 0.9 Hz), 7.78 (s, 1H), 7.51 (ddd, 
                                                 
37 P. Kurach, S. Luliński, J. Serwatowski, Eur. J. Org. Chem. 2008, 3171−3178. 
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(500 MHz, CDCl3) 1H, J = 8.6, 2.6, 1.6 Hz), 7.45 (ddd, 1H, J = 8.2, 2.3, 1.4 
Hz), 0.32 (d, 10H, J = 0.9 Hz). 
 
19F NMR :  
(470 MHz, CDCl3) 
–113.1 (ddd, J = 8.2, 8.0, 2.3 Hz). 
 
 
13C NMR :  
(126 MHz, CDCl3) 
191.4 (d, J = 1.8 Hz), 162.9 (d, J = 251.7 Hz), 145.4 (d, 
J = 3.7 Hz), 137.8 (d, J = 5.5 Hz), 130.7 (d, J = 2.7 Hz), 
125.9 (d, J = 19.2 Hz), 115.5 (d, J = 21.1 Hz), –1.4. 
 
FTIR, cm–1: 
 (thin film) 
2957 (m), 1703 (vs), 1582 (m), 1375 (s), 1254 (vs). 
 
 
HRMS:  
(ESI) 
Calcd for (C10H13FOSi+H)+                   197.0798 
Found                                                      197.0790 
 
TLC 
(9:1 hexanes–ethyl acetate) 
Rf  = 0.49 (UV) 
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N,N-bis(4-methoxybenzyl)cyanamide (225)38 
Cyanamide (2.10 g, 50 mmol, 1 equiv) was added portionwise over 10 min to a 
suspension of sodium methylsulfinylmethide prepared in situ from a 60% dispersion of 
sodium hydride in mineral oil (5.00 g, 125 mmol, 2.5 equiv) and dimethyl sulfoxide (50 
mL).39 After 40 min, 4-methoxybenzyl chloride (17.0 mL, 125 mmol, 2.5 equiv) was 
added slowly. After 16 h, the reaction mixture was poured into ice-water (100 g). The 
resulting mixture was partitioned between ether (200 mL) and saturated aqueous sodium 
chloride solution (100 mL). The layers were separated. The aqueous layer was extracted 
with ether (3 × 150 mL). The organic layers were combined. The combined organic 
layers were washed sequentially with water (200 mL) and saturated aqueous sodium 
chloride solution (200 mL). The washed solution was dried over sodium sulfate. The 
dried solution was filtered and the filtrate was concentrated. The residue was 
recrystallized from ether, affording N,N-bis(4-methoxybenzyl)cyanamide (225) as a 
white solid (10.5 g, 74%).  
 
Melting Point 78–79 ºC 
 
1H NMR:  7.22 (d, 4H, J = 8.8 Hz), 6.90 (d, 4H, J = 8.8 Hz), 4.03 
                                                 
38 A. Donetti, E. Bellora, J. Org. Chem. 1972, 37, 3352−3353. 
39 R. Greenwald, M. Chaykovsky, E. J. Corey, J. Org. Chem. 1963, 28, 1128−1129. 
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(400 MHz, CDCl3) (s, 4H), 3.81 (s, 6H). 
 
13C NMR :  
(100 MHz, CDCl3) 
159.7, 130.0, 126.3, 118.4, 114.2, 55.2, 53.5. 
 
 
FTIR, cm–1: 
 (thin film) 
2959 (m), 2936 (m), 2837 (m), 2207 (s), 1611 (s), 1512 
(vs), 1472 (m), 1246 (s), 1175 (s). 
 
HRMS:  
(ESI) 
Calcd for (C17H18N2O2+H)+             305.1261 
Found                                                305.1254 
 
TLC 
(2:1 hexanes–ethyl acetate) 
Rf  = 0.38 (UV) 
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General Procedure to Prepare tert-Butyl Aldimines (20–40 mmol scale). tert-
Butylamine (3 equiv) was added to a solution of the corresponding aldehyde (1 equiv) in 
benzene (1.0 M). The reaction flask was placed in an oil bath preheated to 80 ºC. After 16 
h, the oil bath was removed and the reaction flask was allowed to cool to 23 ºC. Hexanes 
(30 equiv) were added and the resulting solution was dried over sodium sulfate. The dried 
solution was filtered and the filtrate was concentrated. The aldimines were isolated by 
distillation at reduced pressure or by recrystallization from hexanes, or in some cases (so 
noted) were used directly without further purification. In all cases yields were 70–100%. 
 
 
2-Methylbenzaldehyde tert-Butylimine (192) 
A colorless oil, purified by distillation at reduced pressure, bp: 70–72 ºC, 0.5 mm 
Hg, 85%. Spectral data were identical to those previously reported.40 
 
 
                                                 
40 M. A. Forth, M. B. Mitchell, S. A. C. Smith, K. Gombatz, L. Snyder, J. Org. Chem. 1994, 59, 2616–
2619. 
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4-Fluoro-2-methylbenzaldehyde tert-Butylimine (226) 
A colorless oil, purified by distillation at reduced pressure, 75% yield. 
 
Boiling Point 79–81 ºC, 0.5 mm Hg 
 
1H NMR:  
(500 MHz, CDCl3) 
8.51 (s, 1H), 7.87 (dd, 1H, J = 8.7, 6.4 Hz), 6.91 (app td, 
1H, J = 8.5, 2.7 Hz), 6.84 (dd, 1H, J = 9.6, 2.3 Hz), 2.47 
(s, 3H), 1.31 (s, 9H). 
 
19F NMR:  
(470 MHz, CDCl3) 
–112.4 (ddd, J = 14.9, 6.9, 3.4 Hz). 
 
 
13C NMR :  
(126 MHz, CDCl3) 
163.4 (d, J = 250.8 Hz), 152.3, 139.6 (d, J = 8.2 Hz), 
131.3 (d, J = 2.7 Hz), 129.2 (d, J = 8.2 Hz), 116.9 (d, J 
= 21.1 Hz), 113.0 (d, J = 22.0 Hz), 57.4, 29.6, 19.0. 
 
FTIR, cm–1: 
 (thin film) 
2971 (m), 1602 (m), 1495 (s), 1472 (m), 1265 (vs). 
 
 
HRMS:  
(ESI) 
Calcd for (C12H16FN+H)+                           194.1340 
Found                                                          194.1338 
 
TLC 
(9:1 hexanes–ethyl acetate) 
Rf  = 0.38 (UV) 
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2,4,6-Trimethylbenzaldehyde tert-Butylimine (227) 
A colorless oil, purified by distillation at reduced pressure, 72% yield. 
 
Boiling Point 102–104 ºC, 0.5 mm Hg 
 
1H NMR:  
(500 MHz, CDCl3) 
8.54 (s, 1H), 6.87 (s, 2H), 2.36 (d, 6H, J = 1.4 Hz), 2.30 
(s, 3H), 1.36 (d, 9H, J = 1.8 Hz). 
 
13C NMR :  
(126 MHz, CDCl3) 
155.6, 137.7, 136.3, 132.5, 128.9, 57.8, 29.6, 20.9, 19.9. 
 
 
FTIR, cm–1: 
 (thin film) 
2967 (s), 1638 (m), 1613 (s), 1456 (m), 1222 (s), 1204 
(s). 
 
HRMS:  
(ESI) 
Calcd for (C14H21N+H)+                                   204.1747 
Found                                                                204.1745 
 
TLC 
(9:1 hexanes–ethyl acetate) 
Rf  = 0.46 (UV) 
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4-Methoxy-2,5-dimethylbenzaldehyde tert-Butylimine (228) 
A white solid, purified by recrystallization from hexanes. 
 
Melting Point 67–68 ºC 
 
1H NMR:  
(500 MHz, CDCl3) 
8.54 (s, 1 H), 7.71 (s, 1 H), 6.59 (s, 1 H), 3.84 (s, 3 H), 
2.48 (s, 3 H), 2.22 (s, 3 H), 1.32 ppm (s, 9 H). 
 
13C NMR :  
(126 MHz, CDCl3) 
158.9, 153.1, 136.2, 128.9, 127.2, 124.3, 111.6, 57.0, 
55.1, 29.8, 18.9, 15.5. 
 
FTIR, cm–1: 
 (thin film) 
2967 (s), 1638 (m), 1609 (s), 1505 (s), 1260 (s), 1217 
(s). 
 
HRMS:  
(ESI) 
Calcd for (C14H21NO+H)+                             220.1696 
Found                                                             220.1701 
 
TLC 
(9:1 hexanes–ethyl acetate) 
Rf  = 0.30 (UV) 
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2-Methoxy-6-methylbenzaldehyde tert-Butylimine (229) 
A pale yellow oil, purified by distillation at reduced pressure, 70% yield. 
 
Boiling Point 138–140 ºC, 0.5 mm Hg 
 
1H NMR:  
(500 MHz, CDCl3) 
8.66 (s, 1H), 7.20 (app t, 1H, J = 8.0 Hz), 6.85 (d, 1H, J 
= 7.8 Hz), 6.75 (d, 1H, J = 8.2 Hz), 3.82 (s, 3H), 2.53 (s, 
3H), 1.37 (s, 9H). 
 
13C NMR :  
(126 MHz, CDCl3) 
158.8, 153.4, 138.5, 129.1, 125.1, 123.6, 108.0, 57.8, 
55.4, 29.6, 20.7. 
 
FTIR, cm–1: 
 (thin film) 
2970 (m), 1640 (m), 1580 (m), 1470 (m), 1263 (vs). 
 
 
HRMS:  
(ESI) 
Calcd for (C13H19NO+H)+                         206.1539 
found                                                          206.1535 
 
TLC 
(9:1 hexanes–ethyl acetate) 
Rf = 0.35 (UV) 
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5-Chloro-2-methylbenzaldehyde tert-Butylimine (216) 
A white solid, purified by recrystallization from hexanes, 80%. 
 
Melting Point 39−40 ºC 
 
1H NMR:  
(500 MHz, CDCl3) 
8.50 (s, 1H), 7.81 (d, 1H, J = 8.2 Hz), 7.19 (dd, 1H, J = 
8.2, 1.8 Hz), 7.14 (d, 1H, J = 1.8 Hz), 2.46 (s, 3H), 1.31 
(s, 9H). 
 
13C NMR :  
(126 MHz, CDCl3) 
152.5, 138.8, 135.3, 133.6, 130.3, 128.5, 126.3, 57.6, 
29.7, 18.9. 
 
FTIR, cm–1: 
 (thin film) 
2969 (s), 1636 (m), 1593 (s), 1479 (m), 1371 (m), 1206 
(s). 
 
HRMS:  
(ESI) 
Calcd for (C12H16ClN+H)+                                210.1044 
Found                                                                 210.1053 
 
TLC 
(9:1 hexanes–ethyl acetate) 
Rf  = 0.41 (UV) 
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2,3-Dimethylbenzaldehyde tert-Butylimine (230) 
A light yellow oil, used directly without further purification, 100%.  
 
1H NMR:  
(500 MHz, CDCl3) 
8.71 (d, 1H, J = 1.8 Hz), 7.75 (d, 1H, J = 7.8 Hz), 7.24–
7.10 (m, 2H), 2.42 (s, 3H), 2.35 (s, 3H), 1.39 (s, 9H). 
 
13C NMR :  
(126 MHz, CDCl3) 
154.4, 136.7, 135.4, 135.3, 131.0, 125.5, 125.0, 57.3, 
29.6, 20.1, 14.4. 
 
FTIR, cm–1: 
 (thin film) 
2971 (m), 1638 (m), 1460 (m), 1371 (m), 1265 (vs). 
 
 
HRMS:  
(ESI) 
Calcd for (C13H19lN+H)+                              190.1590 
Found                                                            190.1591 
 
TLC 
(9:1 hexanes–ethyl acetate) 
Rf  = 0.43 (UV) 
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3-Fluoro-2-methylbenzaldehyde tert-Butylimine (231) 
A light orange oil, used directly without further purification, 100%.  
 
1H NMR:  
(500 MHz, CDCl3) 
8.55 (s, 1H), 7.64 (d, 1H, J = 7.8 Hz), 7.18 (app td, 1H, 
J = 7.9, 5.7 Hz), 7.04 (app td, 1H, J = 8.7, 1.4 Hz), 2.41 
(d, 3H, J = 1.8 Hz), 1.33 (d, 9H, J = 0.9 Hz). 
 
19F NMR:  
(470 MHz, CDCl3) 
–118.1 (app dt, J = 4.9, 2.7 Hz). 
 
 
13C NMR :  
(126 MHz, CDCl3) 
161.2 (d, J = 246.3 Hz), 152.8 (d, J = 4.6 Hz), 137.3 (d, 
J = 4.6 Hz), 126.6 (d, J = 9.2 Hz), 124.2 (d, J = 16.5 
Hz), 122.8 (d, J = 2.7 Hz), 116.0 (d, J = 22.0 Hz), 57.7, 
29.6, 9.9 (d, J = 6.4 Hz). 
FTIR, cm–1: 
 (thin film) 
2970 (s), 1643 (m), 1578 (m), 1462 (s), 1270 (s), 1242 
(s). 
 
HRMS:  
(ESI) 
Calcd for (C12H16FN+H)+                                        194.1340 
 Found                                                         194.1347 
 
TLC 
(9:1 hexanes–ethyl acetate) 
Rf  = 0.43 (UV) 
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2-Methyl-5-(trimethylsilyl)benzaldehyde tert-Butylimine (232) 
A pale yellow oil, purified by distillation at reduced pressure, 75% yield. 
 
Boiling Point 118–120 ºC, 0.5 mm Hg. 
 
1H NMR:  
(500 MHz, CDCl3) 
8.58 (s, 1H), 7.91 (s, 1H), 7.42 (d, 1H, J = 7.3 Hz), 7.16 
(d, 1H, J = 7.8 Hz), 2.49 (s, 3H), 1.31 (s, 9H), 0.27 (s, 
9H). 
 
13C NMR :  
(126 MHz, CDCl3) 
154.5, 137.8, 137.7, 134.6, 134.4, 132.3, 130.1, 57.6, 
29.8, 19.4, –1.1. 
 
FTIR, cm–1: 
 (thin film) 
2967 (s), 1641 (m), 1578 (m), 1472 (m), 1368 (s), 1252 
(s). 
 
HRMS:  
(ESI) 
Calcd for (C15H25NSi+H)+                             248.1829 
 Found                                                             248.1835 
 
TLC 
(9:1 hexanes–ethyl acetate) 
Rf  = 0.51 (UV) 
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3-Fluoro-5-(trimethylsilyl)benzaldehyde tert-Butylimine (206) 
A light orange oil, used directly without further purification, 100%.  
 
1H NMR:  
(600 MHz, CDCl3) 
8.26 (d, 1H, J = 1.5 Hz), 7.53 (ddd, 1H, J = 10.0, 2.9, 
1.8 Hz), 7.51 (s, 1H), 7.21 (ddd, 1H, J = 8.2, 2.6, 0.9 
Hz), 1.29 (s, 9H), 0.29 (s, 9H). 
 
19F NMR:  
(376 MHz, CDCl3) 
–114.8 (dd, J = 10.0, 8.5 Hz). 
 
 
13C NMR :  
(126 MHz, CDCl3) 
162.9 (d, J = 240.8 Hz), 154.2 (d, J = 2.9 Hz), 143.8 (d, 
J = 3.7 Hz), 139.0 (d, J = 6.6 Hz), 129.3 (d, J = 2.2 Hz), 
121.5 (d, J = 19.0 Hz), 113.7 (d, J = 22.0 Hz), 57.4, 
29.7, –1.2. 
 
FTIR, cm–1: 
 (thin film) 
2965 (s), 1638 (m), 1360 (m), 1248 (vs), 1090 (s). 
 
 
HRMS:  
(ESI) 
Calcd for (C14H22FNSi+H)+                              252.1578 
Found                                                                252.1586 
 
TLC 
(9:1 hexanes–ethyl acetate) 
Rf  = 0.49 (UV) 
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3-Phenylisoquinoline (194) 
A solution of n-butyllithium in hexanes (2.40 M, 438 μL, 1.05 mmol, 1.05 equiv) 
was added dropwise over 40 min to an ice-cooled solution of imine 192 (175 mg, 1.00 
mmol, 1 equiv) and 2,2,6,6-tetramethylpiperidine (17 μL, 0.10 mmol, 0.1 equiv) in 
tetrahydrofuran (1.5 mL), forming a deep purple solution. After 30 min, the deep purple 
solution was transferred by cannula to a solution of benzonitrile (155 μL, 1.5 mmol, 1.5 
equiv) in tetrahydrofuran (0.4 mL) at –78 ºC, forming a dark red solution. The transfer 
was quantitated with tetrahydrofuran (0.1 mL). After 3 min, iodomethane (125 μL, 2 
mmol, 2 equiv) was added. After 30 min, trifluoroacetic acid (1 mL) was added. The 
cooling bath was removed and the reaction flask was allowed to warm to 23 ºC. The 
reaction mixture was partitioned between saturated aqueous sodium carbonate solution 
(20 mL) and dichloromethane (30 mL). The layers were separated. The aqueous layer 
was extracted with dichloromethane (3 × 20 mL). The organic layers were combined. The 
combined solution was dried over sodium sulfate. The dried solution was filtered and the 
filtrate was concentrated. The residue was purified by flash-column chromatography 
(20:1 hexanes–ethyl acetate initially, grading to 15:1 hexanes–ethyl acetate), furnishing 
3-phenylisoquinoline (194) as a pale yellow solid (164 mg, 80%), mp: 96–97 ºC. The 
spectral properties were identical to those previously reported.41 
 
                                                 
41 H. Sard, J. Heterocycl. Chem. 1994, 31, 1085–1086. 
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4-Methyl-3-phenylisoquinoline (200) 
A solution of n-butyllithium in hexanes (2.40 M, 424 μL, 1.02 mmol, 1.05 equiv) 
was added dropwise over 40 min to an ice-cooled solution of imine 192 (170 mg, 0.970 
mmol, 1 equiv) and 2,2,6,6-tetramethylpiperidine (17 μL, 0.097 mmol, 0.1 equiv) in 
tetrahydrofuran (1.5 mL), forming a deep purple solution. After 30 min, the deep purple 
solution was transferred by cannula to a solution of benzonitrile (150 μL, 1.46 mmol, 1.5 
equiv) in tetrahydrofuran (0.4 mL) at –78 ºC, forming a dark red solution. The transfer 
was quantitated with tetrahydrofuran (0.1 mL). After 3 min, iodomethane (121 μL, 1.94 
mmol, 2 equiv) was added. After 30 min, trifluoroacetic acid (1 mL) was added. The 
cooling bath was removed and the reaction flask was allowed to warm to 23 ºC. The 
reaction mixture was partitioned between saturated aqueous sodium carbonate solution 
(20 mL) and dichloromethane (30 mL). The layers were separated. The aqueous layer 
was extracted with dichloromethane (3 × 20 mL). The organic layers were combined. The 
combined solution was dried over sodium sulfate. The dried solution was filtered and the 
filtrate was concentrated. The residue was purified by flash-column chromatography 
(20:1 hexanes–ethyl acetate initially, grading to 10:1 hexanes–ethyl acetate, then 7:1 
hexanes–ethyl acetate), furnishing 4-methyl-3-phenylisoquinoline (200) as a white solid 
(170 mg, 80%), mp: 101–102 ºC. The spectral properties were identical to those 
previously reported.42 
 
                                                 
42 K. R. Roesch, H. Zhang, R. C. Larock, J. Org. Chem. 1998, 63, 5306–5307. 
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4-Ethyl-3-isopropylisoquinoline (233) 
A solution of n-butyllithium in hexanes (2.52 M, 616 μL, 1.55 mmol, 1.31 equiv) 
was added dropwise over 40 min to an ice-cooled solution of imine 192 (259 mg, 1.48 
mmol, 1.25 equiv) and 2,2,6,6-tetramethylpiperidine (25 μL, 0.148 mmol, 0.125 equiv) in 
tetrahydrofuran (2 mL), forming a deep purple solution. After 30 min, the deep purple 
solution was transferred by cannula to a solution of isobutyronitrile (106 μL, 1.18 mmol, 
1 equiv) in tetrahydrofuran (0.5 mL) at –78 ºC, forming a dark red solution. The transfer 
was quantitated with tetrahydrofuran (0.1 mL). After 5 min, iodoethane (239 μL, 2.96 
mmol, 2.5 equiv) was added. After 10 min, the cooling bath was removed and the 
reaction flask was allowed to warm to 23 ºC. After 30 min, trifluoroacetic acid (1 mL) 
was added. After stirring for 10 min, the reaction mixture was partitioned between 
saturated aqueous sodium carbonate solution (20 mL) and dichloromethane (30 mL). The 
layers were separated. The aqueous layer was extracted with dichloromethane (3 × 20 
mL). The organic layers were combined. The combined solution was dried over sodium 
sulfate. The dried solution was filtered and the filtrate was concentrated. The residue was 
purified by flash-column chromatography (40:1 hexanes–ethyl acetate initially, grading 
to 20:1 hexanes–ethyl acetate, then 15:1 hexanes–ethyl acetate), furnishing 4-ethyl-3-
isopropylisoquinoline (233) as a pale yellow oil (122 mg, 52%).  
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1H NMR:  
(500 MHz, CDCl3) 
9.14 (s, 1H), 7.98 (d, 1H, J = 8.8 Hz), 7.89 (d, 1H, J = 
8.3 Hz), 7.65 (ddd, 1H, J = 8.4, 7.0, 1.2 Hz), 7.48 (ddd, 
1H, J = 8.8, 7.0, 1.2 Hz), 3.51 (spt, 1H, J = 6.7 Hz), 3.09 
(q, 2H, J = 7.3 Hz), 1.38 (d, 6H, J = 6.3 Hz), 1.29 (t, 3H, 
J = 7.8 Hz). 
 
13C NMR :  
(126 MHz, CDCl3) 
157.0, 150.3, 134.9, 129.8, 128.1, 127.9, 127.1, 125.5, 
122.9, 30.6, 22.7, 20.4, 15.2. 
 
FTIR, cm–1: 
 (thin film) 
2965 (s), 1620 (m), 1578 (m), 1472 (m), 1377 (m), 1246 
(m). 
 
HRMS:  
(ESI) 
Calcd for (C14H17N+H)+                                 200.1434 
 Found                                                             200.1441 
 
TLC 
(9:1 hexanes–ethyl acetate) 
Rf  = 0.37 (UV) 
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4-n-Butyl-6-fluoro-3-(methoxymethyl)isoquinoline (234) 
A solution of n-butyllithium in hexanes (2.50 M, 435 μL, 1.09 mmol, 1.31 equiv) 
was added dropwise to an ice-cooled solution of diisopropylamine (161 μL, 1.14 mmol, 
1.38 equiv) in tetrahydrofuran (1.5 mL). After 15 min, a solution of imine 226 (200 mg, 
1.04 mmol, 1.25 equiv) in tetrahydrofuran (0.5 mL) was added by cannula, forming a 
deep purple solution. After 60 min, the deep purple solution was transferred by cannula to 
a solution of methoxyacetonitrile (62 μL, 0.83 mmol, 1 equiv) in tetrahydrofuran (0.4 
mL) at –78 ºC, forming a dark red solution. The transfer was quantitated with 
tetrahydrofuran (0.1 mL). After 60 min, 1-iodobutane (237 μL, 2.07 mmol, 2.5 equiv) 
was added. After 10 min, the cooling bath was removed and the reaction flask was 
allowed to warm to 23 ºC. After 30 min, saturated aqueous ammonium chloride (1 mL) 
was added. After 10 min, the reaction mixture was partitioned between saturated aqueous 
sodium bicarbonate solution (20 mL) and dichloromethane (30 mL). The layers were 
separated. The aqueous layer was extracted with dichloromethane (3 × 20 mL). The 
organic layers were combined. The combined solution was dried over sodium sulfate. 
The dried solution was filtered and the filtrate was concentrated. The residue was purified 
by flash-column chromatography (10:1 hexanes–ethyl acetate initially, grading to 5:1 
hexanes–ethyl acetate, then 2:1 hexanes–ethyl acetate, and finally 1:1 hexanes–ethyl 
acetate), affording 4-butyl-6-fluoro-3-(methoxymethyl)isoquinoline (234) as a pale 
yellow oil (102 mg, 50%).  
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1H NMR:  
(500 MHz, CDCl3) 
9.08 (s, 1H), 7.97 (dd, 1H, J = 9.0, 5.6 Hz), 7.61 (dd, 
1H, J = 10.7, 2.0 Hz), 7.35 (app td, 1H, J = 8.7, 2.2 Hz), 
4.77 (s, 2H), 3.49 (s, 3H), 3.05 (t, 2H, J = 7.5 Hz), 1.70–
1.59 (m, 2H), 1.58–1.48 (m, 2H), 1.01 (t, 3H, J = 7.3 
Hz). 
 
19F NMR :  
(470 MHz, CDCl3) 
–107.0 (ddd, J = 11.43, 8.00, 5.71 Hz). 
 
 
13C NMR :  
(126 MHz, CDCl3) 
163.4 (d, J = 250 Hz), 149.7, 148.6, 137.0 (d, J = 10.1 
Hz), 131.1 (d, J = 10.1 Hz), 130.9 (d, J = 5.5 Hz), 125.4, 
117.2 (d, J = 26.3 Hz), 107.2 (d, J = 21.0 Hz), 74.3, 
58.6, 32.9, 27.5, 23.2, 13.9. 
FTIR, cm–1: 
 (thin film) 
2957 (m), 2928 (m), 2872 (m), 1628 (s), 1501 (s), 1435 
(m), 1196 (s). 
 
HRMS:  
(ESI) 
Calcd for (C15H18FNO +H)+                                    248.1445 
 Found                                                           248.1449 
 
TLC 
(2:1 hexanes–ethyl acetate) 
Rf  = 0.21 (UV) 
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4-Allyl-6,8-dimethyl-3-(diethylaminomethyl)isoquinoline (235) 
A solution of n-butyllithium in hexanes (2.50 M, 490 μL, 1.22 mmol, 1.31 equiv) 
was added dropwise over 40 min to an ice-cooled solution of imine 227 (237 mg, 1.17 
mmol, 1.25 equiv) and 2,2,6,6-tetramethylpiperidine (20 μL, 0.117 mmol, 0.125 equiv) in 
tetrahydrofuran (2 mL), forming a deep purple solution. After 30 min, the deep purple 
solution was transferred by cannula to a solution of 2-(diethylamino)acetonitrile (121 μL, 
0.866 mmol, 1 equiv) in tetrahydrofuran (0.4 mL) at –78 ºC, forming an orange solution. 
The transfer was quantitated with tetrahydrofuran (0.1 mL). After 5 min, 
hexamethylphosphoramide (406 μL, 2.33 mmol, 2.5 equiv) was added. After 10 min, 
allyl bromide (197 μL, 2.33 mmol, 2.5 equiv) was added. After 10 min, the cooling bath 
was removed and the reaction flask was allowed to warm to 23 ºC. After 30 min, 
trifluoroacetic acid (1 mL) was added. After stirring for 10 min, the reaction mixture was 
partitioned between saturated aqueous sodium carbonate solution (20 mL) and 
dichloromethane (30 mL). The layers were separated. The aqueous layer was extracted 
with dichloromethane (3 × 20 mL). The organic layers were combined. The combined 
solution was dried over sodium sulfate. The dried solution was filtered and the filtrate 
was concentrated. The residue was purified by flash-column chromatography (2:1 
hexanes–ethyl acetate initially, grading to 1:1 hexanes–ethyl acetate, then 1:1:0.01 
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hexanes–ethyl acetate–triethylamine), furnishing 4-allyl-6,8-dimethyl-3-
(diethylaminomethyl)isoquinoline (235) as a pale yellow oil (158 mg, 60%).  
 
1H NMR:  
(500 MHz, CDCl3) 
9.26 (s, 1H), 7.61 (s, 1H), 7.17 (s, 1H), 6.11–5.99 (m, 
1H), 5.07–4.98 (m, 1H), 4.95–4.86 (m, 1H), 4.02 (app 
dt, 2H, J = 5.5, 1.8 Hz), 3.86 (s, 2H), 2.73 (s, 3H), 2.58 
(q, 4H, J = 7.0 Hz), 2.50 (s, 3H), 1.05 (t, 6H, J = 7.1 
Hz). 
 
13C NMR :  
(126 MHz, CDCl3) 
150.7, 146.5, 139.8, 136.6, 136.4, 135.4, 129.4, 127.5, 
125.2, 120.5, 115.4, 58.4, 47.0, 31.1, 22.4, 18.6, 11.6. 
 
FTIR, cm–1: 
 (thin film) 
3389 (br), 2969 (s), 1622 (s), 1595 (m), 1452 (s), 1368 
(s), 1200 (m). 
 
HRMS:  
(ESI) 
Calcd for (C19H26N2+H)+                              283.2169 
Found                                                            283.2170 
 
TLC 
(90:9:1 dichloromethane–
methanol–triethyl amine) 
Rf  = 0.23 (UV) 
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4-Benzyl-3-(diethoxymethyl)-6-methoxy-7-methylisoquinoline (236) 
A solution of n-butyllithium in hexanes (2.52 M, 521 μL, 1.31 mmol, 1.31 equiv) 
was added dropwise over 40 min to an ice-cooled solution of imine 228 (274 mg, 1.25 
mmol, 1.25 equiv) and 2,2,6,6-tetramethylpiperidine (21 μL, 0.125 mmol, 0.125 equiv) in 
tetrahydrofuran (2 mL), forming a deep purple solution. After 30 min, the deep purple 
solution was transferred by cannula to a solution of 2,2-diethoxyacetonitrile (139 μL, 
1.00 mmol, 1 equiv) in tetrahydrofuran (0.4 mL) at –78 ºC, forming a dark orange 
solution. The transfer was quantitated with tetrahydrofuran (0.1 mL). After 5 min, benzyl 
bromide (371 μL, 3.13 mmol, 2.5 equiv) was added. After 10 min, the cooling bath was 
removed and the reaction flask was allowed to warm to 23 ºC. After 30 min, 
trifluoroacetic acid (1 mL) was added. After stirring for 10 min, the reaction mixture was 
partitioned between saturated aqueous sodium carbonate solution (20 mL) and 
dichloromethane (30 mL). The layers were separated. The aqueous layer was extracted 
with dichloromethane (3 × 20 mL). The organic layers were combined. The combined 
solution was dried over sodium sulfate. The dried solution was filtered and the filtrate 
was concentrated. The residue was purified by flash-column chromatography (10:1 
hexanes–ethyl acetate initially, grading to 5:1 hexanes–ethyl acetate, then 2:1 hexanes–
ethyl acetate), furnishing 4-benzyl-3-(diethoxymethyl)-6-methoxy-7-methylisoquinoline 
(236) as a pale yellow oil (184 mg, 50%). 
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1H NMR:  
(500 MHz, CDCl3) 
8.99 (s, 1H), 7.65 (s, 1H), 7.22–7.17 (m, 2H), 7.17–7.08 
(m, 3H), 7.01 (s, 1H), 5.79 (s, 1H), 4.68 (s, 2H), 3.76 
(dq, 2H, J = 9.4, 7.1 Hz), 3.70 (s, 3H), 3.58 (dq, 2H, J = 
9.4, 7.1 Hz), 2.32 (s, 3H), 1.15 (t, 6H, J = 6.9 Hz). 
 
13C NMR :  
(126 MHz, CDCl3) 
160.0, 149.1, 148.8, 140.9, 137.1, 129.9, 128.6, 128.3, 
128.2, 126.6, 125.6, 124.2, 105.0, 101.1, 63.0, 55.2, 
32.9, 16.7, 15.1. 
 
FTIR, cm–1: 
 (thin film) 
2974 (m), 1630 (s), 1495 (s), 1418 (m), 1234 (s), 1111 
(s). 
 
HRMS:  
(ESI) 
Calcd for (C23H27NO3+H)+                                           366.2064 
Found                                                               366.2076 
 
TLC 
(2:1 hexanes–ethyl acetate) 
Rf  = 0.41 (UV) 
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4-(4-Bromobenzyl)-8-methoxy-3-(piperidin-1-yl)isoquinoline (237) 
A solution of n-butyllithium in hexanes (2.52 M, 436 μL, 1.10 mmol, 1.05 equiv) 
was added dropwise over 40 min to an ice-cooled solution of imine 229 (215 mg, 1.05 
mmol, 1 equiv) and 2,2,6,6-tetramethylpiperidine (18 μL, 0.105 mmol, 0.1 equiv) in 
tetrahydrofuran (2 mL), forming a deep purple solution. After 30 min, the reaction flask 
was cooled to –78 ºC, and 1-piperidinecarbonitrile (182 μL, 1.57 mmol, 1.5 equiv) was 
added. After 10 min, hexamethylphosphoramide (300 μL, 1.72 mmol, 2 equiv) was 
added. After 10 min, a solution of 4-bromobenzyl bromide (523 mg, 2.10 mmol, 2 equiv) 
in tetrahydrofuran (0.5 mL) was added. After 20 min, the cooling bath was removed and 
the reaction flask was allowed to warm to 23 ºC. After 30 min, trifluoroacetic acid (1 mL) 
was added. After stirring for 10 min, the reaction mixture was partitioned between 
saturated aqueous sodium carbonate solution (20 mL) and dichloromethane (30 mL). The 
layers were separated. The aqueous layer was extracted with dichloromethane (3 × 20 
mL). The organic layers were combined. The combined solution was dried over sodium 
sulfate. The dried solution was filtered and the filtrate was concentrated. The residue was 
purified by flash-column chromatography (40:1 hexanes–ethyl acetate initially, grading 
to 20:1 hexanes–ethyl acetate, then 10:1 hexanes–ethyl acetate, and finally 7:1 hexanes–
ethyl acetate), affording 4-(4-bromobenzyl)-8-methoxy-3-(piperidin-1-yl)isoquinoline 
(237) as a white solid (224 mg, 52%); 
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Melting Point 152–153 ºC 
 
1H NMR:  
(500 MHz, CDCl3) 
9.43 (s, 1H), 7.40 (dd, 1H, J = 8.5, 7.6 Hz), 7.32 (d, 2H, 
J = 8.3 Hz), 7.19 (d, 1H, J = 8.8 Hz), 6.98 (d, 2H, J = 
8.3 Hz), 6.70 (d, 1H, J = 7.3 Hz), 4.42 (s, 2H), 4.00 (s, 
3H), 3.10–2.97 (m, 4H), 1.74–1.62 (m, 4H), 1.62–1.54 
(m, 2H). 
 
13C NMR :  
(126 MHz, CDCl3) 
159.6, 157.1, 145.5, 140.1, 138.7, 131.3, 130.6, 129.9, 
119.4, 118.5, 118.4, 115.8, 102.8, 55.6, 52.7, 32.5, 26.5, 
24.4. 
 
FTIR, cm–1: 
 (thin film) 
2934 (m), 1622 (m), 1570 (s), 1487 (m), 1391 (m), 1265 
(s), 1221 (s). 
 
HRMS:  
(ESI) 
Calcd for (C22H23BrN2O+H)+                         411.1067 
 Found                                                             411.1063 
 
TLC 
(9:1 hexanes–ethyl acetate) 
Rf  = 0.26 (UV) 
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Methyl 7-Chloro-3-morpholinoisoquinoline-4-carboxylate (238) 
A solution of n-butyllithium in hexanes (2.50 M, 420 μL, 1.05 mmol, 1.05 equiv) 
was added dropwise to an ice-cooled solution of diisopropylamine (155 μL, 1.10 mmol, 
1.1 equiv) in tetrahydrofuran (1.5 mL). After 15 min, a solution of imine 216 (210 mg, 
1.00 mmol, 1 equiv) in tetrahydrofuran (0.5 mL) was added by cannula, forming a deep 
purple solution. After 60 min, the reaction flask was cooled to –78 ºC, and 4-
morpholinecarbonitrile (152 μL, 1.50 mmol, 1.5 equiv) was added. After 60 min, methyl 
cyanoformate (150 μL, 2.00 mmol, 2 equiv) was added. After 10 min, the cooling bath 
was removed and the reaction flask was allowed to warm to 23 ºC. After 30 min, 
saturated aqueous ammonium chloride (1 mL) was added. After 10 min, the reaction 
mixture was partitioned between saturated aqueous sodium bicarbonate solution (20 mL) 
and dichloromethane (30 mL). The layers were separated. The aqueous layer was 
extracted with dichloromethane (3 × 20 mL). The organic layers were combined. The 
combined solution was dried over sodium sulfate. The dried solution was filtered and the 
filtrate was concentrated. The residue was purified by flash-column chromatography 
(10:1 hexanes–ethyl acetate initially, grading to 5:1 hexanes–ethyl acetate, then 2:1 
hexanes–ethyl acetate), furnishing methyl 7-chloro-3-morpholinoisoquinoline-4-
carboxylate (238) as a yellow oil (208 mg, 66%).  
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1H NMR:  
(400 MHz, CDCl3) 
δ 8.89 (s, 1H), 8.00 (d, 1H, J = 1.8 Hz), 7.75 (d, 1H, J = 
8.4 Hz), 7.28 (dd, 1H, J = 8.8, 1.8 Hz), 3.99 (s, 3H), 
3.82–3.75 (m, 4H), 3.59–3.52 (m, 4H). 
 
13C NMR :  
(100 MHz, CDCl3) 
168.7, 156.0, 152.7, 138.4, 137.0, 129.6, 125.0, 121.6, 
104.5, 67.1, 52.2, 49.1. 
 
FTIR, cm–1: 
 (thin film) 
2963 (m), 2857 (m), 1707 (vs), 1611 (s), 1487 (s), 1435 
(s), 1215 (s), 1115 (s). 
 
HRMS:  
(ESI) 
Calcd for (C15H15ClN2O3+H)+                                    307.0844 
Found                                                               307.0852 
 
TLC 
(2:1 hexanes–ethyl acetate) 
Rf  = 0.41 (UV) 
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N,N,4,5-Tetramethylisoquinolin-3-amine (239) 
A solution of n-butyllithium in hexanes (2.50 M, 422 μL, 1.05 mmol, 1.05 equiv) 
was added dropwise over 40 min to an ice-cooled solution of imine 230 (190 mg, 1.00 
mmol, 1 equiv) and 2,2,6,6-tetramethylpiperidine (17 μL, 0.10 mmol, 0.1 equiv) in 
tetrahydrofuran (2 mL), forming a deep purple solution. After 30 min, the reaction flask 
was cooled to –78 ºC, and N,N-dimethylcyanamide (122 μL, 1.50 mmol, 1.5 equiv) was 
added, forming a dark red solution. After 15 min, hexamethylphosphoramide (349 μL, 
2.00 mmol, 2 equiv) was added. After 15 min, iodomethane (125 μL, 2.00 mmol, 2 
equiv) was added. After 30 min, trifluoroacetic acid (1 mL) was added. The cooling bath 
was removed and the reaction flask was allowed to warm to 23 ºC. The reaction mixture 
was partitioned between saturated aqueous sodium carbonate solution (20 mL) and 
dichloromethane (30 mL). The layers were separated. The aqueous layer was extracted 
with dichloromethane (3 × 20 mL). The organic layers were combined. The combined 
solution was dried over sodium sulfate. The dried solution was filtered and the filtrate 
was concentrated. The residue was purified by flash-column chromatography (40:1 
hexanes–ethyl acetate initially, grading to 20:1 hexanes–ethyl acetate, then 15:1 hexanes–
ethyl acetate), affording N,N,4,5-tetramethylisoquinolin-3-amine (239) as a pale yellow 
oil (108 mg, 54%). 
 
1H NMR:  8.82 (s, 1H), 7.67 (d, 1H, J = 8.2 Hz), 7.35 (d, 1H, J = 
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(500 MHz, CDCl3) 6.9 Hz), 7.23 (dd, 1H, J = 8.0, 7.1 Hz), 2.91 (s, 6H), 
2.88 (s, 3H), 2.76 (s, 3H). 
 
13C NMR :  
(126 MHz, CDCl3) 
159.7, 149.1, 138.6, 133.9, 132.9, 126.9, 126.7, 123.8, 
115.6, 42.9, 25.2, 19.0. 
 
FTIR, cm–1: 
 (thin film) 
2938 (m), 2861 (m), 1611 (m), 1576 (s), 1482 (s), 1400 
(s), 1332 (m), 1144 (m). 
 
HRMS:  
(ESI) 
Calcd for (C13H16N2+H)+                                   201.1386 
 Found                                                                201.1390 
 
TLC 
(9:1 hexanes–ethyl acetate) 
Rf  = 0.35 (UV) 
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N,N-Dibenzyl-4,5-difluoroisoquinolin-3-amine (240) 
A solution of n-butyllithium in hexanes (2.50 M, 443 μL, 1.11 mmol, 1.32 equiv) 
was added dropwise to a cooled solution of diisopropylamine (164 μL, 1.16 mmol, 1.37 
equiv) in tetrahydrofuran (1.5 mL) at –20 ºC. After 15 min, a solution of imine 231 (204 
mg, 1.06 mmol, 1.25 equiv) in tetrahydrofuran (0.5 mL) was added by cannula, forming a 
deep purple solution. After 60 min, the reaction flask was cooled to –78 ºC, and a 
solution of N,N-dibenzylcyanamide (293 mg, 1.32 mmol, 1.56 equiv) in tetrahydrofuran 
(1 mL) was added. After 60 min, a solution of N-fluorobenzenesulfonimide (266 mg, 
0.844 mmol, 1 equiv) in tetrahydrofuran (1 mL) was added. After 10 min, trifluoroacetic 
acid (1 mL) was added. The cooling bath was removed and the reaction flask was 
allowed to warm to 23 ºC. Saturated aqueous sodium carbonate solution (5 mL) was 
added slowly. The reaction mixture was concentrated to remove the bulk of solvent. The 
concentrate was partitioned between dichloromethane (60 mL) and saturated aqueous 
sodium carbonate solution (10 mL). The layers were separated. The organic solution was 
washed with water (10 mL) then saturated aqueous sodium chloride solution (10 mL). 
The washed solution was dried over sodium sulfate. The dried solution was filtered and 
the filtrate was concentrated. The residue was purified by flash-column chromatography 
(40:1 hexanes–ethyl acetate initially, grading to 20:1 hexanes–ethyl acetate, then 10:1 
hexanes–ethyl acetate), furnishing N,N-dibenzyl-4,5-difluoroisoquinolin-3-amine (240) 
as a yellow oil (226 mg, 74%).  
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1H NMR:  
(500 MHz, CDCl3) 
δ 8.78 (d, 1H, J = 2.3 Hz), 7.61 (ddd, 1H, J = 5.3, 3.9, 
2.3 Hz), 7.41–7.32 (m, 8H), 7.31–7.26 (m, 2H), 7.25–
7.21 (m, 2H), 4.85 (s, 4H). 
 
19F NMR:  
(470 MHz, CDCl3) 
–118.8– –118.4 (m), –143.5 (d, J = 52.0 Hz). 
 
 
13C NMR :  
(126 MHz, CDCl3) 
155.6 (d, J = 255.0 Hz), 144.9 (dd, J = 7.3, 1.8 Hz), 
144.5 (d, J = 8.2 Hz), 138.9, 139.7 (dd, J = 259.0, 2.2 
Hz), 128.4, 127.7, 127.0, 126.9, 123.5 (d, J = 8.2 Hz), 
122.9 (d, J = 3.7 Hz), 119.3 (dd, J = 12.6, 12.0 Hz), 
114.6 (dd, J = 20.2, 1.9 Hz), 52.7 (d, J = 5.5 Hz). 
 
FTIR, cm–1: 
 (thin film) 
3028 (m), 2912 (m), 1595 (s), 1364 (s), 1244 (s), 1049 
(s). 
 
HRMS:  
(ESI) 
Calcd for (C23H18F2N2 +H)+                                             361.1511 
Found                                                                 365.1510 
 
TLC 
(9:1 hexanes–ethyl acetate) 
Rf  = 0.38 (UV) 
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4-Fluoro-N,N-bis(4-methoxybenzyl)-7-(trimethylsilyl)isoquinolin-3-amine (209) 
A solution of n-butyllithium in hexanes (2.50 M, 1.60 mL, 4.00 mmol, 1.31 
equiv) was added dropwise to an ice-cooled solution of imine 232 (943 mg, 3.81 mmol, 
1.25 equiv) and 2,2,6,6-tetramethylpiperidine (65 μL, 0.38 mmol, 0.125 equiv) in 
tetrahydrofuran (5 mL) over 60 min, forming a deep purple solution. After 30 min, the 
reaction flask was cooled to –78 ºC, and a solution of N,N-bis(4-
methoxybenzyl)cyanamide (225) (1.35 g, 4.76 mmol, 1.56 equiv) in tetrahydrofuran (2.5 
mL) was added. After 15 min, a solution of N-fluorobenzenesulfonimide (961 mg, 3.05 
mmol, 1 equiv) in tetrahydrofuran (2 mL) was added. After 10 min, trifluoroacetic acid (3 
mL) was added. The cooling bath was removed and the reaction flask was allowed to 
warm to 23 ºC. Saturated aqueous sodium carbonate solution (15 mL) was added slowly. 
The reaction mixture was concentrated to remove the bulk of solvent. The concentrate 
was partitioned between dichloromethane (120 mL) and saturated aqueous sodium 
carbonate solution (30 mL). The layers were separated. The organic solution was washed 
with water (30 mL) then saturated aqueous sodium chloride solution (30 mL). The 
washed solution was dried over sodium sulfate. The dried solution was filtered and the 
filtrate was concentrated. The residue was purified by flash-column chromatography 
(40:1 hexanes–ethyl acetate initially, grading to 20:1 hexanes–ethyl acetate, then 15:1 
hexanes–ethyl acetate), affording 4-fluoro-N,N-bis(4-methoxybenzyl)-7-
(trimethylsilyl)isoquinolin-3-amine (209) as a yellow oil (863 mg, 60%). 
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1H NMR:  
(500 MHz, CDCl3) 
8.77 (s, 1H), 7.96 (s, 1H), 7.84 (d, 1H, J = 8.7 Hz), 7.68 
(dd, 1H, J = 8.7, 0.9 Hz), 7.23 (d, 4H, J = 8.7 Hz), 6.84 
(d, 4H, J = 8.7 Hz), 4.70 (s, 4H), 3.79 (s, 6H), 0.34 (s, 
9H). 
 
19F NMR :  
(470 MHz, CDCl3) 
 
–148.5 (s). 
13C NMR :  
(126 MHz, CDCl3) 
145.5 (d, J = 5.5 Hz), 143.4 (d, J = 6.4 Hz), 141.5 (d, J 
= 252.7 Hz), 135.7, 134.0, 132.7, 131.1, 129.0, 128.5 (d, 
J = 15.6 Hz), 124.5, 117.1 (d, J = 5.5 Hz), 113.7, 55.2, 
51.7 (d, J = 4.6 Hz), –1.2. 
FTIR, cm–1: 
 (thin film) 
2953 (m), 1732 (s), 1622 (s), 1510 (s), 1499 (s), 1246 
(s). 
 
HRMS:  
(ESI) 
Calcd for (C28H31FN2O2Si+H)+                         475.2212 
Found                                                                475.2191. 
 
TLC 
(9:1 hexanes–ethyl acetate) 
Rf  = 0.32 (UV) 
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4-Chloro-7-(trimethylsilyl)-3-(4-((trimethylsilyl)ethynyl)phenyl)isoquinoline (241) 
A solution of n-butyllithium in hexanes (2.52 M, 362 μL, 0.912 mmol, 1.05 
equiv) was added dropwise to an ice-cooled solution of imine 232 (215 mg, 0.869 mmol, 
1 equiv) and 2,2,6,6-tetramethylpiperidine (15 μL, 0.087 mmol, 0.1 equiv) in 
tetrahydrofuran (1.5 mL) over 40 min, forming a deep purple solution. After 30 min, the 
reaction flask was cooled to –78 ºC, and a solution of 4-
[(trimethylsilyl)ethynyl]benzonitrile (216 mg, 1.09 mmol, 1.25 equiv) in tetrahydrofuran 
(0.5 mL) was added, forming a dark red solution. After 5 min, the bright red solution was 
transferred by cannula to a suspension of hexachloroethane (823 mg, 3.48 mmol, 4 equiv) 
in tetrahydrofuran (1 mL) at –78 ºC. After 15 min, trifluoroacetic acid (1 mL) was added. 
The cooling bath was removed and the reaction flask was allowed to warm to 23 ºC. The 
reaction mixture was partitioned between saturated aqueous sodium carbonate solution 
(20 mL) and dichloromethane (30 mL). The layers were separated. The aqueous layer 
was extracted with dichloromethane (3 × 20 mL). The organic layers were combined. The 
combined solution was dried over sodium sulfate.  The dried solution was filtered and the 
filtrate was concentrated. The residue was purified by flash-column chromatography 
(80:1 hexanes–ethyl acetate initially, grading to 60:1 hexanes–ethyl acetate, then 40:1 
hexanes–ethyl acetate), furnishing 4-chloro-7-(trimethylsilyl)-3-(4-
((trimethylsilyl)ethynyl)phenyl)isoquinoline (241) as a white solid (191 mg, 54%). 
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Melting Point 118–120 ºC 
 
1H NMR:  
(500 MHz, CDCl3) 
9.23 (s, 1H), 8.28 (d, 1H, J = 8.7 Hz), 8.16 (s, 1H), 7.95 
(d, 1H, J = 8.2 Hz), 7.79 (d, 2H, J = 8.2 Hz), 7.61 (d, 
2H, J = 8.2 Hz), 0.40 (s, 9H), 0.30 (s, 9H). 
 
13C NMR :  
(126 MHz, CDCl3) 
150.6, 149.1, 141.3, 139.0, 135.7, 134.6, 133.3, 131.5, 
129.8, 127.9, 125.8, 123.1, 122.8, 105.0, 95.1, 0.0, –1.3. 
 
FTIR, cm–1: 
 (thin film) 
2957 (m), 2158 (m), 1697 (m), 1612 (m), 1568 (m), 
1427 (m), 1250 (s). 
 
HRMS:  
(ESI) 
Calcd for (C23H26ClNSi2+H)+                      408.1365 
 Found                                                          408.1359 
 
TLC 
(9:1 hexanes–ethyl acetate) 
Rf  = 0.45 (UV) 
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3-(3-Bromophenyl)-7-(trimethylsilyl)isoquinolin-4-ol (242) 
A 25-mL three-neck flask was equipped with a magnetic stirrer, two rubber septa, 
one affixed with an argon balloon, and an L-shaped glass tube with male joints at each 
ends, one inserted into a side neck of the three neck reaction flask and the other wired to 
a 5-mL round-bottom flask containing solid oxodiperoxymolybdenum(pyridine)-
(hexamethylphosphoric triamide) (MoOPH) (568 mg, 1.27 mmol, 1.5 equiv). The L-tube 
was angled such that its rotation would allow controlled addition of MoOPH to the 
reaction mixture. The three-neck flask was charged with imine 232 (210 mg, 0.849 
mmol, 1 equiv), 2,2,6,6-tetramethylpiperidine (14 μL, 0.085 mmol, 0.1 equiv), and 
tetrahydrofuran (1.5 mL) and the resulting solution was cooled in an ice bath. A solution 
of n-butyllithium in hexanes (2.52 M, 354 μL, 0.891 mmol, 1.05 equiv) was added 
dropwise over a period of 40 min, forming a deep purple solution. After 30 min, the 
reaction flask was cooled to –78 ºC, and a solution of 3-bromobenzonitrile (193 mg, 1.06 
mmol, 1.25 equiv) in tetrahydrofuran (0.5 mL) was added, forming a bright red solution. 
After 3 min, a solution of potassium bis(trimethylsilyl)amide (169 mg, 0.849 mmol, 1 
equiv) in tetrahydrofuran (0.85 mL) was added. After another 3 min, MoOPH was added 
by rotating the L-tube and gently tapping the 5-mL side flask to dislodge the solids. After 
60 min, trifluoroacetic acid (1 mL) was added. The cooling bath was removed and the 
reaction flask was allowed to warm to 23 ºC. The reaction mixture was partitioned 
between dichloromethane (30 mL) and a 1:1 mixture of saturated aqueous sodium sulfite 
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solution and saturated aqueous sodium carbonate solution (30 mL). The layers were 
separated. The aqueous layer was extracted with dichloromethane (3 × 20 mL). The 
organic layers were combined. The combined solution was dried over sodium sulfate.  
The dried solution was filtered and the filtrate was concentrated. The residue was purified 
by flash-column chromatography (20:1 to 15:1 then 10:1 hexanes–acetone), furnishing 3-
(3-bromophenyl)-7-(trimethylsilyl)isoquinolin-4-ol (241) as a white solid (126 mg, 40%). 
 
Melting Point 215–217 ºC 
 
1H NMR:  
(500 MHz, CDCl3) 
8.91 (s, 1H), 8.18 (d, 1H, J = 8.4 Hz), 8.11 (s, 1H), 7.96 (app 
t, 1H, J = 1.6 Hz), 7.85 (dd, 1H, J = 8.2, 0.9 Hz), 7.72 (ddd, 
1H, J = 7.7, 1.2, 1.0 Hz), 7.53 (app dt, 1H, J = 8.1, 1.3 Hz), 
7.37 (app t, 1H, J = 7.9 Hz), 6.10 (br s, 1H), 0.38 (s, 9H). 
 
13C NMR :  
(126 MHz, CDCl3) 
145.0, 144.1, 141.0, 139.2, 134.7, 134.0, 132.8, 132.1, 131.5, 
130.7, 128.7, 127.8, 127.3, 123.6, 120.2, –1.2. 
 
FTIR, cm–1: 
 (thin film) 
2951 (m), 1728 (m), 1576 (m), 1557 (s), 1346 (s), 1327 (s), 
1250 (s). 
 
HRMS:  
(ESI) 
Calcd for (C18H18BrNOSi+H)+                        372.0414 
 Found                                                              372.0427 
 
TLC 
(10:1 hexanes–acetone) 
Rf  = 0.19 (UV) 
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3-(4-Methoxyphenyl)-4-(methylthio)-7-(trimethylsilyl)isoquinoline (243) 
A solution of n-butyllithium in hexanes (2.52 M, 330 μL, 0.832 mmol, 1.05 
equiv) was added dropwise over 40 min to an ice-cooled solution of imine 232 (196 mg, 
0.792 mmol, 1 equiv) and 2,2,6,6-tetramethylpiperidine (14 μL, 0.079 mmol, 0.1 equiv) 
in tetrahydrofuran (1.5 mL), forming a deep purple solution. After 30 min, the reaction 
flask was cooled to –78 ºC, and a solution of 4-methoxybenzonitrile (158 mg, 1.19 mmol, 
1.5 equiv) in tetrahydrofuran (0.5 mL) was added, forming a dark red solution. After 10 
min, hexamethylphosphoramide (276 μL, 1.58 mmol, 2 equiv) was added. After 5 min, 
dimethyl disulfide (140 μL, 1.58 mmol, 2 equiv) was added. After 30 min, trifluoroacetic 
acid (1 mL) was added. The reaction mixture was partitioned between saturated aqueous 
sodium carbonate solution (20 mL) and dichloromethane (30 mL). The layers were 
separated. The aqueous layer was extracted with dichloromethane (3 × 20 mL). The 
organic layers were combined. The combined solution was dried over sodium sulfate. 
The dried solution was filtered and the filtrate was concentrated. The residue was purified 
by flash-column chromatography (20:1 hexanes–ethyl acetate initially, grading to 10:1 
hexanes–ethyl acetate, then 7:1 hexanes–ethyl acetate), affording 3-(4-methoxyphenyl)-
4-(methylthio)-7-(trimethylsilyl)isoquinoline (243) as a white solid (190 mg, 68%). 
 
Melting Point 122–124 ºC 
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1H NMR:  
(500 MHz, CDCl3) 
9.25 (s, 1H), 8.58 (d, 1H, J = 7.8 Hz), 8.15 (s, 1H), 7.94 (dd, 
1H, J = 8.2, 1.4 Hz), 7.74 (d, 2H, J = 8.7 Hz), 7.02 (d, 2H, J 
= 8.7 Hz), 3.88 (s, 3H), 2.16 (s, 3H), 0.39 (s, 9H). 
 
13C NMR :  
(126 MHz, CDCl3) 
159.5, 156.3, 152.0, 139.9, 138.2, 135.2, 133.9, 133.6, 131.3, 
127.2, 125.8, 124.6, 113.2, 55.3, 19.4, –1.2. 
 
FTIR, cm–1: 
 (thin film) 
2953 (m), 1605 (s), 1512 (s), 1418 (s), 1246 (s), 1175 (s), 
1096 (m), 1034 (m). 
 
HRMS:  
(ESI) 
Calcd for (C20H23NOSSi+H)+                                  354.1342 
Found                                                                        354.1339 
 
TLC 
(4:1 hexanes–acetone) 
Rf  = 0.38 (UV) 
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Diethyl 1-(3-o-Tolyl-7-(trimethylsilyl)isoquinolin-4-yl)hydrazine-1,2-dicarboxylate (244) 
A solution of n-butyllithium in hexanes (2.52 M, 269 μL, 0.679 mmol, 1.05 
equiv) was added dropwise over 40 min to an ice-cooled solution of imine 232 (160 mg, 
0.647 mmol, 1 equiv) and 2,2,6,6-tetramethylpiperidine (11 μL, 0.065 mmol, 0.1 equiv) 
in tetrahydrofuran (1.4 mL), forming a deep purple solution. After 30 min, the reaction 
flask was cooled to –78 ºC, and o-tolunitrile (115 μL, 0.97 mmol, 1.5 equiv) was added, 
forming a dark red solution. After 15 min, hexamethylphosphoramide (203 μL, 1.29 
mmol, 2 equiv) was added. After 15 min, diethyl azodicarboxylate (203 μL, 1.29 mmol, 2 
equiv) was added. After 30 min, trifluoroacetic acid (1 mL) was added. The reaction 
mixture was partitioned between saturated aqueous sodium carbonate solution (20 mL) 
and dichloromethane (30 mL). The layers were separated. The aqueous layer was 
extracted with dichloromethane (3 × 20 mL). The organic layers were combined. The 
combined solution was dried over sodium sulfate. The dried solution was filtered and the 
filtrate was concentrated. The residue was purified by flash-column chromatography 
(20:1 hexanes–ethyl acetate initially, grading to 10:1 hexanes–ethyl acetate, then 5:1 
hexanes–ethyl acetate, and finally 3:1 hexanes–ethyl acetate), affording diethyl 1-(3-o-
tolyl-7-(trimethylsilyl)isoquinolin-4-yl)hydrazine-1,2-dicarboxylate (244) as a yellow oil 
(165 mg, 55%).  
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1H NMR:  
(500 MHz, CDCl3) 
(observed as two rotamers in the ratio of 2:1, asterisk denotes 
minor rotamer peaks) 9.30 (s, 1H), 8.53 (br s, 1H), 8.19 (s, 
1H), 7.96 (br s, 1H), 7.44–7.12 (br m, 5H), 6.08 (br s, 1H), 
4.41–3.94 (br m, 4H), 2.18* (br s, 3H), 2.15 (br s, 3H), 1.35–
1.01 (br m, 6H), 0.39 (s, 9H), 0.36* (s, 9H). 
 
13C NMR :  
(126 MHz, CDCl3) 
(observed as two rotamers in the ratio of 2:1, asterisk denotes 
minor rotamer peaks) 156.1, 155.5, 152.5, 140.7, 138.0, 
136.8, 135.3, 135.1, 134.2, 133.0, 131.4, 131.1, 131.0, 128.9, 
128.0, 126.1, 122.8, 122.7*, 63.2, 63.0*, 62.2, 62.0*, 19.5, 
14.6*, 14.5*, 14.4, 14.3, –1.2, –1.3*. 
 
FTIR, cm–1: 
 (thin film) 
3391 (br), 2957 (m), 1728 (vs), 1479 (m), 1373 (m), 1323 
(s), 1248 (s), 1223 (vs), 1096 (s), 1057 (s). 
 
HRMS:  
(ESI) 
Calcd for (C25H31N3O4Si+H)+                           466.2157 
 Found                                                                466.2168 
 
TLC 
(4:1 hexanes–acetone) 
Rf  = 0.20 (UV) 
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4-Chloro-3-phenylisoquinoline (202) 
A solution of n-butyllithium in hexanes (2.40 M, 438 μL, 1.05 mmol, 1.05 equiv) 
was added dropwise to an ice-cooled solution of imine 192 (175 mg, 1.00 mmol, 1 equiv) 
and 2,2,6,6-tetramethylpiperidine (17 μL, 0.10 mmol, 0.1 equiv) in tetrahydrofuran (1.5 
mL) over 40 min, forming a deep purple solution. After 30 min, the reaction flask was 
cooled to –78 ºC, and benzonitrile (129 μL, 1.25 mmol, 1.25 equiv) was added, forming a 
dark red solution. After 5 min, the bright red solution was transferred by cannula to a 
suspension of hexachloroethane (710 mg, 3.00 mmol, 3 equiv) in tetrahydrofuran (1 mL) 
at –78 ºC. After 10 min, trifluoroacetic acid (1 mL) was added. The cooling bath was 
removed and the reaction flask was allowed to warm to 23 ºC. The reaction mixture was 
partitioned between saturated aqueous sodium carbonate solution (20 mL) and 
dichloromethane (30 mL). The layers were separated. The aqueous layer was extracted 
with dichloromethane (3 × 20 mL). The organic layers were combined. The combined 
solution was dried over sodium sulfate.  The dried solution was filtered and the filtrate 
was concentrated. The residue was purified by flash-column chromatography (40:1 
hexanes–ethyl acetate initially, grading to 20:1 hexanes–ethyl acetate, then 10:1 hexanes–
ethyl acetate), furnishing 4-chloro-3-phenylisoquinoline (202) as a yellow oil (143 mg, 
60%) with spectral properties identical to those previously reported.43 
 
                                                 
43 X. Yu, J. Wu, J. Comb. Chem. 2009, 11, 895–899. 
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N-tert-Butyl-3-phenylisoquinolin-1-amine (203) 
A solution of n-butyllithium in hexanes (2.40 M, 225 μL, 0.539 mmol, 1.05 
equiv) was added dropwise to an ice-cooled solution of imine 192 (90 mg, 0.513 mmol, 1 
equiv) and 2,2,6,6-tetramethylpiperidine (9 μL, 0.051 mmol, 0.1 equiv) in 
tetrahydrofuran (1 mL) over 40 min, forming a deep purple solution. After 30 min, the 
reaction flask was cooled to –78 ºC, and benzonitrile (66 μL, 0.642 mmol, 1.25 equiv) 
was added, forming a dark red solution. After 5 min, the bright red solution was 
transferred by cannula to a suspension of hexachloroethane (487 mg, 2.05 mmol, 4 equiv) 
and diethylamine (212 μL, 2.05 mmol, 4 equiv) in tetrahydrofuran (0.5 mL) at –78 ºC. 
After 30 min, the cooling bath was removed and the reaction flask was allowed to warm 
to 23 ºC. The reaction mixture was partitioned between saturated aqueous sodium 
carbonate solution (20 mL) and dichloromethane (30 mL). The layers were separated. 
The aqueous layer was extracted with dichloromethane (3 × 20 mL). The organic layers 
were combined. The combined solution was dried over sodium sulfate.  The dried 
solution was filtered and the filtrate was concentrated. The residue was purified by flash-
column chromatography (50:1 hexanes–ethyl acetate). The product fractions were 
collected and concentrated. The residue (a yellow solid) was further purified by 
recrystallization from hexanes, furnishing N-tert-butyl-3-phenylisoquinolin-1-amine 
(203) as a white solid (85 mg, 60%). 
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Melting Point 96–97 ºC 
 
1H NMR:  
(500 MHz, CDCl3) 
8.22 (d, 2H, J = 8.7 Hz), 7.78–7.69 (m, 2H), 7.57 (app t, 
1H, J = 7.3 Hz), 7.51 (app t, 2H, J = 7.8 Hz), 7.45 (s, 
1H), 7.45–7.38 (m, 2H), 5.22 (br s, 1H), 1.71 (s, 9H). 
 
13C NMR :  
(126 MHz, CDCl3) 
154.0, 148.7, 140.4, 138.0, 129.3, 128.4, 127.9, 127.8, 
126.6, 125.4, 121.3, 117.8, 106.0, 51.8, 29.2. 
 
FTIR, cm–1: 
 (thin film) 
3457 (m), 3059 (m), 2961 (m), 1568 (s), 1518 (vs), 1425 
(s), 1323 (s), 1213 (s). 
 
HRMS:  
(ESI) 
Calcd for (C19H20N2+H)+                                       277.1699 
Found                                                         277.1700 
 
TLC 
(9:1 hexanes–ethyl acetate) 
Rf  = 0.46 (UV) 
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3,3'-Diphenyl-4,4'-bisisoquinoline (205) 
A solution of n-butyllithium in hexanes (2.40 M, 438 μL, 1.05 mmol, 1.05 equiv) 
was added dropwise to an ice-cooled solution of imine 192 (175 mg, 1.00 mmol, 1 equiv) 
and 2,2,6,6-tetramethylpiperidine (17 μL, 0.10 mmol, 0.1 equiv) in tetrahydrofuran (1.5 
mL) over 40 min, forming a deep purple solution. After 30 min, the deep purple solution 
was transferred by cannula to a solution of benzonitrile (129 μL, 1.25 mmol, 1.25 equiv) 
in tetrahydrofuran (0.4 mL) at –78 ºC, forming a dark red solution. The transfer was 
quantitated with tetrahydrofuran (0.1 mL). After 3 min, a solution of hexachloroethane 
(95 mg, 0.40 mmol, 0.4 equiv) in tetrahydrofuran (1 mL) was added dropwise over 5 min. 
After 60 min, trifluoroacetic acid (1 mL) was added. The cooling bath was removed and 
the reaction flask was allowed to warm to 23 ºC. The reaction mixture was partitioned 
between saturated aqueous sodium carbonate solution (20 mL) and dichloromethane (30 
mL). The layers were separated. The aqueous layer was extracted with dichloromethane 
(3 × 20 mL). The organic layers were combined. The combined solution was dried over 
sodium sulfate.  The dried solution was filtered and the filtrate was concentrated. The 
residue was purified by flash-column chromatography (20:1 hexanes–ethyl acetate 
initially, grading to 10:1 hexanes–ethyl acetate, then 5:1 hexanes–ethyl acetate, and 
finally 3:1 hexanes–ethyl acetate), furnishing 3,3'-diphenyl-4,4'-bisisoquinoline (205) as a 
yellow solid (74 mg, 36%). 
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Melting Point 228–230 ºC 
 
1H NMR:  
(500 MHz, CDCl3) 
9.40 (s, 1H), 8.12 (d, 1H, J = 8.3 Hz), 7.65 (app td, 1H, 
J = 8.0, 1.2 Hz), 7.59 (app td, 1H, J = 7.8, 1.2 Hz), 7.41 
(d, 1H, J = 8.3 Hz), 7.07 (t, 1H, J = 7.9 Hz), 6.93 (app t, 
2H, J = 7.8 Hz), 6.67 (dd, 2H, J = 8.0, 1.5 Hz). 
 
13C NMR :  
(126 MHz, CDCl3) 
152.5, 152.2, 139.9, 137.2, 131.1, 128.9, 128.1, 127.3, 
127.2, 127.1, 126.8, 125.7, 125.6. 
 
FTIR, cm–1: 
 (thin film) 
3059 (m), 3026 (m), 1618 (s), 1576 (m), 1559 (s), 1497 
(s), 1449 (s), 1250 (s). 
 
HRMS:  
(ESI) 
Calcd for (C30H20N2+H)+                       409.1699 
 Found                                                    409.1706 
 
TLC 
(4:1 hexanes–ethyl acetate) 
Rf  = 0.17 (UV) 
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5-Fluoro-4-methyl-3-phenyl-7-(trimethylsilyl)isoquinoline (207) 
A solution of n-butyllithium in hexanes (2.32 M, 436 μL, 1.01 mmol, 1.17 equiv) 
was added to a cooled solution of 2,2,6,6-tetramethylpiperidine (181 μL, 1.06 mmol, 1.23 
equiv) in tetrahydrofuran (1 mL) at –15 ºC. After 20 min, a solution of imine 206 (242 
mg, 0.963 mmol, 1.11 equiv) in tetrahydrofuran (0.5 mL) was added by cannula, forming 
a dark green mixture. The reaction mixture was allowed to warm to 0 ºC over 90 min. 
The reaction flask was then cooled to –78 ºC, and iodomethane (54 μL, 0.866 mmol, 1 
equiv) was added. After 15 min, the cooling bath was removed and the reaction flask was 
allowed to warm to 23 ºC. After 1 h, the reaction flask was cooled to –40 ºC, and a 
freshly prepared solution of lithium diisopropylamide (1.01 mmol, 1.17 equiv) in 
tetrahydrofuran (1.0 mL) was added by cannula, forming a dark red solution. After 60 
min, the reaction flask was cooled to –78 ºC, and benzonitrile (124 μL, 1.20 mmol, 1.39 
equiv) was added. After 30 min, iodomethane (120 μL, 1.93 mmol, 2.23 equiv) was 
added. After 10 min, the cooling bath was removed and the reaction flask was allowed to 
warm to 23 ºC. After 30 min, trifluoroacetic acid (1 mL) was added. The reaction mixture 
was partitioned between saturated aqueous sodium carbonate solution (20 mL) and 
dichloromethane (30 mL). The layers were separated. The aqueous layer was extracted 
with dichloromethane (3 × 20 mL). The organic layers were combined. The combined 
solution was dried over sodium sulfate. The dried solution was filtered and the filtrate 
was concentrated. The residue was purified by flash-column chromatography (40:1 to 
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20:1 finally 10:1 hexanes–ethyl acetate), furnishing 5-fluoro-4-methyl-3-phenyl-7-
(trimethylsilyl)isoquinoline (207) as a light yellow solid (120 mg, 45%). 
 
Melting Point 95–96 ºC 
 
1H NMR:  
(500 MHz, CDCl3) 
9.15 (d, 1H, J = 2.3 Hz), 7.90 (s, 1H), 7.56 (app dt, 2H, J = 
6.9, 1.8 Hz), 7.51–7.46 (m, 2H), 7.46 (dd, 1H, J = 13.3, 1.0 
Hz), 7.41 (app tt, 1H, J = 7.8, 1.4 Hz), 2.77 (d, 3H, J = 6.4 
Hz), 0.38 (s, 9H). 
 
19F NMR:  
(470 MHz, CDCl3) 
–113.6– –113.5 (m). 
 
 
13C NMR :  
(126 MHz, CDCl3) 
159.1 (d, J = 258.2 Hz), 153.4, 149.6 (d, J = 1.8 Hz), 141.0, 
140.9 (d, J = 4.6 Hz), 129.8, 129.7 (d, J = 4.6 Hz), 129.4 (d, 
J = 3.7 Hz), 128.1, 127.7, 126.9 (d, J = 12.8 Hz), 122.6 (d, J 
= 4.6 Hz), 119.1 (d, J = 21.1 Hz), 18.7 (d, J = 11.0 Hz), –1.3. 
 
FTIR, cm–1: (thin film) 2955 (m), 1568 (m), 1343 (m), 1248 (s). 
 
HRMS:  
(ESI) 
Calcd for (C19H20FNSi+H)+                                          310.1422 
Found                                                               310.1420 
 
TLC                                 Rf  = 0.29 (UV) 
(9:1 hexanes–ethyl acetate) 
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5-Fluoro-N,N-bis(4-methoxybenzyl)-7-(trimethylsilyl)isoquinolin-3-amine (208) 
A solution of n-butyllithium in hexanes (2.50 M, 910 μL, 2.28 mmol, 1.17 equiv) 
was added to a cooled solution of 2,2,6,6-tetramethylpiperidine (407 μL, 2.39 mmol, 1.23 
equiv) in tetrahydrofuran (3 mL) at –15 ºC. After 20 min, a solution of imine 206 (545 
mg, 2.17 mmol, 1.11 equiv) in tetrahydrofuran (1 mL) was added by cannula, forming a 
dark green mixture. The reaction mixture was allowed to warm to 0 ºC over 90 min. The 
reaction flask was then cooled to –78 ºC, and iodomethane (122 μL, 1.95 mmol, 1 equiv) 
was added. After 15 min, the cooling bath was removed and the reaction flask was 
allowed to warm to 23 ºC. After 1 h, the reaction flask was cooled to –40 ºC, and a 
freshly prepared solution of lithium diisopropylamide (2.28 mmol, 1.17 equiv) in 
tetrahydrofuran (2.0 mL) was added by cannula, forming a dark red solution. After 60 
min, a solution of N,N-bis(4-methoxybenzyl)cyanamide (225) (826 mg, 2.93 mmol, 1.5 
equiv) in tetrahydrofuran (2 mL) was added. After 40 min, trifluoroacetic acid (2 mL) 
was added. The cooling bath was removed and the reaction flask was allowed to warm to 
23 ºC. The reaction mixture was partitioned between saturated aqueous sodium carbonate 
solution (30 mL) and dichloromethane (50 mL). The layers were separated. The aqueous 
layer was extracted with dichloromethane (3 × 40 mL). The organic layers were 
combined. The combined solution was dried over sodium sulfate. The dried solution was 
filtered and the filtrate was concentrated. The residue was purified by flash-column 
chromatography (40:1 hexanes–ethyl acetate initially, grading to 20:1 hexanes–ethyl 
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acetate, then 15:1 hexanes–ethyl acetate), furnishing 5-fluoro-N,N-bis(4-methoxybenzyl)-
7-(trimethylsilyl)isoquinolin-3-amine (208) as a yellow oil (506 mg, 55%).  
 
1H NMR:  
(500 MHz, CDCl3) 
8.98 (s, 1H), 7.70 (s, 1H), 7.21 (d, 1H, J = 12.7 Hz), 7.20 (d, 
4H, J = 8.7 Hz), 6.85 (d, 4H, J = 8.7 Hz), 6.77 (s, 1H), 4.83 
(s, 4H), 3.80 (s, 6H), 0.33 (s, 9H). 
 
19F NMR:  
(470 MHz, CDCl3) 
–128.2 (d, J = 12.7 Hz). 
 
 
13C NMR :  
(126 MHz, CDCl3) 
158.7, 155.9, 156.5 (d, J = 253.0 Hz), 151.2 (d, J = 2.7 Hz), 
133.5 (d, J = 2.7 Hz), 130.2, 130.0 (d, J = 17.4 Hz), 129.0 (d, 
J = 3.7 Hz), 128.4, 124.0 (d, J = 5.5 Hz), 116.2 (d, J = 16.5 
Hz), 114.0, 89.3 (d, J = 4.6 Hz), 55.2, 50.5, –1.2. 
 
FTIR, cm–1: 
 (thin film) 
2953 (m), 2835 (m), 1626 (m), 1589 (s), 1510 (s), 1246 (s). 
 
 
HRMS:  
(ESI) 
Calcd for (C28H31FN2O2Si+H)+                       475.2212 
Found                                                              475.2206 
 
TLC Rf  = 0.30 (UV) 
(9:1 hexanes–ethyl acetate) 
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4-Fluoro-7-iodoisoquinolin-3-amine (210) 
A solution of iodine monochloride in dichloromethane (1.0 M, 1.81 mL, 1.81 
mmol, 2 equiv) was added slowly over 5 min to an ice-cooled solution of 4-fluoro-N,N-
bis(4-methoxybenzyl)-7-(trimethylsilyl)isoquinolin-3-amine (208) (430 mg, 0.906 mmol, 
1 equiv) in dichloromethane (5 mL). After 60 min, saturated aqueous sodium thiosulfate 
solution (5 mL) was added. The cooling bath was removed and the reaction flask was 
allowed to warm to 23 ºC. After 10 min, the reaction mixture was partitioned between 
saturated aqueous sodium carbonate solution (20 mL) and dichloromethane (30 mL). The 
layers were separated. The aqueous layer was extracted with dichloromethane (3 × 30 
mL). The organic layers were combined. The combined solution was dried over sodium 
sulfate. The dried solution was filtered and the filtrate was concentrated. The residue was 
filtered through silica gel (eluting with 7:1 hexanes–ethyl acetate) and the filtrate was 
concentrated. The solid residue was transformed directly in the following step. 
Trifluoroacetic acid (5 mL) was added to the solid residue prepared above, 
forming a bright red solution. After 60 min, the reaction mixture was partitioned between 
saturated aqueous sodium carbonate solution (40 mL) and dichloromethane (40 mL). The 
layers were separated. The aqueous layer was extracted with dichloromethane (3 × 30 
mL). The organic layers were combined. The combined solution was dried over sodium 
sulfate. The dried solution was filtered and the filtrate was concentrated. The residue was 
purified by flash-column chromatography (20:1 hexanes–ethyl acetate initially, grading 
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to 10:1 hexanes–ethyl acetate, then 5:1 hexanes–ethyl acetate), furnishing 4-fluoro-7-
iodoisoquinolin-3-amine (210) as a yellow solid (196 mg, 75%). 
 
1H NMR:  
(500 MHz, CDCl3) 
8.58 (s, 1H), 8.19 (app t, 1H, J = 1.6 Hz), 7.78 (dd, 1H, 
J = 8.9, 1.6 Hz), 7.58 (d, 1H, J = 9.2 Hz), 4.58 (br s, 
2H). 
 
19F NMR:  
(470 MHz, CDCl3) 
–156.8 (d, J = 2.4 Hz). 
 
 
13C NMR :  
(126 MHz, CDCl3) 
144.8 (d, J = 7.3 Hz), 142.4 (d, J = 12.8 Hz), 138.8, 
139.2 (d, J = 250.0 Hz), 135.9 (d, J = 1.8 Hz), 126.1, 
125.8 (d, J = 12.8 Hz), 119.4 (d, J = 3.7 Hz), 87.5. 
 
FTIR, cm–1: 
 (thin film) 
3383 (m), 3263 (m), 3160 (s), 2940 (m), 1732 (s), 1645 
(s), 1584 (s), 1466 (s), 1261 (s). 
 
HRMS:  
(ESI) 
Calcd for (C9H6FIN2+H)+ 288.9633 
 Found 288.9642 
 
TLC 
(4:1 hexanes–ethyl acetate) 
Rf  = 0.16 (UV) 
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3,4-Difluoro-7-iodoisoquinoline (211) 
A solution of sodium nitrite (25 mg, 0.365 mmol, 5 equiv) in water (0.5 mL) was 
added dropwise to an ice-cooled suspension of 4-fluoro-7-iodoisoquinolin-3-amine (210) 
(21 mg, 0.073 mmol, 1 equiv) in hydrogen fluoride pyridine (70% HF, 1 mL) in a Teflon 
reaction vessel over 5 min. After 30 min, the cooling bath was removed and the reaction 
vessel was allowed to warm to 23 ºC. After 60 min, saturated aqueous sodium carbonate 
solution (15 mL) was added slowly (CAUTION: gas evolution). The reaction mixture 
was then partitioned between saturated aqueous sodium chloride (15 mL) and 
dichloromethane (20 mL). The layers were separated. The aqueous layer was extracted 
with dichloromethane (3 × 15 mL). The organic layers were combined. The combined 
solution was dried over sodium sulfate. The dried solution was filtered and the filtrate 
was concentrated. The residue was purified by flash-column chromatography (20:1 
hexanes–ethyl acetate), affording 3,4-difluoro-7-iodoisoquinoline (211) as a white solid 
(18 mg, 85%). 
 
Melting Point 135–136 ºC 
 
1H NMR:  
(500 MHz, CDCl3) 
8.63 (s, 1H), 8.40 (s, 1H), 7.99 (d, 1H, J = 8.8 Hz), 7.84 
(d, 1H, J = 8.8 Hz). 
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19F NMR:  
(470 MHz, CDCl3) 
–97.3 (d, J = 20.7 Hz), –154.6 (d, J = 20.7 Hz). 
 
 
13C NMR :  
(126 MHz, CDCl3) 
147.8 (dd, J = 235.0, 13.7 Hz), 143.2 (dd, J = 13.7, 7.7 
Hz), 139.7, 139.2 (dd, J = 262.0, 26.4 Hz), 135.9, 130.0 
(d, J = 2.6 Hz), 128.1 (dd, J = 12.8, 2.6 Hz), 121.0 (dd, J 
= 7.3, 3.0 Hz), 92.4 (d, J = 2.6 Hz). 
 
FTIR, cm–1: 
 (thin film) 
3055 (m), 2930 (m), 1732 (s), 1626 (s), 1591 (s), 1442 
(s), 1263 (s). 
 
HRMS:  
(ESI) 
Calcd for (C9H4F2IN+H)+                                 291.9429 
Found                                                                291.9429 
 
TLC 
(9:1 hexanes–ethyl acetate) 
Rf  = 0.48 (UV) 
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3-Chloro-4-fluoro-7-iodoisoquinoline (212) 
A solution of sodium nitrite (53 mg, 0.764 mmol, 5 equiv) in water (0.5 mL) was 
added dropwise to an ice-cooled suspension of 4-fluoro-7-iodoisoquinolin-3-amine (210) 
(44 mg, 0.153 mmol, 1 equiv) in concentrated aqueous hydrochloric acid solution (37 wt 
%, 1.5 mL) over 5 min. After 15 min, a solution of copper(I) chloride (76 mg, 0.764 
mmol, 5 equiv) in concentrated aqueous hydrochloric acid solution (37 wt %, 0.5 mL) 
was added dropwise over 5 min. After 30 min, the cooling bath was removed and the 
reaction flask was allowed to warm to 23 ºC. After 60 min, the reaction mixture was 
partitioned between aqueous ammonium hydroxide solution (30 wt%, 10 mL) and 
dichloromethane (20 mL). The layers were separated. The aqueous layer was extracted 
with dichloromethane (3 × 15 mL). The organic layers were combined. The combined 
solution was dried over sodium sulfate. The dried solution was filtered and the filtrate 
was concentrated. The residue was purified by flash-column chromatography (20:1 
hexanes(ethyl acetate), affording 3-chloro-4-fluoro-7-iodoisoquinoline (212) as a white 
solid (35 mg, 75%). 
 
Melting Point 145–147 ºC 
 
1H NMR:  
(500 MHz, CDCl3) 
8.81 (s, 1H), 8.41 (s, 1H), 8.04 (dd, 1H, J = 8.8, 1.0 Hz), 
7.81 (d, 1H, J = 8.8 Hz). 
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19F NMR:  
(470 MHz, CDCl3) 
–131.2 (s). 
 
 
13C NMR :  
(126 MHz, CDCl3) 
150.2 (d, J = 264.0 Hz), 145.8 (d, J = 7.3 Hz), 140.1, 
135.9 (d, J = 1.8 Hz), 131.3 (d, J = 18.3 Hz), 130.5, 
126.3 (d, J = 15.6 Hz), 121.0 (d, J = 2.7 Hz), 93.8. 
 
FTIR, cm–1: 
 (thin film) 
2930 (m), 1734 (s), 1578 (m), 1406 (s), 1217 (m), 1153 
(m). 
 
HRMS:  
(ESI) 
Calcd for (C9H4ClFIN+H)+                             307.9134 
Found                                                               307.9125 
 
TLC 
(9:1 hexanes–ethyl acetate) 
Rf  = 0.43 (UV) 
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4-Chloro-5-fluoro-7-iodoisoquinolin-3-amine (213) 
A solution of iodine monochloride in dichloromethane (1.0 M, 1.66 mL, 1.66 
mmol, 2 equiv) was added slowly over 5 min to an ice-cooled suspension of 5-fluoro-
N,N-bis(4-methoxybenzyl)-7-(trimethylsilyl)isoquinolin-3-amine (208) (395 mg, 0.832 
mmol, 1 equiv) and sodium bicarbonate (210 mg, 2.50 mmol, 3 equiv) in 
dichloromethane (5 mL). After 2 h, a second portion of iodine monochloride solution (1.0 
M in dichloromethane, 0.42 mL, 0.416 mmol, 0.5 equiv) was added. After 60 min, 
saturated aqueous sodium thiosulfate solution (5 mL) was added. After 10 min, the 
reaction mixture was partitioned between saturated aqueous sodium carbonate solution 
(20 mL) and dichloromethane (30 mL). The layers were separated. The aqueous layer 
was extracted with dichloromethane (3 × 30 mL). The organic layers were combined. The 
combined solution was dried over sodium sulfate. The dried solution was filtered and the 
filtrate was concentrated. The residue was filtered through silica gel (eluting with 7:1 
hexanes–ethyl acetate) and the filtrate was concentrated. The solid residue was 
transformed directly in the following step. 
Trifluoroacetic acid (5 mL) was added to the solid residue prepared above, 
forming a bright red solution. After 60 min, the reaction mixture was partitioned between 
saturated aqueous sodium carbonate solution (40 mL) and dichloromethane (40 mL). The 
layers were separated. The aqueous layer was extracted with dichloromethane (3 × 30 
mL). The organic layers were combined. The combined solution was dried over sodium 
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sulfate. The dried solution was filtered and the filtrate was concentrated. The residue was 
purified by flash-column chromatography (20:1 hexanes–ethyl acetate initially, grading 
to 10:1 hexanes–ethyl acetate, then 5:1 hexanes–ethyl acetate), furnishing 4-chloro-5-
fluoro-7-iodoisoquinolin-3-amine (213) as a yellow solid (174 mg, 65%).  
 
1H NMR:  
(500 MHz, CDCl3) 
8.64 (d, 1H, J = 2.3 Hz), 7.95 (s, 1H), 7.50 (dd, 1H, J = 
11.7, 1.6 Hz), 5.11 (br s, 2H). 
 
19F NMR:  
(470 MHz, CDCl3) 
–115.5 (d, J = 12.7 Hz). 
 
 
13C NMR :  
(126 MHz, CDCl3) 
155.5 (d, J = 262.9 Hz), 152.4, 148.5 (d, J = 1.8 Hz), 133.0 
(d, J = 5.0 Hz), 127.7 (d, J = 3.7 Hz), 125.3 (d, J = 10.0 
Hz), 124.8 (d, J = 23.9 Hz), 101.6, 84.0 (d, J = 7.3 Hz). 
 
FTIR, cm–1: 
 (thin film) 
3412 (m), 3291 (s), 3175 (s), 2934 (m), 1734 (s), 1634 (s), 
1582 (s), 1460 (s), 1319 (s), 1234 (s). 
 
HRMS:  
(ESI) 
Calcd for (C9H5ClFIN2+H)+                        322.9243 
Found                                                           322.9255 
 
TLC                                    Rf  = 0.24 (UV) 
(4:1 hexanes–ethyl acetate) 
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4-Chloro-3,5-difluoro-7-iodoisoquinoline (214) 
A solution of sodium nitrite (21 mg, 0.310 mmol, 5 equiv) in water (0.5 mL) was 
added dropwise to an ice-cooled suspension of 4-chloro-5-fluoro-7-iodoisoquinolin-3-
amine (213) (20 mg, 0.062 mmol, 1 equiv) in hydrogen fluoride pyridine (70% HF, 1 
mL) in a Teflon reaction vessel over 5 min. After 30 min, the cooling bath was removed 
and the reaction vessel was allowed to warm to 23 ºC. After 60 min, saturated aqueous 
sodium carbonate solution (15 mL) was added slowly (CAUTION: gas evolution). The 
reaction mixture was then partitioned between saturated aqueous sodium chloride (15 
mL) and dichloromethane (20 mL). The layers were separated. The aqueous layer was 
extracted with dichloromethane (3 × 15 mL). The organic layers were combined. The 
combined solution was dried over sodium sulfate. The dried solution was filtered and the 
filtrate was concentrated. The residue was purified by flash-column chromatography 
(20:1 hexanes–ethyl acetate), affording 4-chloro-3,5-difluoro-7-iodo isoquinoline (214) 
as a white solid (16 mg, 79%). 
 
Melting Point 151–153 ºC 
 
1H NMR:  
(500 MHz, CDCl3) 
δ 8.75 (d, 1H, J = 1.4 Hz), 8.20 (s, 1H), 7.71 (dd, 1H, J 
= 11.4, 0.9 Hz). 
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19F NMR:  
(470 MHz, CDCl3) 
–76.5 (d, J = 5.7 Hz), –112.9 (dd, J = 11.4, 6.9 Hz). 
 
 
13C NMR :  
(126 MHz, CDCl3) 
157.4 (d, J = 234.4 Hz), 156.7 (dd, J = 267.3, 11.0 Hz), 
147.2 (dd, J = 14.6, 3.7 Hz), 133.0 (d, J = 3.7 Hz), 131.0 
(d, J = 2.7 Hz), 126.6 (dd, J = 10.5, 2.3 Hz), 125.8 (d, J 
= 23.8 Hz), 108.2 (dd, J = 34.8, 2.7 Hz), 89.7 (dd, J = 
7.8, 3.2 Hz). 
 
FTIR, cm–1: 
 (thin film) 
2930 (m), 1584 (s), 1429 (s), 1325 (s). 
 
 
HRMS:  
(ESI) 
Calcd for (C9H3ClF2IN+H)+                       325.9040 
Found                                                          325.9036 
 
TLC 
(9:1 hexanes–ethyl acetate) 
Rf  = 0.39 (UV) 
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3-Bromo-4-chloro-5-fluoro-7-iodoisoquinoline (215) 
Bromine (19 μL, 0.372 mmol, 6 equiv) was added to an ice-cooled suspension of 
4-chloro-5-fluoro-7-iodoisoquinolin-3-amine (213) (20 mg, 0.062 mmol, 1 equiv) in 
concentrated aqueous hydrobromic acid solution (48 wt %, 1 mL). After 10 min, a 
solution of sodium nitrite (21 mg, 0.310 mmol, 5 equiv) in water (0.5 mL) was added 
dropwise over 5 min. After 30 min, the cooling bath was removed and the reaction flask 
was allowed to warm to 23 ºC. After 60 min, the reaction mixture was partitioned 
between saturated aqueous sodium carbonate solution (15 mL) and dichloromethane (20 
mL). The layers were separated. The aqueous layer was extracted with dichloromethane 
(3 × 15 mL). The organic layers were combined and then dried over sodium sulfate. The 
dried solution was filtered and the filtrate was concentrated. The residue was purified by 
flash-column chromatography (20:1 hexanes–ethyl acetate), affording 3-bromo-4-chloro-
5-fluoro-7-iodoisoquinoline (215) as a white solid (19.5 mg, 81%). 
 
Melting Point 165–167 ºC 
 
1H NMR:  
(500 MHz, CDCl3) 
8.82 (d, 1H, J = 2.3 Hz), 8.18 (s, 1H), 7.74 (dd, 1H, J = 
11.2, 1.6 Hz). 
 
19F NMR:  
(470 MHz, CDCl3) 
–109.8 (d, J = 11.8 Hz). 
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13C NMR :  
(126 MHz, CDCl3) 
155.7 (d, J = 268.2 Hz), 148.3 (d, J = 1.8 Hz), 139.1, 
133.0 (d, J = 5.5 Hz), 131.0, 126.20 (d, J = 25.63 Hz), 
125.3 (d, J = 3.7 Hz), 124.9 (d, J = 9.2 Hz), 91.5 (d, J = 
7.3 Hz). 
 
FTIR, cm–1: 
 (thin film) 
2926 (m), 1553 (s), 1460 (s), 1397 (s), 1298 (s). 
 
 
HRMS:  
(ESI) 
Calcd for (C9H3BrClFIN+H)+                 385.8239 
 Found                                                     385.8230 
 
TLC 
(9:1 hexanes–ethyl acetate) 
Rf  = 0.33 (UV) 
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7-Chloro-1-fluoro-3-(3-fluorophenyl)isoquinoline (218) 
A solution of n-butyllithium in hexanes (2.32 M, 226 μL, 0.525 mmol, 1.05 
equiv) was added dropwise to an ice-cooled solution of diisopropylamine (78 μL, 0.550 
mmol, 1.1 equiv) in tetrahydrofuran (1.0 mL). After 15 min, a solution of imine 216 (105 
mg, 0.500 mmol, 1 equiv) in tetrahydrofuran (0.5 mL) was added by cannula, forming a 
deep purple solution. After 60 min, the reaction flask was cooled to –78 ºC, and 3-
fluorobenzonitrile (67 μL, 0.625 mmol, 1.25 equiv) was added, forming a dark brown 
solution. After 5 min, the dark brown solution was transferred by cannula to a suspension 
of hexachloroethane (473 mg, 2.00 mmol, 4 equiv) and diethylamine (207 μL, 2.00 
mmol, 4 equiv) in tetrahydrofuran (0.5 mL) at –78 ºC. After 30 min, the cooling bath was 
removed and the reaction flask was allowed to warm to 23 ºC. After 30 min, the reaction 
mixture was partitioned between saturated aqueous sodium bicarbonate solution (20 mL) 
and dichloromethane (30 mL). The layers were separated. The aqueous layer was 
extracted with dichloromethane (3 × 20 mL). The organic layers were combined. The 
combined solution was dried over sodium sulfate. The dried solution was filtered and the 
filtrate was concentrated. The residue was purified by flash-column chromatography 
(50:1 hexanes–ethyl acetate), affording N-tert-butyl-7-chloro-3-(3-fluorophenyl) 
isoquinolin-1-amine (217) as a pale yellow oil (75 mg, 45%).  
A solution of sodium nitrite (79 mg, 1.14 mmol, 5 equiv) in water (1 mL) was added 
dropwise to an ice-cooled suspension of N-tert-butyl-7-chloro-3-(3-fluorophenyl) 
isoquinolin-1-amine (217) (75 mg, 0.228 mmol, 1 equiv) in hydrogen fluoride pyridine 
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(70% HF, 2 mL) in a Teflon reaction vessel over 5 min. After 30 min, the cooling bath 
was removed and the reaction vessel was allowed to warm to 23 ºC. After 60 min, 
saturated aqueous sodium carbonate solution (20 mL) was added slowly (CAUTION: gas 
evolution). The reaction mixture was then partitioned between saturated aqueous sodium 
chloride (15 mL) and dichloromethane (20 mL). The layers were separated. The aqueous 
layer was extracted with dichloromethane (3 × 20 mL). The organic layers were 
combined. The combined solution was dried over sodium sulfate. The dried solution was 
filtered and the filtrate was concentrated. The residue was purified by recrystallization 
from hexanes, furnishing 7-chloro-1-fluoro-3-(3-fluorophenyl) isoquinoline (218) as a 
pale yellow solid (44 mg, 70%). 
 
Melting Point 118–119 ºC 
 
1H NMR:  
(500 MHz, CDCl3) 
8.10 (d, 1H, J = 8.7 Hz), 7.89 (s, 1H), 7.85 (d, 1H, J = 
8.2 Hz), 7.84 (s, 1H), 7.80 (app dt, 1H, J = 10.5, 2.1 
Hz), 7.58 (dd, 1H, J = 8.7, 1.8 Hz), 7.45 (app td, 1H, J = 
8.0, 6.0 Hz), 7.12 (app td, 1H, J = 8.2, 2.7 Hz). 
 
19F NMR:  
(470 MHz, CDCl3) 
–69.7 (s), –113.0 (ddd, J = 10.3, 8.0, 5.7 Hz). 
 
 
 
13C NMR :  163.3 (d, J = 246.3 Hz), 159.5 (d, J = 243.5 Hz), 148.3 
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(126 MHz, CDCl3) (d, J = 17.4 Hz), 141.2 (d, J = 5.5 Hz), 139.8 (d, J = 7.3 
Hz), 138.4, 130.3 (d, J = 8.2 Hz), 129.0, 125.8 (d, J = 
3.7 Hz), 125.0, 122.3 (d, J = 2.7 Hz), 116.2 (d, J = 22.0 
Hz), 115.1 (d, J = 33.9 Hz), 114.0 (d, J = 5.5 Hz), 113.9 
(d, J = 22.9 Hz). 
 
FTIR, cm–1: 
 (thin film) 
2980 (m), 2970 (m), 1738 (s), 1379 (vs), 1314 (m). 
 
 
HRMS:  
(ESI) 
Calcd for (C15H8ClF2N+H)+                          276.0386 
Found                                                     276.0378 
 
TLC 
(20:1 hexanes–ethyl acetate) 
Rf  = 0.32 (UV) 
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220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 
 271 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 
 272 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 
 273 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 
 274 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 
 275 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
O
CH3
OTBS
H
HO
147
OH
N3
 276 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 
 
O
CH3
OTBS
H(CH3)2N
HO
OH
148
 277 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
O
CH3
O
H(CH3)2N
HO
OH
23  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 
 
 278 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
O
CH3
O
H(CH3)2N
TESO
OTES
108  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 
 279 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40
Chemical Shift (ppm)  
 280 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 281 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)  
 
 
 282 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
O
CH3
(CH3)2N H
N
OH
TESO
OTES
159
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 
 283 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                               
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 
 284 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
tetra-n-butylammonium salts
elimination product as a trace impurity
 
Purification of Cortistatin A (1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) After Davisil® column 
 
  
b) After LH-20 column (tetra-n-butylammonium salts 
d)
c) After HPLC (eliminated product removed) 
 
 285 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 
 286 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
216 208 200 192 184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0 -8
Chemical Shift (ppm)  
 287 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 288 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
Purification of Cortistatin L (11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) After Davisil® column 
 
 
b) After HPLC (eliminated product removed) 
 
 elimination product as a trace impurity 
 289 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 290 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 291 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
Purification of Cortistatin J (9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) After Davisil® column 
b) After HPLC (eliminated product removed) 
 
 
elimination product as a trace impurity
 292 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 293 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 294 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
Purification of Cortistatin K (10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) After Davisil® column 
b) After HPLC (eliminated product removed) 
 
 
 
elimination product as a trace impurity
 
 295 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
216 208 200 192 184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0 -8
Chemical Shift (ppm)  
 296 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 
 
 297 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5 -1.0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 
 
 298 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 
 
 299 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)  
 
 
 300 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 301 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5 -1.0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)  
 
 
 302 
 
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30
Chemical Shift (ppm)  
 303 
 
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 304 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30
Chemical Shift (ppm)  
 305 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 306 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 307 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 308 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 309 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 310 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 311 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 312 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30
Chemical Shift (ppm)  
 313 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30
Chemical Shift (ppm)  
 314 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30
Chemical Shift (ppm)  
 315 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 316 
 
14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 -1
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 317 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 318 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 319 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30
Chemical Shift (ppm)  
 320 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 321 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 322 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 323 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 324 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
N
OH
242
TMS
Br
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 325 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 326 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 327 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 328 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30
Chemical Shift (ppm)  
 329 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 330 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 331 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 332 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20
Chemical Shift (ppm)  
 333 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 334 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 335 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 336 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
 337 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)  
